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A1.1 Fragmentation of the peptide main chain giving rise to the 








Background: Chronic obstructive pulmonary disease (COPD) represents a spectrum of 
disorders encompassing chronic bronchitis and emphysema, associated with cough, 
excess mucus and exercise-related dyspnoea and characterized by a progressive 
reduction in airflow. Development of these symptoms is associated with chronic 
exposure to noxious particles or gas, most commonly from tobacco smoking, which 
triggers abnormal inflammation in the lung. Consistent with this increased 
inflammatory burden, oxidative stress has been demonstrated in COPD patients, 
largely through determination of antioxidant and oxidative damage marker 
concentrations in exhaled breath condensate and induced sputum. Whilst these 
samples are easier to obtain than bronchoscopy-based lavage, there remains 
contention concerning how well they reflect the distal airway lining fluids and hence 
the actual disease state. In the present study, I therefore investigated the oxidative 
status of bronchoalveolar lavage fluids (BAL) from well defined groups of COPD 
patients; current and ex-smoker, as well as aged and smoking matched controls. In 
addition, as COPD has been argued to be a disease of accelerated ageing a group of 
young controls was included to examine the extent to which age influences the 
endpoints under consideration. 
 
Chapter 2: In the first experimental chapter I investigated the evidence for oxidative 
stress in the airways of subjects with COPD (smokers and ex-smoking) relative to age 
and smoking matched controls. In addition, young healthy non-smokers and mild 
asthmatics were included to investigate the impact of age on the examined 
parameters, as well as to compare antioxidant defences in the context of acute and 
chronic inflammation. In this chapter, I examined respiratory tract lining fluid 
antioxidants sampled in bronchoalveolar lavage fluid, focusing on low molecular 
weight antioxidants (glutathione, urate and ascorbate) and their oxidation products 
(glutathione disulphide and dehydroascorbate), the lipid oxidation product 4-hydroxy-
2-nonenal and the endogenous metal transport and storage proteins (transferrin, 
lactoferrin and ferritin). I found no simple evidence of oxidative stress related to the 
xiv 
 
presence of COPD, but observed smoking-related increases in glutathione and ferritin, 
and age-related increases in dehydroascorbate and 4-hydroxy-2-nonenal.  
 
Chapter 3: In the second experimental chapter I attempted to understand the age-
related increase in oxidation markers observed in the lavage samples from chapter 2. 
Pro-oxidant metal (Fe and Cu) concentrations were determined in the lavage samples 
from each of the groups used in chapter 2, by inductively coupled plasma mass 
spectrometry and a novel assay was developed based on metal catalysed oxidation of 
ascorbate, to provide a functional measure of the catalytically active metal pools at 
the surface of the lung. Through the use of selective chelators, the relative 
contribution of labile Fe and Cu pools was assessed. In this chapter I was able to 
demonstrate that respiratory tract lining fluid Cu concentrations increased with age, in 
parallel to an increased pro-oxidant status in the RTLF and evidence of a non-
transferrin bound Fe pool. These indices appeared related to the concentration of 
oxidation markers reported in chapter 2. 
 
Chapter 4: Given the failure to detect increases in gross measures of oxidative damage 
in COPD patients, it was decided that the focus should shift toward a more refined 
focus on specific oxidations to proteins functionally related to the pathogenesis of the 
disease. I decided based on the pre-existing literature, that there was merit in focusing 
on 4-hydroxy-2-nonenal adduction of proteins. To achieve this, I attempted to develop 
a mass spectrometry-based method for the identification of adducted proteins and 
protein sequences. This was an ambitious undertaking and unfortunately I was only 
able to take these experiments so far, but at least was able to demonstrate the 
feasibility of the method. The methodology developed was sufficiently promising to 
warrant further investigation after the completion of my PhD.  
 
Short conclusion: In this study I was unable to demonstrate any evidence of oxidative 
stress in the airways of patients with COPD, either ex- or current smokers. I did 
however, observe evidence of increased oxidative damage, catalytic metal (Cu) 
concentrations and pro-oxidant metal activities (Cu and non-transferrin bound Fe) 
with age. At the end of this thesis, despite the attempt to investigate markers of 
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oxidative stress in a relevant compartment (the distal lung) and in carefully controlled 
































4-HNE   4-hydroxy-2-nonenal 
AA   Ascorbic acid 
AAT   α1-antitrypsin 
ACN    Acetonitrile 
AGC   Automatic Gain Control 
AH2   Ascorbate / Ascorbic acid 
AP-1   Activator protein-1 
ASCII    American Standard Code for Information Interchange 
AT   Angiotensin 
BAL   Bronchoalveolar lavage 
BCA   Bicinchoninic acid 
BHT   Butylated hydroxytoluene 
BSA   Bovine Serum Albumin 
BW   Bronchial wash 
CID   Collision-Induced Dissociation 
COPD   Chronic Obstructive Pulmonary Disease / Disorder  
CT   Computed tomography 
D3-4-HNE  Deuterated 4-hydroxy-2-nonenal 
DEE   Diethylether 
DEP   Diesel exhaust particles 
DES   Desferal (deferoxamine mesylate) 
DNA   Deoxyribonucleic acid 
DNPH   Dinitrophenylhydrazine 
DTNB   5,5’-dithiobis(2-nitrobenzoic acid) 
DTPA   Diethylene triamine pentaacetic acid 
DTT   Dithiothreitol 
ECD   Electron-Capture Dissociation 
ECSOD   Extra-cellular superoxide dismutase 
EDTA   Ethylenediaminetetraacetic acid 
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ELISA   Enzyme-linked immunosorbent assay 
ESI   Electrospray ionisation 
ETD   Electron-Transfer Dissociation 
FEV1   Forced Expiratory Volume in one second 
FVC   Forced Vital Capacity 
GC   Gas chromatography 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
GOLD   Global Initiative for Chronic Obstructive Lung Disease 
GPx   Glutathione peroxidase 
GSH   Glutathione (reduced) 
GSSG   Glutathione disulphide (oxidised glutathione) 
GSTM1  Glutathione-S-transferase 1 
HDAC-2  Histone deacetylase II 
HO-1   Heme oxygenase 
IAM   Iodoacetamide 
ICAM   Intercellular adhesion molecule 
IgA   Immunoglobulin A 
IgG   Immunoglobulin G 
IL   Interleukin 
INOS   Inducible nitric oxide synthase 
LC   Liquid chromatography 
LRTI   Lower respiratory tract infections 
LTB4   Leukotriene B4 
MALDI-TOF  Matrix Assisted Laser Desorption - Time of Flight 
MCPBA  3-chloroperoxybenzoic acid 
MMP   Matrix metalloprotease 
MPA   Metaphosphoric acid 
MS   Mass spectrometry 
MW   Molecular weight 
NAB   N-nitrosoanabasine 
NAT   N-nitrosoanatabine 
NF-κB   Nuclear factor-κB 
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NMR   Nuclear Magnetic Resonance spectroscopy 
NNK   4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
NNN   N-nitrosonornicotine 
Nrf2   Nuclear erythroid-related factor-2 
NT   Neurotensin 
NTA   Nitrilotriacetate 
PBS   Phosphate buffer solution 
PMN   Polymorphonuclear leukocytes 
PTM   Post-translational modification 
RNS   Reactive nitrogen species 
ROS   Reactive oxygen species 
RTLF   Respiratory tract lining fluid 
SHS   Second hand smoke 
SIRT   Sirtuin 
SMOC2  Secreted modular calcium-binding protein 2 
SNP   Single nucleotide polymorphism 
SRM   Selected reaction monitoring 
TCEP   Tris(2-carboxyethyl)phosphine 
TFE   Trifluoroethanol 
(TGF)-β  Transforming growth factor 
TIC   Total ion count 
TMS   Tetramethylsilane 
TNF-α   Tumour necrosis factor-α 
UA   Urate / Uric acid 
UHPLC   Ultra high performance liquid chromatography 
UV   Ultraviolet 
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Chapter 1:  
Introduction 
 
1.1 Definition and diagnosis of Chronic Obstructive Pulmonary Disease  
Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease state 
characterized by chronic, progressive airflow limitation, which is not fully reversible 
(through bronchodilator treatment) and exhibits an abnormal inflammatory response 
of the lungs to irritant stimuli. In addition to its pulmonary pathology, it is also 
associated with significant extra-pulmonary effects and important co-morbidities 
(GOLD 2008). This definition can be further expanded to include a pathophysiologic 
spectrum of diseases including chronic bronchitis, emphysema and small airways 
disease. Symptomatically COPD is associated with chronic cough, sputum production, 
wheezing and shortness of breath, related to underlying airway pathology.  
 
The diagnosis of COPD is confirmed by spirometry, based on Forced Vital 
Capacity (FVC) and the Forced Expiratory Volume in one second (FEV1). To distinguish 
between asthma and COPD a bronchodilator test is performed with lung function 
commonly measured following inhalation of Salbutamol. In COPD a bronchodilator 
response is often absent. The 2006 GOLD (Global Initiative for Chronic Obstructive 
Lung Disease) report classified COPD into four main diagnostic stages from mild to 
very severe, reflecting disease progression/severity and based on post-bronchodilator 
spirometry (Table 1.1). As a normal function of ageing, lung volumes are expressed as 
FEV1/FVC ratio decreases, so to avoid the problematic fixed ratio of 0.7 the values 
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obtained are related to population reference values to prevent an over-diagnosis of 
COPD. These functional cut-offs, however, are not clinically validated in the absence of 
additional presenting symptoms such as general breathlessness and reduced exercise 
capacity (Calverley, 2004). The spirometry tests are however useful as a guide to 
disease progression and in assessing the effectiveness of disease management. 
 
1.2 Prevalence, morbidity and mortality 
 COPD is a major cause of premature mortality worldwide, with current 
estimates indicating that 80 million individuals suffer from moderate to severe disease 
globally (Rabe, 2007). Placed as the sixth most prevalent cause of death in 1990 
(Raherison, 2009), The World Health Organization (WHO) issued statistics in 2004 
placing it as the fourth leading cause of mortality,  with an estimated 3.02 million 
deaths attributable to this condition (WHO, 2008). With an increasing mortality rate, 
largely related to rates of cigarette and biomass smoke exposure, it is estimated that 
this spectrum of obstructive pulmonary disorders will become the third most common 
cause of chronic disability and death by the year 2020, following ischaemic heart 
disease and stroke (Gudmundsson, 2006).  
 







% predicted FEV1 
 





Stage II: Moderate <0.7 ≤50-80% 
Stage III: Severe <0.7 ≤30-50% 
Stage IV: Very Severe <0.7 ≤30-50%  plus chronic 
respiratory failure 
FEV1 = forced expiratory volume in 1 second and FVC = forced vital capacity.  
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 In the UK alone, approximately 900,000 individuals have been diagnosed with 
COPD. This does not take into account the acknowledged under-diagnosis of this 
condition, with the actual figure estimated to be in excess of 1.5 million (Devereux, 
2006). Often escaping diagnosis until clinically advanced, death often occurs from 
secondary causes such as heart failure (Kon, 2008), resulting in COPD not being 
detailed as the cause of death. This misclassification of the precipitating cause of 
death also contributes toward the lack of public awareness of this condition, with 
almost half of all newly diagnosed patients unaware of the disease. COPD is also 
associated with other co-morbidities such as diabetes mellitus, malnutrition, 
depression, osteoporosis, gastro-oesophageal reflux, normocytic anaemia and lung 
cancer (Barnes, 2009), which mask its true prevalence in official statistics. This issue is 
further exacerbated by methodological issues relating to the absence of standardised 
spirometry protocols between countries for COPD diagnosis (Halbert, 2006). Even with 
these limitations it is evident that the prevalence of COPD is increasing, and that it is 
appreciably higher in current and ex-smokers over 40 years of age (Rabe, 2007).  
 
 Based on the current literature, global COPD mortality attributable to cigarette 
smoking is estimated at 54% for men and 24% for women, aged between 30-69 years 
(Ezzati, 2003). For those aged 70 or older, the estimates are similar; 52% and 19% for 
men and women respectively. Cigarette smoking makes a substantially greater 
contribution to COPD rates in industrialised countries; 84% for men and 62% for 
women aged 30-69. Studies carried out in developed countries have shown that the 
prevalence of COPD is almost equal between the two sexes which is believed to be as 
a direct consequence of increased tobacco smoking amongst women in general since 
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the 1960’s (Rabe, 2007). Using primary health care data from the UK covering the 
period 1990 to 1997, Soriano et al. (2000) found that whilst more men were 
diagnosed with COPD than women, the annual prevalence rates for women had 
increased from 0.80% to 1.36%. By the mid 1990’s, the prevalence of COPD in women 
aged 20-44 years had surpassed the figure for men; prevalence for women between 
45-65 years was broadly equivalent to the male rates.  
 
1.3 Aetiology  
 In the developed world over 90% of patients with COPD are reported to have a 
history of smoking (Lokke, 2006). Correspondingly, the occurrence of COPD among 
those who have never smoked is estimated to be between 3-15% in various 
populations (Buist, 2007; Menezes, 2005), suggesting that other inhaled irritants can 
play a role in the aetiology of obstructive airway disease. Globally however, as 
illustrated in the previous section the exposure of individuals to indoor air pollution 
derived from the combustion of biofuels for space heating and cooking in poorly 
ventilated housing, is also a significant contributor to the global burden of COPD. The 
role of cigarette smoking and occupational/environmental exposure to inhaled 
irritants will be discussed in the following sections. 
 
1.3.1 Tobacco smoking 
Tobacco smoke can be divided into “sidestream” and “mainstream” smoke, 
with the former attributable to the burning tip of a cigarette and the latter the smoke 
inhaled through the mouth piece. Cigarette smoke consists of a highly complex 
combustion-derived aerosol, including 95 known carcinogenic compounds (Fowles, 
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2000). The full toxicological profile of cigarette smoke has not been fully 
characterised, with data only available for a fraction of its constituents. The gaseous 
phase contains; carbon monoxide, ammonia, dimethylnitrosamine, formaldehyde, 
hydrogen cyanide and acrolein; whilst the particulate phase consists of metals, 
nicotine, tar, benzene, benzo[a]pyrene, nitrosamine, minor alkaloids, N-nitroso 
derivatives and polycyclic aromatic hydrocarbons (PAHs) (Cohen, 2007). A non-
exhaustive list of the compounds associated with unburnt tobacco is presented in 
Table 1.2.  
 
The role of cigarette exposure in COPD is well illustrated by the Fletcher curve 
(Figure 1.1), which illustrates a longitudinal series of lung function measurements in a 
cohort of men, including current, ex- and never smokers. The study by Fletcher (1977) 
demonstrated that age-related declines in lung function were accelerated in cigarette 
smokers, with clear differences between individuals in relation to their susceptibility 
to this response. Smoking cessation in this cohort of smokers was found to reduce the 
rate of functional decline to that seen in healthy non-smokers, but without restoration 
of the long-term loss in lung function. 
 
1.3.2 Second-hand smoke exposure and the risk of COPD 
The noxious irritants within tobacco smoke have also been shown to adversely 
affect the pulmonary function of individuals through second-hand smoke (SHS) 
exposure (Eisner, 2005; Jayet, 2005; Leuenberger, 1994). Studies have found that 
cumulative lifetime exposure to SHS, both at home and at work (Yin, 2007; Sezer, 
2006) presents a greater risk for the development of COPD in later life. Consistent 
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with SHS having a detrimental effect on the lungs of non-smokers, worldwide studies 
on bar and hospitality workers, who have traditionally experienced high SHS 
exposures, have shown a significant reduction in cough and expectorate following the 
introduction of non-smoking laws in public buildings and workplaces (Menzies, 2006; 





















Table 1.2: Representative cigarette constituents (non brand specific) and their 
approximate weight ranges per cigarette. 
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NNN (N-nitrosonornicotine); NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone); 
NAT (N-nitrosoanatabine); NAB (N-nitrosoanabasine). 
 
1.3.3 Outdoor air pollution (traffic and other sources) 
Outdoor air pollutants are derived from a variety of combustion sources 
including industrial, traffic and heating sources. Unlike other risk factors, exposure to 
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air pollution is continuous, occurring throughout our lifetime. Weather conditions and 
changes in pollutant emissions result in variable daily exposures over time, with strong 
evidence indicating a correlation with acute exacerbations of COPD (Sunyer, 2001).  
 
 
Figure 1.1: The Fletcher curve relating age related declines in lung function to 
cigarette smoking and illustrating the beneficial role of smoking cessation. The 
yellow/orange/red shaded areas illustrate how reductions in lung capacity are related 
to the onset of COPD symptoms. 
 
Causal relationships between outdoor pollutant concentrations (including 
nitrogen dioxide, ozone and inhalable particulate matter, i.e. with a median 
aerodynamic diameter of <10, or 2.5µm, and decreased lung function have been 
shown in numerous cross-sectional studies (Holguin, 2007; Hogervorst, 2006). In 
support of a causal link between air pollution and poor lung function, studies have 
demonstrated improvements in respiratory health following reduction in ambient 
pollutant concentrations (particularly in ambient particulate matter) in cross-sectional 
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analyses (Sugiri, 2006; Frye, 2003). A further study demonstrated greater black carbon 
content (as a biomarker of exposure to particulate matter from fossil combustion) in 
sputum macrophages from individuals living near traffic and demonstrated that high 
black carbon loadings were associated with reduced FEV1 (Kulkarni, 2006). Several 
longitudinal studies in children have also produced evidence that traffic derived 
pollutants may retard the lung development (Gauderman, 2007; Gauderman, 2000; 
Peters, 1999). Other large-scale cohort studies performed in Mexico and Europe have 
also associated impaired lung growth with chronic exposure to ambient particulate 
matter and nitrogen dioxide (a marker of traffic-related pollution) (Rojas-Martinez, 
2007; Ihorst, 2004; Frischer, 1999). Whilst there is clear evidence from numerous 
cohort studies of a link between air pollutant exposure and impaired lung function 
(Downs, 2007; Schikowski, 2005) and retarded lung growth (Gauderman, 2007; Rojas-
Martinez, 2007; Horak, 2002), at this time there is no definitive evidence linking 
outdoor pollutant exposure to the development of COPD.  
 
1.3.4 Occupational exposure and the risk of COPD 
As many workers with COPD have concurrent exposure to direct and indirect 
cigarette smoke, the role of occupational exposures in the aetiology of the disease is 
often difficult to distinguish from other risk factors. In addition, many studies are 
limited due to the difficultly in tracking job-leavers which effectively results in the 
under estimation of the role of these exposures. Nevertheless, a considerable body of 
literature exists linking specific occupational exposures to the development of COPD 
including: in miners of coal (Seixas, 1993; Attfield, 1992) and hard-rock minerals 
(Hnizdo, 1990; Holman, 1987), as well as tunnel (Ulvestad, 2001), concrete-
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manufacturing (Meijer, 2001) and non-mining workers (Kauffmann, 1982). 
Toxicological studies also support the potential linkage between many of these 
exposure scenarios with lung pathology consistent with the induction of COPD.  
Agents such as endotoxin, sulphur dioxide, mineral dusts and vanadium have been 
shown to induce pathologically defined chronic bronchitis in animal models (Bonner, 
2000; Harkema, 1993) and are known to be associated with chronic bronchitis in 
humans. Additionally, cadmium, coal and silica dusts (Shapiro, 2000) have been shown 
to induce emphysema in experimental animal models.  
 
1.3.5 Biomass smoke and the risk of COPD 
A significant proportion of COPD cases have been identified amongst never-
smokers in developing countries, particularly in women who utilise open-fire stoves 
indoors for cooking and space heating, often in poorly ventilated homes. The fuel 
typically used in such stoves largely consists of wood, animal dung or crop residues 
collectively referred to as biomass. The combustion of such biomass results in 
particulate emissions far exceeding the concentrations observed in outdoor air (Smith, 
1987). In the developing world, such exposure to biomass smoke begins in utero and 
spans an entire lifetime. The exposure during infancy has been shown to impair 
pulmonary function and defence, leading to the increased risk of developing 
respiratory infections and tuberculosis (Fullerton, 2008; Mudway, 2005; Smith, 2000). 
Numerous case-control and cross-sectional studies have demonstrated chronic 
bronchitis and/or airflow obstruction associated with biomass exposure in developing 
countries (Orozco-Levi, 2006; Kiraz, 2003). In a Mexican study a 4% decrease in 
FEV1/FVC was observed in female never-smokers who cooked regularly with indoor 
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open-fire stoves (Regalado, 2006). A further study from Colombia demonstrated a 
greater risk of COPD development (defined by spirometry as per the GOLD criteria) 
upon use of biomass stoves for 10 or more years (Caballero, 2008). Countries such as 
China and India also use soft coal or “smoky coal” as fuel for domestic use, which is 
more polluting than conventional biomass fuels. The use of soft coal has been 
associated with COPD diagnosis in China (Zhou, 1995) and improved indoor ventilation 
with reduced incidents of COPD diagnosis (Chapman, 2005).  
 
1.3.6 Chronic asthma and COPD 
The development of asthma in later adulthood (≥65 years of age) is associated 
with less airway obstruction than that observed in subjects with early-onset asthma 
(Braman, 1991). This suggests a causal linkage between the effects of asthma and 
chronic airway obstruction; with prolonged asthma sufferers displaying more severe 
airway obstruction. Computed tomography (CT) of the thoracic region carried out on 
adults diagnosed with asthma and irreversible airway obstruction combined, have 
revealed a thickening of the bronchial wall (Vignola, 2004). Such scans also observed 
emphysema in some non-smoking asthmatic patients, in particular, those who had 
suffered long-standing asthma, irreversible airway obstruction and asthma of a 
greater severity (Kondoh, 1990). 
 
As a normal function of ageing, lung capacity generally declines at 
approximately 20 ml/yr from the age of 25 onwards (Lange, 1998). The Copenhagen 
City Heart Study revealed an association between asthma and an accelerated decline 
in pulmonary function in both smoking and non-smoking subjects (Ulrik, 1994). Other 
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factors contributing towards an excess decline in pulmonary function for those with 
asthma included: low FEV1 (Ulrik, 1992), decreased reversibility to β2-agonists (Ulrik, 
1999), increased severity in bronchial hyper-responsiveness (Van Schayck, 1991), 
excess mucus production (Lange, 1998), frequent exacerbations (Bai, 2007) and being 
male (Ulrik, 1994). In addition, evidence suggests lung function impairment observed 
in adulthood is closely linked with childhood asthma (Tennant, 2008). In the Tucson 
study, asthmatic phenotypes such as persistent wheezing observed in 3-6 year old 
children was associated with a lower FEV1 in 16 year olds (early adulthood) (Morgan, 
2005). 
 
In summary, chronic airway obstruction and accelerated loss of pulmonary 
function are associated with chronic asthma. As airway obstruction can lead directly to 
the progression to COPD, asthma (both in the presence and absence of other risk 
factors) can therefore be assumed as a predisposition to the development of COPD. It 
is not confirmed, however, whether asthmatic adults meet COPD criterion such as the 
GOLD spirometric values or are similar or distinct in phenotype and pathology from 
clinically encountered COPD. Asthma, although an allergic airway disease, may display 
an increased neutrophil infiltration into the airways related to disease severity, which 
is more aligned with COPD (Wenzel, 1999). In order to establish a definitive causal link, 
further studies are required to elucidate the sub-phenotypes of COPD.  
 
1.3.7 Tuberculosis and the risk of COPD 
Tuberculosis has been strongly associated with a greater risk of developing 
COPD (Caballero, 2008; Menezes, 2007). An increased risk of tuberculosis has also 
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been linked with exposure to cigarette (Lowe, 1956) and biomass smoke (Pérez-
Padilla, 2001; Mishra, 1999), illustrating the complex interactions between smoke 
inhalation and altered lung function.  
 
1.3.8 Genetic factors and COPD 
Whilst the development of COPD has been associated with exposure to 
tobacco smoke, only around 15% of smokers develop the disease (ATS, 1996). Thus an 
individual’s genetic background is clearly important in determining whether the 
disease will occur and subsequently the rate at which it progresses, and/or responds 
to treatment (Silverman, 2006; Young, 2006). The first and only proven genetic risk 
factor for COPD is the α1-antitrypsin gene (SERPINA1), which is estimated to be 
present in 1% of individuals with COPD (DeMeo, 2006). This gene, SERPINA1, located 
on chromosome 14 encodes a serine protease inhibitor which provides protection 
against proteolytic damage in the lung (Ekeowa, 2011). Deficiency in α1-antitrypsin 
(AAT) is an established genetic risk factor for COPD in non-smoking individuals and is 
an autosomal recessive-inherited deficiency (Bossé, 2009). Two common alleles (S and 
Z) are associated with AAT deficiency, with individuals homozygous for the Z allele at 
high risk of COPD. Recently, evidence has emerged that the MZ genotype is also 
associated with lung function decline in the general population and smokers (Dahl, 
2002; Sandford, 2001), as well as airway obstruction in COPD patients (Sandford, 





Other rare genetic disorders implicated in the possible pathogenesis of COPD 
in non-smokers include Cutis Laxa, a rare hereditary disorder of the elastic fibres, 
caused by mutations in the elastin gene (Rodriguez-Revenga, 2004). This condition has 
been linked with emphysema during childhood and adolescence in non-smoking 
subjects, as well as in those who smoke (Van Maldergem, 1988; Turner-Stokes, 1983). 
Marfan syndrome (Wood, 1984), Ehlers-Danlos syndrome (Dowton, 1996) and Birt-
Hogg-Dube syndrome (Ayo, 2007) have also been proposed as possible risk factors for 
the development of COPD, however, no definitive association has been observed to 
date.  
 
A number of linkage studies have been performed to identify genes involved in 
COPD and impaired lung function. Amongst these is the Framingham study, which 
employed >300 families and identified a region on chromosome 6q as being 
potentially related to an increased risk of COPD (Joost, 2002). In addition, a number of 
chromosomal regions influencing lung function (FEV1 and FVC) were also identified. 
One candidate gene on chromosome 6, SMOC2 (secreted modular calcium-binding 
protein 2), which contains a serine protease inhibitor domain has been studied in 
detail, with significant associations noted between a number of single-nucleotide 
polymorphisms (SNPs) and lung function in never-smokers (Wilk, 2007). A smaller 
linkage study of 72 families found evidence for linkage between mild obstructive lung 
disease in smokers with a region on chromosome 12 containing microsomal 




Alternative approaches to gene identification include candidate gene 
association studies. A number of candidate genes involved in inflammation, immune 
response, antioxidant defence, protease/anti-protease imbalance and xenobiotic 
metabolism have been investigated in the quest to elucidate the genetic determinants 
of COPD, along with related phenotypes of the disease. Around 57 genes have been 
reported as having a positive association with COPD and lung function (Bossé, 2009); 
however, there are notable disparities and inconsistencies in the results (Hersh, 2005). 
Higher SERPINE2 expression has been reported in subjects with moderate to severe 
emphysema, independent of α1-antitrypsin deficiency, compared with controls 
(DeMeo, 2006) and five significant SNPs have been reported in this gene related to a 
range of COPD phenotypes (DeMeo, 2006; Zhu, 2007). Similarly, a study by Joos et al. 
(2002) associated various SNPs in the MMP1 gene and promoter region and MMP12 
to rapid lung function decline in a group of 284 smokers.  
 
The low activity haplotype (His113–His139) in the gene for phase two 
xenobiotic enzyme microsomal epoxide has also been identified as being related to 
rapid lung function decline in smokers (Sandford, 2001). In addition, possession of this 
haplotype combined with a family history of COPD was associated with a six-fold 
increase in the risk of enhanced lung function decline in these smokers (Sandford, 
2001). The His113 genotype in this gene has also been associated with COPD 
(Yoshikawa, 2000; Cheng, 2004). 
 
In terms of inflammatory genes, the Q551R genotype in the gene for the IL-4 
receptor (IL4RA, 5q31) has been associated with rapid decline in lung function in 
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smokers (He, 2003), as have the IL1β/IL1RN haplotypes (Joos, 2002). Specifically with 
respect to COPD, medium sized (53-182 patients versus 65-454 matched controls) 
association studies have shown an increased frequency in the IL-13 promoter 
polymorphism C-1055T  (Van der Pouw, 2002) and IL-8RA G2044A SNPs (Stemmler, 
2005) in patients than controls.  
 
A recent genome-wide association study, examining 823 COPD subjects 
(current and ex-smoking) with 810 smoking control subjects,  identified two single-
nucleotide polymorphisms at the α-nicotinic acetylcholine receptor (CHRNA 3/5) as 
being associated with COPD (Pillai, 2009). The CHRNA 3/5 locus has previously been 
associated with increased smoking intensity, increased airflow obstruction and 
emphysema in COPD patients. Similarly, this locus has been identified a genetic risk 
factor for nicotine dependence and carcinoma of the lung (Spitz, 2008). Pillai et al. 
(2009) also identified a consistent replication of the hedgehog interacting protein 
(HHIP) locus and FAM13A locus on chromosome 4, although this was not shown to be 
significant genome-wide (Boezen, 2009). The HHIP locus has also been associated with 
both the systemic components of COPD and the frequency of COPD exacerbations, 
whilst the FAM13A locus is associated with airflow obstruction in COPD patients.  
 
In summary, AAT deficiency and Cutis Laxa have been clearly associated with 
the development of COPD in non-smokers, whilst CHRNA 3/5, HHIP and FAM13A have 
been unequivocally associated with COPD amongst smokers (Pillai, 2010). These 
genetic epidemiology studies have confirmed the important influence of genetics in 
the development of COPD.  Nonetheless, inconsistencies remain in the results of these 
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genetic association studies highlighting the need for further work to identify genetic 
variations causally linked to the development of COPD. 
 
1.3.9 Diet and the risk of COPD 
Dietary intake may affect pulmonary development, maintenance, function and 
response to injury (Aniwidyaningsih, 2008; Romieu, 2001). As an imbalance between 
oxidant production and endogenous antioxidant concentrations has been argued to 
predispose individuals to developing COPD, one might contend that a diet rich in 
antioxidants may proffer a protective defence against airway disease characterised by 
chronic and/or acute inflammation (Romieu, 2001).  
 
A considerable body of evidence has demonstrated the beneficial effects of 
vitamin C on pulmonary function, with diets rich in this antioxidant being associated 
with greater FEV1. Other antioxidants have also been evaluated and found to have 
beneficial effects on lung function, including: vitamin E, β-Carotene (Bonner, 2000; 
Churg, 1989), lutein (Harkema, 1993) and catechin (Shapiro, 2000). The importance of 
a good intake of dietary antioxidants was highlighted by a 25-year longitudinal 
investigation of 793 healthy middle-aged men in Zutphen, Netherlands, where an 
inverse relationship was established between the intake of fruits such as apples and 
pears and the incidence of chronic lung disease (Miedema, 1993). In contrast, 
randomised placebo-controlled trials using vitamin supplements C, E and β-carotene 
on a daily basis for 3 and 7 years have failed to demonstrate a positive impact upon 
the rate of decline of FEV1 (Heart Protection Study Collaborative Group, 2002; 
Rautalahti, 1997). The effects of omega-3 polyunsaturated fatty acids and fish intake 
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have not been definitively established and whilst some studies have shown protective 
effects (Schunemann, 2001; Chuwers, 1997), others have found none (Guenegou, 
2006; Kelly, 2003). Vitamin D has been positively associated with a potential effect on 
tissue remodelling and a higher mean FEV1 in relation to a higher intake (Black, 2005).  
 
In stark contrast, the intake of foods such as cured and processed meats has 
been shown to have deleterious effects (Varraso, 2007; Ricciardolo, 2006). Higher 
consumptions of such foods has been linked to lower FEV1 and incidence of COPD, 
although it has been noted that these individuals are more likely to smoke, either 
actively or passively, have a higher body mass index, have reduced physical activity 
and consume a higher calorie vitamin deficient diet (Jiang, 2008; Jiang, 2007).  
 
1.4 Pathology of COPD 
 The symptoms experienced by patients with COPD reflect long-term chronic 
remodelling of their airways due to their prolonged exposure to inhaled xenobiotics, 
particularly in the industrialised world to cigarette smoke. The recurrent cycles of 
injury, inflammation and repair over many years result in a range of pathologies 
leading to the development of mucus hyper-secretion, tissue destruction, and 
disruption to the normal repair and defence mechanisms. The results of these changes 
are increased airway resistance in small conducting airways, altered lung compliance, 
and the premature collapse of airways during expiration. The characteristic 




 1.4.1 Heterogeneity of COPD 
 As a condition, COPD encompasses several different diseases including chronic 
bronchitis, emphysema and small airways disease.  These will be considered in the 
proceeding sections with a focus on the underlying tissue pathology and its impact on 
lung function. It should be noted however, that there is considerable overlap between 
these conditions and it is often difficult to dissect out the relative contribution of 
chronic bronchitis and emphysema to the clinical presentation of the disease. In 
addition, there can be substantial overlap with other obstructive lung diseases. 
  
  Although a clinically separate entity, long-standing chronic asthma (non-atopic 
intrinsic asthma) that fails to respond to treatment and becomes relatively irreversible 
also contributes towards COPD and is often clinically indistinguishable, causing 
diagnostic uncertainty. Whilst asthma is generally characterised by variable airflow 
obstruction, this is generally reversible upon administration of inhaled steroids. In 
long-standing chronic asthma, extensive remodelling of the airway including 
hypertrophy of the bronchial smooth muscle as well as collagen deposition in the 
basement membrane and submucosa can result in a degree of fixed airflow 
obstruction (Bellamy and Booker, 2005). As a result, the airways become unable to 
fully bronchodilate, similar to the situation in COPD.  
 
1.4.2 Chronic bronchitis 
 Chronic bronchitis is classified as a chronic inflammation of the mucus 
membranes of the bronchi, associated with persistent cough and production of 
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sputum from the tracheobronchial tree for three or more consecutive months, over 
two successive years (Sethi, 1999). Clinically, as the condition worsens patients display 
a more chronic and persistent cough, exceptional dyspnoea and cyanosis. The 
presence of oedema, together with cyanosis secondary to cor pulmonale has resulted 
in the labelling of these patients as ‘blue bloaters’. 
 
 The major pathologic feature of bronchitis is an increase in the mucus 
secreting apparatus of the airways, characterised by hyperplasia and hypertrophy of 
mucus cells and an increased number of goblet cells in the bronchial epithelium. The 
resultant excess mucus production observed in bronchitis contributes towards a 
decline in lung function as it obstructs the upper airways. Notably, inflammatory cells 
in the airways of patients with chronic bronchitis have been shown to release serine 
proteases and reactive oxygen species that act as secretagogues for mucus production 
exacerbating airway obstruction further (Sommerhoff, 1990; Shao, 2004). This 
obstruction through the expansion in the mucus secretory apparatus is also 
exacerbated by airway oedema. Damage to the airway epithelium, both through direct 
interaction with the toxic components of cigarette smoke and collateral injury arising 
from airway inflammation, is also apparent, reflected by squamous metaplasia of the 
bronchial epithelium and thickening of the basement membrane. Loss of ciliated 
epithelial cells also impairs the mucociliary elevator, promoting lower respiratory tract 
infections (LRTI). This results in further injury with irreversible damage to the smaller 
peripheral airways, where narrowing and distortion are observed (Barnett, 2006). Not 
all individuals develop COPD following bronchitis; approximately 80% of smokers do 
not exhibit an accelerated decline in their lung functions and can be diagnosed as 
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having ‘simple bronchitis’ (Bellamy and Booker 2005). A generalised illustration of the 
major pathologic features of the airway in chronic bronchitis is presented in Figure 
1.2.  
 
Figure 1.2: Illustration of the typical airway morphology in chronic bronchitis. 




1.4.3 Small airways disease 
 Bronchiolitis reflects pathologic changes to the bronchioles of the small 
airways (<2mm diameter), and is long-established as being a major cause of the 
obstruction characteristic of COPD (Hogg, 1968). Small airway obstruction has been 
associated with a remodelling (fibrosis and limited smooth muscle hypertrophy) and a 
thickening of the airway wall, allied to dysfunction of mucociliary clearance 
mechanisms (Hogg, 2004; Bellamy and Booker, 2005). The basis for this pathologic 
tissue adaptation has been proposed to be related both to the ongoing inflammation 
in the small airways (Saetta, 1998), with increased release of transforming growth 




 Emphysema is defined as the abnormal and irreversible dilation of the 
terminal air spaces distal to the terminal bronchioles, accompanied by the destruction 
of their walls and loss of lung elasticity, in the absence of obvious fibrosis (Currie, 
2007). Patients are characterised by the presence of a non-productive cough, in 
contrast to chronic bronchitis, associated with exertional dyspnoea. Radiologically 
they demonstrate hyperinflation of the lung, characterised by a depressed diaphragm 
and a barrel chest. Due to the higher ventilation rate in these patients they are able to 
maintain blood oxygenation and are therefore referred to as ‘pink puffers’. It is a long-
term progressive disease, with the rate of functional decline and the extent of 
pulmonary injury associated with an individual’s smoking history. Approximately 40% 
of heavy smokers develop substantial emphysema (Hogg, 2004).  
  
 The protease-mediated destruction of alveolar walls in emphysema results in 
reduced maximal expiratory airflow via decreased elastic recoil. This occurs as a 
secondary consequence of the inflammation in the lung, due to the release of elastin, 
as well as by the apoptosis of endothelial cells and type I pneumocytes (Majo, 2001). 
The role of protease-antiprotease imbalance in the tissue destruction characteristic of 
emphysema is highlighted in subjects with α1-antitrypsin enzyme deficiency, who 
display emphysemic pathologies even in the absence of exposure to inhaled 
xenobiotics, although this condition contributes toward just 2% of premature COPD.
  
 Morphologically, emphysema is classified according to the location of the 
lesions within the acinus: panacinar (panlobular) or centriacinar (centrilobular) as 
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illustrated in Figure 1.3. The former classification is in reference to the mid-to-lower 
half of the lungs where distension and destruction are seen; the latter in reference to 
the upper lobes in the apex region of the lungs, where the respiratory bronchioles are 
damaged. In addition, a third classification exists, localised or paraseptal emphysema, 
in which the injury to the acinus occurs sporadically throughout the lung, with the 
remainder of the pulmonary parenchyma remaining largely unaffected. The lesions 
are often located at the apex of the upper lobes, where their progression can result in 
the formation of bulla; large areas of destruction. 
 
1.4.5 Co-morbidities 
 It is now widely accepted that COPD is a systemic disease and that its 
morbidity and mortality is strongly related to co-morbid conditions (Sinden, 2010). For 
example, it is well-established that low FEV1 is a risk factor for cardiovascular diseases 
and events and that chronic bronchitis can result in cor pulmonale (Sin, 2005). In 
addition to the established link with cardiovascular disease (Sin, 2005), associations 
have also been noted with lung cancer (Mannino, 2003), obesity and exercise 
intolerance (Sundh, 2011), diabetes (Song, 2010), osteoporosis (Dam, 2010), and 
anxiety/depression (Eisner, 2010). Mechanistically, presence of systemic inflammation 
in COPD provides a link between the pulmonary manifestations of COPD and the 
extra-pulmonary complications of this disease. This systemic inflammation has been 
hypothesised to reflect 'overspill' of inflammatory mediators produced in the lung into 







Figure 1.3: Morphologic features of emphysema. The upper panel illustrates a normal 
acinus distal to the terminal bronchiole, with the lower left and right hand panels 
demonstrating the sites of injury associated with centrilobular (injury to the 
respiratory bronchioles) and panacinar emphysema (affecting the whole acinus). 
Modified from a figure in Rubin’s “Essentials of Pathology” (Rubin, 2009). 
 
1.5 Mechanisms of injury in COPD 
 The pathologic features of COPD, and the characteristic remodelling of the 
airway leading to the irreversible obstruction, reflect the chronic impact of recurrent 
episodes of inflammation on the lung. The following sections will review three key 
areas that have been related to the aetiology and progression of COPD: pulmonary 
and extra-pulmonary inflammation, oxidative stress and protease/anti-protease 
imbalance. Each of these processes are inter-related and all contribute significantly to 
the evolution of chronic bronchitis and emphysema. 
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1.5.1 Neutrophilic inflammation in COPD 
 COPD is characterised by a chronic inflammation of the small airways and lung 
parenchyma, with elevated numbers of macrophages, neutrophils and T lymphocytes 
observed (Barnes, 2003). The role of neutrophils has been highlighted by increased 
cell numbers, as well as enhanced concentrations of neutrophil degranulation 
products (such as elastase and proteinase-3) in lavage samples obtained from COPD 
patients relative to age-matched controls (Lacoste, 1993; Linden, 1993). Consistent 
with these findings, increased concentrations of  neutrophil chemoattractants (TNF-α, 
IL-8 and IL-6) have been reported in induced sputum samples from patients with 
COPD, with their levels seemingly related to the degree of obstruction (Hacievliyagil, 
2006). Significantly, the number of neutrophils in BAL fluid and sputum appears to 
increase as FEV1 declines (Di Stefano, 1998; Stanescu, 1996) suggesting a link between 
neutrophilia and airflow limitation. In support of this contention, increased 
submucosal neutrophil numbers have been reported in severe COPD relative to 
smoking controls (Di Stefano, 2001), and increased neutrophilic inflammation has 
been observed during COPD exacerbations, associated with increased concentrations 
of LTB4 (Sapey, 2006), TNF-α, GM-CSF and neutrophil elastase (Fujimoto, 2005).  
 
1.5.2 The role of airway macrophages in COPD 
Macrophages play a central coordinating role in the pathophysiology of COPD 
with evidence of increased numbers in the bronchial submucosa (Di Stefano, 1996; 
Saetta, 1993), bronchial glands (Saetta, 1998) and small airway epithelium (Turato, 
2002) of COPD patients, and an apparent relationship between their number and the 
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extent of tissue destruction (Finkelstein, 1995) and disease severity (Russell, 2002). 
Their role in the aetiology of the condition has been inferred from the observation of 
increased numbers of macrophages in the respiratory bronchioles of the autopsied 
lungs of young accident victims, who were known smokers (Niewoehner, 1974). 
Macrophages release a number of compounds including inflammatory cytokines, 
reactive oxygen species, chemotactic factors, mucus gland activators, extracellular 
matrix proteins and a variety of matrix metalloproteases such as MMP-1 (Interstitial 
collagenase), MMP-2 (Gelatinase-A), MMP-7 (Matrilysin), MMP-9 (Gelatinase-B) and 
MMP-12 (Macrophage metalloelastase) (O’Donnell, 2006; Montano, 2004), capable of 
degrading a similar spectrum of proteins to those targeted by the neutrophilic neutral 
proteases (Neutrophil elastase, Cathepsin G, Proteinase-3, Lysozyme, Collagenase and 
Gelatinase) (Tetley, 1993) and therefore potentially relevant to the injury profile 
observed in COPD (Kumagai, 1999). Whilst the potential to induce mucus 
hypersecretion exists, through the secretagogue activity of products such as 
leukotriene B4 (LTB4) and interleukin 1 (IL-1), the main focus on the role of 
macrophages in COPD and specifically emphysema, has centred on their capacity to 
degrade the extracellular matrix. In vitro studies have shown increased concentrations 
of MMP-1 and MMP-9 in the cultured alveolar macrophages harvested from the lungs 
of COPD patients (Finlay, 1997), whilst in vivo studies have demonstrated increased 
MMP-2, MMP-9 (Segura-Valdez, 2000) and MMP-12 immunoreactivity in airway 





Macrophages harvested from the lungs of COPD patients have also been 
shown to have impaired phagocytosis, internalising fewer E. coli (Prieto, 2001) and H. 
Influenza (Berenson, 2006) than cells from relevant control groups. This deficiency is 
highly significant as almost half of all hospitalisations for exacerbations in COPD are 
related to bacterial infections, and bacterial colonisation of the lower airways is 
apparent in many patients (Weinreich, 2008). A recent study by Taylor et al. (2010) 
confirmed this reduced phagocytic activity to bacteria in monocyte derived 
macrophages from COPD patients and demonstrated that this was not related to 
patient medication, or the expressions of cell surface receptors involved in bacterial 
recognition: toll-like receptors 2 and 4, CD163, CD36 or the mannose receptor. 
 
1.5.3 Lymphocytes in COPD 
Airway lymphocytosis has also been reported in patients with COPD, with 
expansion of cytotoxic and helper T-cell numbers reported compared with both 
‘healthy’ age-matched smokers and never-smokers. Cytotoxic T-cells (CD8+) are 
understood to be the predominant subtype in COPD, with increased numbers 
observed in the large (O’Shaughnessy, 1997; Di Stefano, 2009) and small (Saetta, 
1998) airway mucosa, as well as the smooth muscle (Baraldo, 2004) and bronchial 
arteries (Saetta, 1999). Significantly, a relationship has been demonstrated between 
the number of airway CD8+ cells and lung function decline in COPD (O’Shaughnessy, 
1997; Saetta, 1998), suggesting a functional role for these cells in the pathogenesis of 
the disease. Whilst the key function of this cell is to defend against viruses, via 
cytolysis of infected cells or the induction of apoptosis, collateral tissue damage may 
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occur during periods of inflammation (Cannon, 1988). The mechanism of damage to 
the lung parenchyma has not been fully resolved, but likely involves direct injury 
related to the release of the lytic substances perforin and granzyme (Garcia-Sanz, 
1988). This contention found recent support with the observation that CD8+ cells 
recovered from the sputum of COPD patients showed increased perforin expression 
and cytotoxic activity compared with cells extracted from control subjects 
(Chrysofakis, 2004). This is consistent with the evidence of activation of CD8+ cells in 
both smokers and patients with COPD (Roos-Engstrand, 2009). 
 
Along with CD8+ cells, increased numbers of T-helper cells (CD4+) have been 
reported in the small airways of smokers with COPD (Turato, 2002). Increased CD4+ 
cell numbers have also been observed in the large airways of smoking COPD patients 
relative to ex-smokers (Lapperre, 2006). T-helper cells contribute in the inflammatory 
process through the production of a variety of pro-inflammatory mediators including; 
the Th1 cytokines, TNF-α, granulocyte-macrophage colony-stimulating factor (GM-
CSF), IFN-γ and IL-2, as well as members of the Th2 family (IL-4, IL-5 and IL-6). In 
addition to CD4+ and CD8+ cells, natural killer (NK) T lymphocytes have also been 
proposed as playing a role in COPD, with increased numbers reported in the large 
airway submucosa of COPD smokers, and their recruitment thought to occur as a 




1.5.4 Evidence of eosinophilic inflammation in COPD 
Eosinophilic inflammation, although usually considered a feature of asthma 
and often used as a distinguishing factor, has been demonstrated in patients with 
COPD. Induced sputum samples from patients with stable COPD have reportedly 
shown the presence of eosinophilic inflammation in 20-40% of cases (Brightling, 2005; 
Pizzichini, 1998), mildly overlapping with the 50% of cases noted for asthmatic 
patients (Douwes, 2002). The recruitment of such cells is selectively mediated by Th2 
cytokine-producing T cells and whilst the origin of eosinophilic inflammation in COPD 
is not well understood, it is assumed that its presence is indicative of an asthmatic 
component in fixed airway obstruction (Barnes, 1998). However, most studies on 
COPD patients exclude subjects with airflow obstruction and those with asthmatic 
features, thereby suggesting that eosinophil influx into the airway mucosa may be as a 
result of smoking and other mechanisms (Saha, 2006). Bronchial biopsies sampled 
from patients during acute COPD exacerbations have shown a 30-fold increase in 
eosinophil counts compared with samples from stable COPD patients (Saetta, 1994).  
 
1.5.5 Mast cells in COPD 
Mast cells have also been considered in the pathology of COPD, with greater 
numbers reported in smokers compared to ex-smokers (Mortaz, 2011). The activation 
of mast cells results in the coordinated release of pro-inflammatory mediators such as 
IL-4 and IL-3 which can influence the response of T cells, as well as histamine and 
cysteinyl leukotrienes which activate lung macrophages causing the generation of 
nitric oxide, lysosomal enzymes and cytokines. Mast cell-mediated injury in smokers 
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has been demonstrated in a number of studies; with histamine and tryptase 
concentrations elevated in bronchoalveolar lavage samples from smokers compared 
to healthy controls (Yamamoto, 1997; Kalenderian, 1988), and increased numbers of 
degranulated mast cells in lavage and bronchial tissue from smokers (He, 2004). 
Additionally, an increase in mast cell numbers has been observed in the airways and 
lung parenchyma of COPD patients in several human studies (Rahman, 2002). 
However, it remains unclear whether mast cells play a leading or supporting role in 
the pathogenesis of COPD. 
 
1.5.6 Protease/antiprotease imbalance 
The observation of emphysema in the lungs of non-smokers with α1-antitrypsin 
deficiency (Laurell, 1963), coupled with the induction of emphysemic pathology in the 
lungs of rats following the intra-tracheal instillation of the cysteine protease papain 
(Gross, 1965), led to the contention that protease-antiprotease imbalance in the lung 
may be critical to the development of COPD. It is hypothesised that an imbalance 
between proteases and antiproteases in the lungs may occur either as a consequence 
of increased release of proteases from activated neutrophils and macrophages 
recruited to the airway, inhibition, or down-regulation of their corresponding 
antiproteases, or a combination of both. A list of the major proteases and their 





 Acute exposure to cigarette smoke has been shown to result in the 
recruitment and activation of neutrophils in the lung, associated with the release of 
neutrophil elastase (see section 1.5.1). Under normal circumstances α1-antitrypsin 
(AAT) inhibits the activity of unbound neutrophil elastase and provides in excess of 
90% of the protection against this protease within the lower respiratory tract 
(Vogelmeier, 1996). Therefore in individuals deficient in α1-antitrypsin, tissue 
destruction as a result of unopposed proteolysis has been conjectured to be related to 
rapid lung function decline and the premature onset of COPD. Cigarette smoke-
induced injury can also be seen in COPD patients without AAT deficiency, with 
evidence that elastase activity in bronchoalveolar lavage samples from these subjects 
is positively correlated with both the degree of emphysema, as assessed by computed 
tomography and airway diffusing capacity (Fujita, 1999). In this study the extent of 
tissue destruction was also found to be negatively associated with lavage AAT activity, 
again supporting the importance of protease-antiprotease imbalance in COPD. 
Cigarette smoke itself has been reported to directly inhibit AAT activity (Gadek, 1979), 
though this finding remains contentious (Stone, 1983). In addition to this enhanced 
degradation of elastin, severe AAT deficiency results in Z antitrypsin polymerisation in 
the lung, which acts as a neutrophil chemoattractant, enhancing neutrophil 








Table 1.3: The main proteases associated with neutrophils and macrophages, with 












Neutrophils Neutrophil elastase 
 Cathepsin G Secretory leucoprotease inhibitor 








Macrophages Cathepsins A,B,E, K,L,S 
 Matrix metalloproteases (MMP-8, 
MMP-9, MMP-12) 
 





 The relationship between elastase-induced injury and the expression of AAT 
is also not straight forward as lavage from COPD patients with severe AAT deficiency 
was found to retain significant elastase inhibitory activity, implying that other 
antiproteases may compensate for the loss of AAT activity (Morrison, 1987). Further 
to this, once AAT is bound to elastin it no longer appears to be significantly inhibited 
(Morrison, 1990). 
 
It has also been argued that alveolar macrophages contribute to protease-
antiprotease imbalance in COPD. Airway macrophage numbers are elevated in COPD 
patients and are rich sources of MMPs (as reviewed in section 1.5.2), the excess 
production of which has been argued to contribute to the accelerated breakdown of 
connective tissue (Kim, 2004). In support of this view, increased elastolytic activity is 
evident from the cultured macrophages from COPD patients relative to healthy 
controls (Mulley, 1994). Increased expression of MMP1, 9 and 12 has been observed 
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in macrophages harvested from the lungs of COPD patients relative to controls (Finlay, 
1997; Molet, 2005), and increased MMP1, 2, 8 and 9 have been reported in airway 
biopsies by immunohistochemistry (Segura-Valdez, 2000). Importantly, alveolar 
macrophages from COPD patients have been shown to release less TIMP1 (tissue 
inhibitor of metalloproteinases and a major inhibitor of most MMPs) than controls 
(Pons, 2005), which would support an imbalance between protease and antiprotease 
activity in vivo. 
 
Human secretory leucoprotease inhibitor (SLPI) also serves to protect the lung 
from protease-induced degradation, in conjunction with its antimicrobial and anti-
inflammatory properties. A dominant serine protease inhibitor, SLPI is a cationic 
protein of 11.7 kDa found in the upper respiratory tract at the mucosal surface 
(Weldon, 2009). Neutrophils, macrophages, acinar cells of submucosal glands and 
epithelial cells have all been shown to be rich sources of SLPI. Proteases such as 
elastase, cathepsin G and trypsin (neutrophil derived), chymase and tryptase (mast 
cell derived) are all released during an inflammatory response (Doumas, 2005) and 
their detrimental actions are inhibited in part by the subsequent release of SLPI. In 
addition, SLPI has also been shown to possess immunomodulatory activity through the 
suppression of neutrophil elastase and IL-8 in the lung (Vogelmeier, 1996). Lavage 
studies targeting the physiological role of SLPI have suggested its main function is as a 
neutrophil elastase inhibitor, thus providing protection within the upper and lower 
respiratory tract. In contrast to α1-antitrypsin, SLPI is capable of inhibiting neutrophil 
elastase that is bound to elastin and can therefore protect against both its free and 
bound forms.  
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The interaction between airway inflammation and protease/antiprotease 
imbalance is illustrated in Figure 1.4. This figure demonstrates how these processes 
contribute to the pathological features of the disease (reviewed in section 1.4), 
through the promotion of tissue injury and airway remodelling, as well as the 








Figure 1.4: Inflammation, proteolysis and fibrosis in the lung caused by cigarette 
smoke. This figure illustrates the protease/antiprotease imbalance induced by 
cigarette smoke and the resulting injuries such as inflammation, mucus 
hypersecretion, fibrosis and damage of emphysematous tissue. CCL2 = C-C motif 
ligand 2 which is a monocyte chemoattractant protein-1 chemokine; CXCL1= C-X-C 
motif ligand which activates neutrophils (CXCL8 recruits neutrophils, CXCL9/10/11 are 
T-cell chemoattractants induced by interferon-γ); CCR2 = chemokine C-C motif 
receptor 2 which is a receptor for CCL2; CXCR2 = C-X-C motif receptor 2 which is a 
receptor for CXCL8 (CXCR3 is a receptor for CXCL9/10/11); MMP = matrix 
metalloproteinases; NE = neutrophil elastase; TGF-β = transforming growth factor 
beta; Th1 = T helper cell which is a lymphocyte (Th17 is a T helper cell that produces 
interleukin-17); Tc1 = cytotoxic T cell that secretes interferon-γ, interleukin-2 and 
tumour necrosis factor-α (Tc2 secretes interleukin-4); T reg = regulatory T cells that 




1.5.7 Oxidative Stress 
Biological systems are continuously exposed to free radicals and oxidants 
generated both endogenously and exogenously. Free radicals are defined as “any 
species capable of existing independently and which contain one or more unpaired 
electrons” (Halliwell and Gutteridge, 2007). Reactive oxygen species may contain non-
radical derivatives of oxygen which have the capacity to participate in redox reactions, 
such as hydrogen peroxide, hypochlorous acid and ozone. Endogenous reactive 
oxygen species (ROS) are generated through normal cellular processes such as 
electron leakage from the mitochondrial electron transport chain during respiration 
and the activation of phagocytes during inflammation. Exogenous oxidants, or pro-
oxidants (species that can promote reactive oxygen species generation in vivo) can be 
directly inhaled from the environment as a result of smoking, as well as exposure to 
ambient gaseous (ozone and nitrogen dioxide ) and particulate pollutants (Rahman 
and MacNee 1996). 
 
The gas and tar phases of cigarette smoke are known to contain high 
concentrations of reactive oxygen (ROS) and reactive nitrogen species (RNS) 
underpinning its capacity to elicit oxidative stress, both within the lung and 
systemically. Gas phase smoke alone has been conjectured to contain in excess of 1014 
carbon- and oxygen-centred radicals per puff, including alkyl peroxynitrite, 
peroxynitrate esters, nitric oxide (NO) and nitrogen dioxide (NO2) (Pryor, 1983; Cueto, 
1994). The tar phase has also been shown to contain semiquinones (Pryor, 1997) and 
catalytic metals such as Fe, Cu, Ni and Cr (Stavrides, 2006) capable of redox cycling at 
the air-lung interface. This ‘initial’ oxidative insult is subsequently exacerbated by the 
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induction of inflammation, with further ROS produced via the activation of the  
phagocytic nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Kon, 
Hansel et al. 2008) – Figure 1.5. 
 
The toxicity of exogenous oxidants to the lung, especially those present in 
cigarette smoke, needs to be viewed in the context of the endogenous antioxidant 
defences present at the air-lung interface, both within the extracellular respiratory 
tract lining fluid as well as intracellularly within the airway epithelial and resident 
inflammatory cell populations. These defences will be reviewed in section 1.6. The 
imposition of oxidative stress in vivo requires that the balance between the 
endogenous generation of oxidant species and the protective antioxidant pool is 
perturbed, either by increased production of the former, or decreases in the latter. 
This shift not only promotes damage to cellular components through lipid 
peroxidation, protein and DNA oxidation, but is also sufficient to trigger the up-
regulation of redox sensitive transcription factors, such as nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) which promotes the transcription of pro-
inflammatory mediators, such as interleukin 8 (IL8) and IL6. The subsequent activation 
of airway phagocytes results in further production of ROS amplifying the damage and 
resulting in a detrimental cycle of inflammation and injury. In smokers and patients 
with COPD, the increased burden of oxidants arising from smoking and airway 
inflammation has been shown to result in oxidative stress, evidenced through 
increased concentrations of oxidative damage markers in the alveolar space, blood, 
breath and urine (MacNee, 2000). The intimate association between oxidative damage 




Figure 1.5: ROS induction by cigarette smoke and COPD airways. This simple scheme 
illustrates the initial formation of superoxide, via the reduction of oxygen and its 
subsequent transformation in vivo into more reactive species (hydroxyl radical), either 
via Fenton-type chemistry, or conversion to reactive halides, such as hypochlorous 
acid (HOCl).  
 
1.6 Defence mechanisms of the lung 
As the primary entry route of inhaled xenobiotics, the lung has evolved into a 
comprehensive antioxidant network at the air-lung interface, both within airway 
epithelial cells and the thin liquid layer that bathes the surface of the lung: the 
respiratory tract lining fluid (RTLF). The primary antioxidants found within the RTLF 
include the low molecular weight antioxidants glutathione, urate and ascorbate; the 
metal chelators lactoferrin, transferrin, ferritin and caeruloplasmin and the 
antioxidant enzymes extracellular superoxide dismutase and plasma glutathione 
























Figure 1.6: Oxidant-mediated lung injury in smokers.  
 
1.6.1 Antioxidant defences within the RTLF 
The RTLF exists as a bi-layered structure, with an upper mucus (Gel phase) and 
the lower aqueous layer (Sol phase), derived from plasma exudation and local 
synthesis from the lung epithelium and resident immune cells. It is believed to be 
continuous from the nasal airway to the alveolar region of the lung, though its 
thickness decreases from 10 µm in the former region to around 1 µm in the latter. This 
compartment therefore represents the first physical interface encountered by inhaled 
particulates and gases, and as such, is critical in mitigating against oxidative injury to 
the underlying epithelium. Importantly, there are marked regional variations in the 
concentrations of antioxidants contained within this compartment, with urate and 
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lactoferrin purported to be high in the upper versus lower airways, and glutathione 
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Figure 1.7: Regional variation in the composition of human RTLFs. UA, urate; AA, 
ascorbate; GSH, glutathione; A-Toc, alpha-tocopherol (vitamin E), ecCuZn SOD, 
extracellular Cu, Zn superoxide dismutase; ecGSHPx, extracellular (plasma) glutathione 
peroxidase. 
 
Much of our knowledge about the composition of this compartment has arisen 
from the use of bronchoscopy based lavage. Bronchoalveolar lavage (BAL) involves the 
instillation of saline into defined lung segments, which is then recovered by aspiration. 
Despite its importance, there is little agreement on the best way to account for the 
variable dilution of the RTLFs which is inherent with the technique and consequently 
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the literature values for the concentration of RTLF components are expressed with a 
high degree of uncertainty. In addition to this issue, the lavage dwell time prior to 
aspiration, the location sampled and sampling handling/storage issues also complicate 
the determination of accurate RTLF reference values. Common approaches used by 
research groups to correct for lavage dilution include the use of endogenous markers 
such as urea or instilled dyes such as methylene blue (Van der Vliet, O'Neill et al. 
1999). However, the value of both these methods has been questioned (Haslam and 
Baughman 1999).   
 
The urea method, which has been the most widely applied correction in the 
literature, is based on the assumption that this low molecular weight molecule is 
freely diffusible across the blood-air barrier. Therefore, by calculating the ratio 
between the plasma and lavage concentrations a dilution factor can be generated that 
can be applied to other measured constituents. One criticism of this approach is that 
lavage urea concentrations will be augmented as it moves down the imposed 
concentration gradient from the plasma to the instilled saline bolus in the airway, with 
this effect becoming magnified with longer saline dwell times in the lung. In an 
attempt to overcome this problem and generate meaningful reference values for RTLF 
low molecular weight antioxidants, Van der Vliet and colleagues (1999) developed a 
single-cycle BAL technique in which 60 mL of saline was instilled and immediately 
aspirated (<1 minute) into four 15 mL syringes. Based on this study, following urea 
correction, the predominant low molecular weight antioxidant present in RTLF from 
the distal airways was urate at 207 ± 167 µM followed by glutathione (GSH), ascorbate 
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and α-tocopherol at 109 ± 64, 40 ± 18 and 0.7 ± 0.3 respectively. These data are 
presented in Table 1.4, with plasma and nasal lavage values included for reference.  
 
Table 1.4: Single-cycle BAL and nasal lavage performed on 12 healthy volunteers.  
 
Footnote: Protein levels were calculated from urea values and compared with the 
relevant plasma reading. Bronchoalveolar concentrations were determined from the 
final 2 fractions. ND = not determined. Table adapted from Van der Vliet et al. (1999).  
 
 
1.6.2 Low molecular weight antioxidants 
 In the following section I will review the major low molecular weight 
antioxidants found within the healthy RTLF and provide information concerning 
changes in their concentration in relation to smoking status and the presence of 
COPD. These antioxidants, predominately by order of concentration; ascorbate, urate 
and glutathione, are often thought of simplistically as acting as sacrificial substrates 
for ROS/RNS that are introduced or generated at the air-lung interface. In this view 
they react with ROS/RNS forming non-toxic products and by doing so spare more 
ELF
Antioxidant (µM) Nasal Bronchoalveolar Plasma
ND 9.5 ± 6.1 74 ± 19
109 ± 64 1.0 ± 0.7
28 ± 19 40 ± 18 67 ± 25










critical targets. This view is however a little too simplistic and I will also develop the 
theme in the proceeding sections of how components of cigarette smoke may actually 
subvert their protective function, to actually promote radical generation and airway 
injury. 
 
1.6.2.1  Urate 
Urate is formed as the end product of purine metabolism and represents one 
of the most abundant antioxidants within human plasma and RTLFs. It has the capacity 
to neutralise free radicals (including hydroxyl and peroxyl radicals), singlet oxygen 
(Cross and Motchnik, 1992) and MPO-derived hypochlorous acid (Winterbourn, 1985) 
through single-electron oxidation. During this process urate (UA) is irreversibly 
oxidised to allatonin, oxonic/oxaluric and parabanic acids along with several other 
unidentified oxidation products (Kaur and Halliwell, 1990). Urate has also been shown 
to be a powerful scavenger of O3 and NO2 suggesting that it is one of the major 
defences in the airways against these common ambient pollutant gases (Mudway, 
2000). The capacity to scavenge the NO2 radical is clearly important with regard to 
cigarette smoke, as is its neutralising reaction with peroxynitrate (Whiteman, 2002). 
These protective actions against RNS are potentially of major relevance in COPD, both 
because α1-antitrypsin is protected from nitration and inhibition by UA in vitro 
(Whiteman, 2002), but also because of the negative role nitration is thought to play in 
the inactivation of  histone deacetylase 2 in COPD (Osoata, 2009). Urate has also been 
proposed to inhibit the transition metal-catalysed oxidation of ascorbate, through the 
formation of non-catalytic stable complexes with iron (Davies, 1986). Again, this is a 
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potentially significant protective role given the presence of catalytic metals in 
cigarette smoke aerosol.  
 
Relatively few studies have examined the role of urate in COPD and those that 
have tend to focus on plasma concentrations. Two studies have reported conflicting 
results relating plasma/serum urate concentrations with lung function in COPD 
(Garcia-Pachon, 2007; Hageman, 2003). Garcia-Pachon and colleagues (2007) 
demonstrated an association between high serum UA with low FEV1, whilst an earlier 
study reported lower plasma UA concentrations in COPD patients (Hageman, 2003). In 
a recent larger scale study investigating 500 smokers (367 with COPD) low plasma 
urate was associated with more severe COPD, based on airflow obstruction (Nicks, 
2011). Urate concentrations have been shown to be elevated in the saliva, but not BAL 
fluid from COPD smokers and ex-smokers relative to aged and smoking status 
matched controls (Yigla, 2007). 
 
1.6.2.2  Ascorbate 
Ascorbate is not synthesised within the human body (due to the lack of 
gluconolactone oxidase) and as such our nutritional needs are met through the diet, 
which may account for the wide inter-individual variation in reported lavage 
concentrations (Kelly, 1999). Ascorbate is highly water soluble and extensively 
distributed around the aqueous regions of the body. Its function as an antioxidant lies 
in its ability to scavenge •OH, H2O2, O2•-, hypochlorous acid and singlet oxygen. 
Ascorbate is an unstable molecule and can be readily oxidised, with the rate being 
dependent upon the pH of the environment and the presence of catalytic metals 
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(Favier, 1995). During its oxidation the ascorbyl radical is formed. The unpaired 
electron belonging to the ascorbyl radical is found in the delocalised π-system and as 
such remains relatively unreactive. If no further oxidation occurs, a disproportionation 
reaction will take place between two ascorbyl radicals, leading to the regeneration of 
one ascorbate and one dehydroascorbate (DHA) molecule (Roginsky and Stegmann, 
1994). The DHA formed in this reaction, or directly via a two step oxidation, is highly 
unstable under physiological conditions and will rapidly undergo hydrolysis to 2,3-
diketo-L-gulonic acid and a range of further degradation products such as oxalic and L-
threonic acid. There is evidence that DHA can be recycled back to ascorbate, following 
uptake into cells via facilitated glucose transporters, GLUT1, GLUT3 and GLUT4, (Liang, 
2001). Once internalised, the DHA is rapidly reduced to ascorbate by NADPH-
dependent dehydroascorbate reductases (Wilson, 2002). Whether such recycling 
occurs within the extracellular RTLF compartment is currently not known, although 
the high concentrations of GSH reported within this compartment (Van der Vliet, 
1999) would support some reduction of DHA to ascorbate (Winkler, 1994). This is a 
critical issue as it implies that ascorbate lost from this compartment as a function of its 
radical scavenging capacity must be replenished by redistribution from other 
compartments, either from transduction from the plasma pool or the airway cells 
themselves. Ultimately, the intake of dietary ascorbate should dictate the extent of 
protections observed. 
 
As with urate, the majority of the studies examining ascorbate (vitamin C) in 
lung function decline, smoking and COPD are based on plasma concentrations or 
estimated dietary intakes. There is currently an absence of studies examining RTLF 
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ascorbate concentrations in patients with COPD. The study cited above by Yigla et al.  
(2007) did not examine ascorbate in the lavage samples from their COPD patients, and 
only a limited literature exists demonstrating cigarette smoke induced decreases in 
lavage ascorbate in rats, as well as in smokers versus non-smokers (Ghio, 2008). 
 
It has long been established that high plasma concentrations of nutritional 
antioxidants (vitamins C and E) and high intakes of foods rich in these vitamins are 
associated with better indices of lung function (FEV1 and FVC) in the general 
population (Britton, 1995; Grievink, 1998; Schwartz, 1994; McKeever, 2008). However, 
recent studies have demonstrated a similar relationship in populations with airways 
disease. A study of 218 asthmatic and COPD patients found that estimated dietary 
intakes of ascorbate was positively associated with FEV1 and FVC (Ochs-Balcom, 2006). 
In broad agreement with this, low intakes of vitamin C and E were associated with 
more wheezing, phlegm production and dyspnoea (Schwartz, 1990; Grievink, 1998). 
Furthermore an increase of 20 micromol/L in plasma vitamin C has been associated 
with a 13% reduction in the risk of developing obstructive airway disease OR: 0.87 
(Sargeant, 2000).  
 
1.6.2.3  Glutathione 
As the most fundamental nonprotein sulphydryl in cells, GSH (L-γ-glutamyl-L-
cysteinylglycine) is integral in maintaining the cellular redox status. Its effectiveness as 
an antioxidant has been demonstrated in vitro, where it has been shown to scavenge a 
broad spectrum of ROS including •OH, HOCl, RO• and RO2•. In addition to its direct 
ROS scavenging properties and its role as a substrate for peroxidase and transferase 
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enzymes, GSH can also protect against oxidative stress by chelating copper ions 
(Jimenez and Speisky, 2000), regenerating vitamin C (May, Qu et al. 2001) and 
preventing the oxidation of protein thiols (-SH) (Kelly and Mudway 2003). Many of 
these processes result in the oxidation of GSH to glutathione disulphide (GSSG), or the 
formation of mixed protein disulphides. GSH is an integral component of the 
antioxidant network and therefore it is essential to maintain high GSH/GSSG ratios in 
cells and extracellular fluids. This is achieved either by the enzymatic regeneration of 
GSH from GSSG or by de novo GSH synthesis. The synthesis of GSH is performed in two 
enzymatic steps that are catalysed by glutamate cysteine ligase (the rate-limiting 
enzyme) and glutathione synthetase. Regeneration of GSSG occurs via the action of 
glutathione reductase and other reductase enzymes, at the expense of NADPH, which 
is in turn regenerated by the pentose-phosphate shunt (Filosa, Fico et al. 2003).  
 
Typical GSH concentrations within plasma range from 1-3 µM and between 40-
200 µM in BAL (Halliwell and Gutteridge, 2007) although some research groups have 
reported ranges of 90-500 µM in BAL obtained from healthy subjects (Van der Vliet, 
O'Neill et al. 1999). Human lavage studies have demonstrated a 2-4-fold increase in 
GSH concentrations in the RTLFs of chronic smokers compared to non-smokers 
(Morrison, 1999; Cantin, 1987). In chronic smokers this extracellular increase in GSH 
was not matched by increased concentrations in airway leukocytes and was in fact 
associated with a decreased expression of γ-GCS (Neurohr, 2003). This suggests that 
the increased extracellular GSH concentrations observed are unlikely to be protective 
against chronic exposure to cigarette smoke. These in vivo results are somewhat at 
odds with the reported induction of γ-GCS activity and γ-GCS heavy subunit mRNA in 
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cultured immortalised human type II alveolar epithelial cells (A549) treated with 
cigarette smoke condensate (Rahman, 1996). 
 
In COPD the data on RTLF and airway cell GSH concentrations are somewhat 
conflicting and difficult to interpret due to the influence of patient smoking status.  
Increased RTLF GSH concentrations have been reported in COPD patients, though this 
may simply have reflected their smoking status and concentrations were reported to 
fall significantly during exacerbations (Drost, 2005).  
 
1.6.3 Enzymatic antioxidants 
The most important enzymatic antioxidants within the RTLFs are extracellular 
superoxide dismutase (ECSOD) and plasma glutathione peroxidase (plGPx). While 
reports exist of other enzymatic antioxidants within this extracellular compartment 
including catalase (Ulker, 2007) and glutathione disulphide reductase (Smith, 1997), 
these data are contentious and likely reflect contamination of the extracellular sample 
with intracellular material, arising from damage to the airway epithelium during the 
bronchoscopy. The following section will therefore focus only on the data on ECSOD 
and plGPx. 
 
1.6.3.1  Extracellular SOD 
 Three SOD enzymes (CuZnSOD [SOD1], MnSOD [SOD2], and ECSOD [SOD3]) 
have been characterized in mammalian cells (Arcaroli, 2009). Of these forms only 
extracellular SOD (ECSOD) exists in the RTLF in close association with the epithelial 
surface through its interaction with collagen, hyaluronan and heparin sulphate (Gao, 
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2008). ECSOD is a tetrameric glycoprotein with each subunit containing a copper and 
zinc atom which functions to catalyse the conversion of superoxide radicals (O2•-) to 
H2O2 (Halliwell and Gutteridge, 2007). Mice lacking ECSOD have been shown to have 
increased sensitivity of a range of insults characterised by the induction of oxidative 
stress, including hyperoxia (Carlsson, 1995) and asbestos (Fattman, 2006), as well as 
cigarette smoke and elastase-induced emphysema (Yao, 2010). Consistent with this 
enzyme protecting against oxidative stress, its over-expression appears protective 
against hyperoxia (Folz, 1999) and cigarette smoke in experimental murine models 
(Tollefson, 2010). The importance of ECSOD in COPD has been emphasised by recent 
genetic studies demonstrating that polymorphisms in this gene, especially the 
Arg213Gly polymorphism, associated with increased circulating levels of this enzyme 
are protective against COPD in smokers (Young, 2006; Oberley-Deegan, 2009).  
 
There are few reports examining ECSOD in human subjects after smoking or in 
patients with COPD. In a recent study, plasma, sputum and bronchoalveolar lavage 
fluid concentrations of ECSOD were compared in smokers with and without COPD to 
non-smoking controls. Whilst plasma ECSOD concentrations were equivalent in the 
groups examined, increased concentrations were apparent in induced sputum 
supernatants obtained from current smokers and COPD patients compared with non-
smoking controls. This apparent increase in the upper airways was not apparent in 
bronchoalveolar lavage fluid, reflective of lower airway lining fluids, and decreases in 
ECSOD immunoreactivity were observed around blood vessels and bronchioles in 




There is somewhat more data available regarding the intracellular SODs, 
though much of this information is limited to peripheral blood leukocytes. Red blood 
cell (RBC) SOD activity has been reported in stable COPD patients relative to non-
smoking controls, parallel to increased plasma concentrations of lipid 
(malondialdehyde) and protein oxidation (carbonyls) markers (Nadeem, 2005). In this 
study RBC SOD activities were not related to the extent of airway obstruction in the 
COPD patients, and there was no difference between patients at disease stage II or III.  
In contrast, patients undergoing exacerbation demonstrated increased RBC SOD 
activities while the activities of glutathione disulphide reductase and glutathione 
peroxidase fell (Gumral and Nazirolglu, 2009).  
 
1.6.3.2  Plasma glutathione peroxidase 
Glutathione peroxidases (GPx) are a family of selenium-dependent and 
independent antioxidant enzymes located in both intracellular and extracellular 
compartments (Mak, 2008). These tetrameric proteins catalyse the reduction of H2O2 
to water through the oxidation of glutathione. The glutathione disulphide (GSSG) 
formed in this reaction is subsequently reduced back to GSH by glutathione reductase 
at the expense of NADPH (Rahman and Biswas, 2006), though the extent to which this 
occurs extracellularly is debatable. Certain isoforms of GPx can also break down lipid 
hydroperoxides (LOOH) in tandem with the oxidation of glutathione producing GSSG, 
LOH and OH-. Eight different isoforms of glutathione peroxidase (GPx1-8) have been 
identified in humans, which vary in cellular location and substrate specificity. The most 
abundant form is glutathione peroxidase 1 (GPx1), which is present in nearly all 
mammalian tissues and catalyses the reduction of H2O2. Glutathione peroxidase 2 
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(GPx2) is an extracellular enzyme located in the intestine, while glutathione 
peroxidase 3 (plGPx) has been shown to be present in human plasma and RTLF 
(Avissar and Reed, 2000). Glutathione peroxidase 4 (GPx4) like GPx1 is cytosolic and 
widely distributed throughout the body, albeit at lower levels, where it plays a 
significant role in the reduction of lipid hydroperoxides. 
 
Much of the work investigating glutathione peroxidases in COPD has focused 
on plasma/erythrocyte enzyme activities. Erythrocytic GPx1 activity has been shown 
to be significantly decreased between GOLD Stages II, III and IV in COPD patients 
relative to controls, with the residual activity inversely related to systemic indices of 
inflammation (Tkacova, 2007). The observation of decreased GPx1 activity in 
peripheral blood was recently confirmed in a study of 109 stable COPD patients and 
51 controls, though notably with no incremental difference between patients at 
different disease stages (Biljak, 2010). This study also demonstrated increased 
glutathione reductase activities in the peripheral blood from these subjects, parallel to 
the reduction in GPx1. In contrast to peripheral blood, few studies have investigated 
GPx in the airways of COPD patients, and there are no reports specifically addressing 
plGPx (GPx3). GPx3 has been reported within healthy human RTLFs and been shown 
to decrease acutely following exposure to the oxidant gas ozone (Avissar and Reed, 
2000), suggesting that it may be prone to oxidative inactivation. However, recent data 
suggests that expression of GPx1 is reduced in airway cells in subjects with 
emphysema, related to reduced nuclear localisation of the nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) transcription factor (Goven, 2008). In this study the expression 
of GPx1 was inversely correlated with the degree of airway obstruction 
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1.6.4 Chelator proteins 
The RTLF also contains endogenous metal chelators (transferrin, lactoferrin, 
ferritin and caeruloplasmin), which perform the important antioxidant role of 
sequestering redox active metals, to prevent the formation of highly reactive radicals 
via Fenton-like chemistry. These proteins will be discussed in the following sections. 
 
1.6.4.1  Transferrin 
 Transferrin is an iron-binding glycoprotein, predominantly synthesised by 
hepatocytes, but which can also be produced by pulmonary epithelial cells and 
submucosal glands within the lung (Shigemura and Nasuhara, 2010). In healthy 
individuals, transferrin is only loaded with 20-30% iron and therefore has 70% of its 
binding capacity available for the uptake of iron (Halliwell and Gutteridge, 2007). 
Transferrin levels, expressed as a percentage of total protein, are significantly higher 
in BAL (4-5.6%) than in plasma, suggesting that transferrin is locally synthesised within 
the lung and is not purely derived from plasma through transudation (Mateos, 1998). 
Decreased levels of transferrin in BAL has been observed in patients with COPD 
(Shigemura and Nasuhara, 2010), whilst smoking alone does not appear to alter BAL 
fluid concentrations of transferrin, despite the influx of iron.  
 
Transferrin functions as an iron transport protein as two ferric irons (Fe3+) can 
be reversibly bound; one binds to the N-terminal domain and one binds to the C-
terminal domain. CD71 is a transferrin receptor which mediates the cellular uptake of 
iron. B and T lymphocytes along with macrophages within the alveolar region express 
CD71, clearly indicating that the iron transport capabilities of transferrin are required 
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for the maintenance of metabolic function within such cells. Transferrin is a recyclable 
protein and the affinity of iron to bind with transferrin is largely pH-dependent as 
transferrin cannot effectively bind iron at a pH of less than 4.5. The transferrin 
receptors bind transferrin at the cell surface at a biological pH of approximately 7.4 
and then internalises it within endocytic vesicles. The release of iron from the 
transferrin upon endosomal acidification (pH of less than 4.5) then follows and the 
newly formed apotransferrin-transferrin receptor complex undergoes dissociation 
which sees the release of the apotransferrin from the receptors (Ponka, 1999). The 
pH-dependent binding of Fe is significant as studies have shown the RTLF (based on 
the pH of exhaled breath condensate) of asthmatics to be 5.3 ± 0.21 (Hunt and Fang, 
2000), which would limit the uptake and sequestration of Fe and hence indirectly 
promote a pro-oxidant state in this compartment. It should be noted that this is a 
highly contentious observation that has largely failed to be corroborated in the 
subsequent literature. Whilst the pH of exhaled breath condensate from COPD 
patients has been shown to be lower compared with age and smoking status matched 
controls, and to decrease with disease stage, the differences are minor and near 
neutrality and therefore unlikely to impact on metal handling (Papaioannou, 2011). 
 
1.6.4.2  Lactoferrin 
Lactoferrin is a monomeric, cationic iron-binding glycoprotein that is 
synthesised by the secretory epithelium and myeloid cells (Ghio and Stonehuerner, 
2008). It possesses a high affinity for iron at low pH, a property that transferrin lacks, 
and can effectively bind two iron (Fe3+) molecules. It is found in nasal secretions, bile, 
tears, seminal fluid, mucosal secretions and saliva (Bournazou and Mackenzie, 2010) 
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and is present in the secondary granules of neutrophils. During an inflammatory 
response, lactoferrin transports iron across the cell membrane after which follows its 
deposition into ferritin. Within BAL, the mean concentration of lactoferrin is 
approximately 10 times lower than the concentration of transferrin. The lactoferrin 
present in BAL is sourced predominantly from the airway as opposed to the alveolar 
region offering an explanation as to why smokers exhibit increased levels of lactoferrin 
in BAL (Mateos, 1998).  
 
1.6.4.3  Ferritin 
Ferritin is an iron storage protein that can essentially store up to 4500 iron ions 
(Halliwell and Gutteridge, 2007) and can detoxify intracellular non-functional iron 
(Ponka, 1999). It exerts an antioxidant effect through the sequestration of iron but 
also serves as an iron source. It is present in mitochondria but is mainly cytosolic. Iron 
enters ferritin as Fe2+ and undergoes oxidation by the protein to form Fe3+. Ferritin can 
release iron through its degradation within lysosomes where iron is released and the 
protein shell is converted into an insoluble product known as haemosiderin (Halliwell 
and Gutteridge, 1984). Instillation of iron-containing particles into human volunteers 
has been shown to result in an increase in lavage ferritin (Ghio and Carter, 1998). This 
occurred in parallel to increased lavage lactoferrin and decreased transferrin 
concentrations. This induction of a protective response was subsequently confirmed in 
cultured human bronchial epithelial (NHBE) cells challenged with residual oil fly ash 
(rich in transition metals) where increased ferritin protein was observed, parallel to 
increased lactoferrin mRNA and protein (Ghio et al. 1998). Similar increases have been 
reported in rat and human respiratory epithelial cells exposed to cigarette smoke 
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and/or condensate (Ghio et al. 2008). In this paper, these in vitro findings were 
confirmed in airway lavage samples from smokers and patients with COPD, which 
displayed elevated concentrations of iron and ferritin relative to healthy non-smoking 
controls. 
 
1.6.4.4  Caeruloplasmin 
 Caeruloplasmin is a copper transport protein that also exhibits ferroxidase 
activity. It is synthesised within the lung and secreted into the surrounding lining fluids 
(Halliwell and Gutteridge, 2007). It aids in the loading of Fe into transferrin, and 
possibly ferritin by oxidising Fe2+ to Fe3+. This protein also serves as a peroxidase which 
in the presence of GSH is capable of removing H2O2 and lipid peroxides. 
Caeruloplasmin also has the capability of binding to myeloperoxidase, thus inhibiting 
the formation of HOCl without hindering its ferroxidase function.  
 
1.7 Evidence of oxidative stress in COPD 
Evidence of increased oxidative stress in the airways of smokers and patients 
with COPD is largely based on the measurement of ROS or markers of oxidative 
damage in exhaled breath condensate, due to the difficulty in obtaining lavage 
samples from these subjects. Smokers and patients with COPD have been shown to 
display higher levels of exhaled H2O2 than non-smokers, with concentrations further 
elevated during exacerbations (Kharitonov, 2001; Montuschi et al. 2000). Similarly, the 
concentrations of lipid oxidation products such as 8-iso-prostaglandin F2α (8-
isoprostane) and thiobarbituric acid-reactive substances (TBARS) have been shown to 
be elevated in the EBC in healthy smokers relative to non-smokers and more markedly 
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in patients with COPD (Montuschi et al. 2000; Nowak et al. 1999). Urinary 
concentrations of 8-iso-prostaglandin have also been shown to be increased in COPD 
patients relative to age-matched controls, consistent with the presence of systemic 
oxidative stress (Pratico, 1998). Actual oxidative damage to the airway epithelium, 
endothelium and neutrophils has been observed in lung tissue specimens obtained 
during lung resections from patients with and without COPD. In these specimens, 
increased staining for 4-hydroxy-2-nonenal (4-HNE)-modified proteins was observed in 
COPD patients (Rahman, van Schadewijk et al. 2002) providing direct evidence of 
increased oxidative stress in the airway, with some evidence that this was related to 
lung function in these subjects.  
 
1.7.1 The oxidative stress response model in COPD 
In the previous sections I have discussed evidence supporting antioxidant 
dysregulation and the presence of oxidative stress in the airways of subjects with 
COPD. These observations need, however, to be placed into the context of how the 
lung responds to oxidative stress in order to understand how this imbalance 
contributes to the genesis and progression of the pathologies associated with COPD. 
In addition to the inherent protection of the airway against acute oxidative insults, via 
the extensive antioxidant network both within the RTLF and airway epithelium, the 
lung is also able to adapt to acute insults to mitigate injury. This in part is achieved 
through the action of the redox sensitive transcription factors, activator protein-1 (AP-
1) and nuclear erythroid-related factor-2 (Nrf2), which bind to antioxidant response 
elements and drive the transcription of cytoprotective genes related to antioxidant 
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defence, xenobiotic metabolism and metal handling (Biswas and Rahman, 2009; Cho 
and Kleeberger, 2010). In a healthy airway the combination of these endogenous 
antioxidant defences and inducible protective mechanisms are usually sufficient to 
protect the airway, but if the insult is sufficiently large or chronic, the capacity of these 
defences may be overwhelmed resulting in oxidative stress and injury to the lung. The 
imposition of oxidative stress, often described in the literature as an increase in the 
cellular GSH:GSSG ratio (Rahman et al. 2005), has been associated with the induction 
of inflammation, ostensibly through the activation and nuclear mobilisation of nuclear 
factor-κB (NF-κB) and ultimately with cell proliferation, arrest and death as the 
magnitude of the oxidative insult increases further (Halliwell, 2000). More recently 
this graded response to oxidative stress has been defined in the hierarchical response 
model by the group of Nel (2006), specifically in relation to nanoparticle toxicity and 
summarised in Figure 1.8. This model in its original form defined the response to 
oxidative stress into three tiers: adaption, inflammation and cell death. The transition 
through these stages in response to oxidative stress was confirmed by this group in 
vitro using immortalised macrophages (THP-1) challenged with increasing doses of 
diesel exhaust particles (DEP). At the lowest dose employed, greater expression of 
heme oxygenase (HO-1) was observed, with increases in the secretion of IL-8 protein 
only apparent as the DEP dose and GSH:GSSG ratio increased. At the highest dose, 
evidence of apoptosis was seen using annexin V staining and flow cytometry (Li, 2003). 
This scheme has been illustrated in Figure 1.8, but modified to include an additional 
tier of protection related to the endogenous antioxidant defences at the air-lung 
interface, which were not integrated into the model by Nel (2006). In addition, the 
expanded model includes information of the major transcription factors regulating the 
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transition from adaption to inflammation, as well as important gene products relevant 
to the airway response to oxidative stress.  
 
1.7.2 Redox activation of Nrf2 in COPD 
Nuclear erythroid-related factor-2 (Nrf2) is a basic-region leucine zipper 
transcription factor, which binds to the cis-regulatory antioxidant response element 
and transcriptionally up-regulates a variety of cytoprotective enzymes including HO-1, 
glutamate cysteine ligase (the rate-limiting enzyme of GSH synthesis), as well as 
detoxifying enzymes such as NADPH:quinone oxidoreductase 1 (NQO1) and 
glutathione-S-transferase (Cho, 2006). Under normal cellular conditions Nrf2 is held in 
the cytoplasm in a complex with Kelch-like ECH-associated protein 1 (Keap1), which 
contains a Kelch repeat domain that anchors Nrf2 by binding to both the transcription 
factor and actin filaments of the cytoskeleton (Itoh, 2010; Kobayashi, 2004). Several 
cysteine residues within Keap1 are responsible for the maintenance of the Nrf2-Keap1 
complex (Dinkova-Kostova et al. 2002). In addition, Keap1 forms a bridge between 
Nrf2 and the cullin-3 (CUL-3) E3 ubiquitin ligase complex thereby promoting Nrf2 
proteasomal degradation, limiting its accumulation (Jeong, 2006). Upon the 
imposition of oxidative stress, Nrf2 dissociates from Keap1 and translocates to the 
nucleus, where it accumulates and binds to AREs in a heterodimeric complex with one 
of a subset of the small Maf-family of transcription factors (Blank, 2008), resulting in 




Recent literature proposes that electrophilic modification of critical cysteine 
residues in Keap1, particularly C151 in the BTB domain, leads to de-ubiquitination of 
Nrf2 in favour of ubiquitination of Keap1 (Eggler, 2005). Thus, Nrf2 protein is stabilized 
and the turnover of Keap1 is increased. He et al. (2007) demonstrated that cells 
lacking Nrf2 expression exhibited elevated ROS production and apoptosis compared to 
control cells when exposed to chromium (VI). Additionally, Marzec et al. (2007) 
observed a higher risk of acute lung injury in a limited population with a single-
nucleotide polymorphism located in the promoter region of Nrf2.  
 
Recent studies have demonstrated impaired Nrf2 transcriptional activity in 
patients with COPD, with reduced Nrf2 protein concentrations in lung tissue and 
alveolar macrophages reduced in patients with COPD and emphysema compared to 
age-matched controls (Goven et al. 2008). This occurred in parallel to increased Keap1 
and Bach1 (a cap'n'collar type of basic region leucine zipper factor that inhibits the 
expression of MAF proteins) protein expression, associated with decreased HO-1, 
NQO1 and glutathione peroxidase 2 mRNA. This suggests that Nrf2 could be regarded 
as a candidate susceptibility gene for COPD and illustrates its critical role in 





Figure 1.8: Diagrammatic representation of the hierarchical response of cells to PM-
induced oxidative stress at the air-lung interface. This diagram represents an 
extension of the earlier model proposed by Nel et al. (2006), to include the influence 
of the antioxidant defences within the respiratory tract lining fluids which overlay the 
epithelium. In this modified model, the initial defence against PM-induced oxidative 
stress resides within the RTLFs, initially characterised by acute early losses of 
ascorbate (AA), urate (UA) and glutathione (GSH). In light of the findings in the present 
study we suggest this initial loss is partially offset by movements of these antioxidants, 
particularly GSH, from the epithelium to the extracellular compartment. When these 
defences are overwhelmed the underlying cells initially induce adaptive strategies, 
under the regulation of Nrf2 and AP-1 to deal with the oxidative stress, or process the 
inhaled xenobiotics. The figure illustrates a number of genes known to be up-
regulated in these adaptive responses, under the regulation of Nrf2 and AP-1, 
including the glutathione S transferase and heme oxygenase-1. Further oxidative 
stress, reflected by a decrease in the cellular GSH/GSSH ratio, leads to the 
transcription of genes under the regulation of NFκB, such as pro-inflammatory 
cytokines and inducible nitric oxide. Further oxidative stress subsequently leads to cell 
arrest and induction of cell death, either by apoptosis or necrosis. These later two 
processes can also be associated with either regulated (apoptosis) export of 
intracellular GSH, or its unregulated release by necrosis associated with its subsequent 




1.8 The ageing hypothesis in COPD 
 COPD has long been recognised as sharing many features with the aged lung, 
summarised in Table 1.5. This is perhaps not surprising given that the majority of 
COPD sufferers are of late middle-age to elderly. In addition, many COPD co-
morbidities are also degenerative diseases of accelerated senescence, including heart 
failure, atherosclerosis, osteoporosis, and diabetes. Recently however, it has been 
proposed that the normal physiologic ageing of the lung, associated with degraded 
homeostatic and repair mechanisms and the accumulation of molecular damage, is 
accelerated in COPD due to recurrent episodes of inflammation and airway 
remodelling, driving mitotic cells toward senescence (Ito, 2009). In support of this 
view, shortened telomeres have been observed in the alveolar type II cells and 
endothelial cells (Tsuji, 2006), peripheral mononuclear blood cells (Morla, 2006) and 
fibroblasts (Muller, 2006) from the lungs of COPD subjects compared to age-matched 
non-smoking subjects. The development of emphysematous pathology is also seen to 
occur early in the lungs of animal models of accelerated ageing, such as the Klotho and 
the SMP30 mice, concurrent with increased oxidative stress (Sato et al. 2007; Sato et 
al. 2007). 
 
Antioxidant enzyme activity, the expression of anti-ageing molecules such as 
the protein deacetylase sirtuin 1 (SIRT1) and sensitivity to corticosteroids are all 
decreased with age, with further declines apparent in COPD patients (reviewed in Ito, 
2009). These changes occur against a background of increased basal age-related 
inflammation characterised by increased neutrophilia and pro-inflammatory cytokines 
(IL-1β, IL-6, IL-8 and TNF-α) production. This immuno-ageing effect also appears to be 
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exacerbated in COPD in comparison to age-matched controls (reviewed in Ito, 2009). 
The activity of enzymes such as superoxide dismutase has also been reported as being 
lower in aged smokers and stable COPD patients than in healthy age-matched controls 
(Kirkil, 2008) although there is still a degree of uncertainty surrounding these data 
(Nadeem, 2005).  
 
Table 1.5: Comparison table of normal aged lung and COPD lung, adapted from a 














     dismutase, catalase
Adhesion molecules
     (E-selectin, P-selectin,










































VCAM = vascular cell adhesion molecule; iNOS = inducible nitric oxide synthase; 
ICAM = intercellular adhesion molecule; VEGF = vascular endothelial growth factor;  
↑  indicates degree of increase;  ↓  indicates degree of decrease; → indicates no 
change; ? indicates unknown.
 
 
A reduced expression of sirtuins (anti-ageing molecules), in particular SIRT1 
and SIRT6, have been reported in the lung tissue and peripheral blood mononuclear 
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cells of COPD patients (Vuppusetty, 2007; Rajendrasozhan, 2008) and with SIRT1 being 
a major inhibitory regulator of MMP-9, a decline in its expression may lead to 
structural changes of the lung such as emphysema. A reduction in SIRT6 expression 
(Meyer, 1998) leaves DNA vulnerable to damage. Additionally, a reduction in the 
activity and expression of histone deacetylase II (HDAC-2) in the peripheral lung tissue 
and alveolar macrophages of COPD patients has been attributed to enhanced 
inflammation and corticosteroid insensitivity (Ito, 2005; Ito, 2006).  
 
1.9 Overview 
The presence of oxidative stress in the COPD lung has been proposed to be 
critical in the development of the underlying disease pathology. There is however, a 
paucity of data concerning the status of the antioxidant defences present at the air-
lung interface in COPD to support this contention, with much of the published data 
related to markers determined in blood and exhaled breath condensate. The extent to 
which the latter can be employed as a surrogate for actual sampling of the lower 
airway RTLFs remains a highly contentious issue. The aim of the studies described in 
this thesis were therefore to present a comprehensive analysis of antioxidant 
defences, including metal homeostasis at the surface of the lung, specifically within 
the respiratory tract lining fluids of patients with COPD. This was achieved by 
comparing antioxidant and oxidative damage marker concentrations in 
bronchoalveolar lavage fluid samples from COPD patients (both smokers and ex-
smokers) with those determined in age and smoking status matched control subjects. I 
hypothesised that there would be clear evidence of oxidative stress within the RTLF of 
COPD patients and that the extent of antioxidant depletion, or macromolecule 
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oxidation, would be quantitatively related to the extent of airway inflammation and 
the functional impairment of the lung. The experimental data in this thesis are 
presented in three chapters, which deal with the following areas: (1) evidence of 
oxidative stress in COPD; (2) quantification of a catalytically active metal pool in COPD 
patients, consistent with the propagation of damaging oxidation reactions within this 
compartment, and (3) the development of a novel mass spectrometry based method 
to assess specific protein oxidative modifications in vivo. This final chapter is limited 
only to a consideration of the early developmental stages of establishing a robust 
quantitative method, but provides the basis for future work as discussed in the final 
concluding chapter (chapter 5). 
 
1.9.1 Experimental chapter synopsis 
Chapter 2 is presented in two parts; the first (I) providing a detailed account of 
the antioxidant defences present at the air-lung interface (measured in 
bronchoalveolar lavage) in patients with COPD, both within current and ex-smokers, 
versus their appropriate age and smoking status matched controls. This includes data 
on both the major low molecular weight antioxidants (ascorbate, urate and 
glutathione) and endogenous chelator proteins (ferritin, lactoferrin and transferrin) 
within this compartment. The formation of 4-HNE-protein adducts is also discussed. In 
order to place these results into context and in part to address the accelerated ageing 
hypothesis in COPD, I then addressed a more restricted list of oxidative stress markers 
in young adult non-smokers and subjects with mild atopic asthma. These analyses 
presented in part II, permitted a comparison of young and aged healthy adults as well 
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as a comparison of antioxidant status in two airway diseases characterised by differing 
modes of airway inflammation. The data presented in this chapter are novel and this 
study represents the first comprehensive assessment of oxidative stress in COPD 
within distal airway RTLFs. 
 
Chapter 3 employed the same clinical samples as the previous chapter (COPD 
and asthma studies) but sought to quantify the concentration of ‘catalytically’ active 
metals in the recovered lavage fluid samples (Cu and Fe), together with a panel of 
non-redox metals (Zn) and metals reflective of cigarette smoke inhalation (Cd and As). 
Here, I hypothesised that increased rates of biologically damaging oxidation reactions 
would be observed in COPD patients and smokers, related to the presence of non-
transferrin bound and hence catalytically active Fe and Cu pools in their RTLFs. To 
establish this, both inductively coupled plasma mass spectrometry and a novel 
functional assay of metal catalysis in biological fluids was employed. This latter 
method is novel and employs exogenous metal chelators (diethylene triamine 
pentaacetic acid – DTPA and nitrilotriacetic acid - NTA) to isolate whether a pro-
oxidant signal can be related to Fe or other redox active metal, likely in biological 
systems to be Cu. This methodology is again novel and the data presented in this 
chapter represent the first attempt to examine this question in asthma and COPD. 
 
Whilst chapters 2 and 3 addressed global markers of oxidative stress or altered 
metal homeostasis at the air-lung interface, chapter 4 focused on the requirement for 
more precise mass spectrometry based tools to interrogate oxidative post-
translational modifications to functional proteins within the RTLF. One could 
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speculate, for example, that selective oxidations to key functional proteins such as 
proteases or antiproteases in COPD, may play a significant role in the pathophysiology 
of the condition, even in the absence of global changes in the redox environment of 
the lung. Based on the available literature at the time, I decided to focus this 
exploratory method development on the identification and quantification of 4-HNE-
protein adducts considering the Michael additions of 4-HNE to lysine, histidine and 
cysteine residues, with the ultimate objective of employing this technology in human 
lavage fluid samples. This was a highly ambitious undertaking and the data presented 
in this chapter is best viewed as exploratory, presenting a work-up of the method 
using simple peptides and albumin 4-HNE adducts, to a limited examination in the 
more complex lavage samples. This chapter provides data that justifies further 









Is oxidative stress at the air-lung interface characteristic of the 
COPD phenotype? 
 
2.1 Introduction  
Oxidative stress is believed to play a central role in the aetiology and 
progression of inflammatory airway diseases such as asthma and COPD. This 
contention is supported by evidence of antioxidant deficiencies and increased 
oxidative damage marker concentrations within the respiratory tract lining fluids 
(RTLF) (Xie et al. 2009; Kelly et al. 1999), induced sputum (Kinnula et al. 2007; Beeh et 
al. 2004), exhaled gases (Montuschi P et al. 2001; Horváth et al. 1998; Zayasu et al. 
1997) and exhaled breath condensate (Nowak et al. 1999; Montuschi et al. 1999; 
Loukides et al. 2002) of these patient groups (see Table 2.1). Evidence of increased 
signalling through redox sensitive pathways (Di Stefano et al. 2002; Goven et al. 2008; 
Hart et al. 1998) and oxidative damage within the respiratory epithelium (Ricciardolo 
et al. 2005; Rahman et al. 2002) has also been reported and related to disease severity 
(also illustrated in Table 2.1). The increased oxidant burden within the lungs of 
patients with these conditions has been related to the accumulation and activation of 
inflammatory cells such as neutrophils, eosinophils and macrophages in the distal and 
proximal airways, with evidence of exaggerated generation of reactive oxygen species 
from these cells during the oxidative burst (Crystal, 1991). Generally speaking, the 
evidence for oxidative stress in RTLFs is greater for asthma than COPD with the data in 
the latter group largely derived from measurements in exhaled breath condensate 
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and induced sputum samples. There is considerable debate within the literature as to 
what extent measurements made using these methods accurately reflect changes in 
the bronchial airways and alveolar compartments of the lung, with some recent 
papers appearing to demonstrate some underlying relationship in certain markers 
























Table 2.1: Published evidence of oxidative stress in a variety of biological samples 










↑ H2O2 [a] 
↑ PGF2α [b] 
 
 
↑ H2O2 [c] 
↑ PGF2α [d, e] 
 
Induced sputum ↑ PGF2α [f] 
↑ GSSG [g] 
↑ 3-bromotyrosine [h] 
↑PGF2α [i] 
↓ AA [j] 
 
Exhaled gases ↑ CO [k] 
↑ NO [k, l] 
 
↑ CO [m,n] 
Airway lavage No data 
 
↑ 8-isoprostane [o] 
↓ AA, ↑ GSSG [p] 
 
Airway tissue ↑ NFκB [q] 
↓ IκB-α [r] 
↓ Nrf2 [s] 
↑ 4-HNE [t] 
↑ 3-NT [u] 
 
↑ NFκB [v] 




Abbreviations: H2O2: hydrogen peroxide; PGF2α: prostaglandin F2alpha; GSSG: 
glutathione disulphide; AA: ascorbic acid; CO: carbon monoxide; NO: nitric oxide; NFκB 
: nuclear factor kappa light chain enhancer of activated B cells;  IκB-α : nuclear factor 
of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; Nrf2: nuclear 
factor erythroid 2-related factor 2; 4-HNE: 4-hydroxynonenal; 3-NT: 3-nitrotyrosine; 
SOD: superoxide dismutase. 
References: ‘a’, Nowak et al. 1999; ‘b’, Montuschi et al. 2000; ‘c’, Loukides et al. 2002; 
‘d’, Montuschi et al. 1999; ‘e’, Zanconato et al. 2004; ‘f’, Kinnula et al. 2007; ‘g’, Beeh 
et al. 2004; ‘h’, Aldridge et al. 2002; ‘i’, Wood et al. 2005; ‘j’, Kongerud et al. 2003; ‘k’, 
Montuschi et al. 2001; ‘l’, Ansarin et al. 2001; ‘m’, Horváth et al. 1998; ‘n’, Zayasu et 
al. 1997; ‘o’, Xie et al. 2009; ‘p’, Kelly et al. 1999; ‘q’, Di Stefano et al. 2002; ‘r’, 
Szulakowski et al. 2006; ‘s’, Goven et al. 2008; ‘t’, Rahman et al. 2002; ‘u’, Ricciardolo 




Despite the wealth of data summarised in Table 2.1, there is a complete 
absence of information in the literature related to RTLF antioxidant concentrations in 
COPD patients, with much inferred from the alterations in redox status observed in 
the lungs of chronic smokers or in subjects after acute inhalation of cigarette smoke 
(reviewed in Rahman and MacNee, 1999). Such information is vital in assessing the 
sensitivity of individuals or disease groups to oxidative injury. At this time, despite the 
preliminary evidence of some association between inflammatory markers made in 
exhaled breath condensate and bronchoalveolar lavage, bronchoscopy based lavage 
still remains the ‘gold standard’ method of assessing airway immunopathology and 
redox status.  
 
 In the first part of this chapter, I will address whether antioxidant defences at 
the air-lung interface are depressed in COPD patients, both smokers and ex-smokers, 
relative to appropriate age and smoking status matched ‘healthy’ controls. These data 
are derived from bronchoscopy based lavages in these subject groups and therefore 
represent a unique examination of antioxidant defences (low molecular weight 
antioxidants: ascorbate, urate and glutathione; metal chelating proteins: transferrin, 
lactoferrin and ferritin; plus a range of oxidative damage markers: glutathione 
disulphide, dehydroascorbate, 4-hydroxynonenal) within the regions of the lung 
affected in this disorder. This information will then be compared against antioxidant 
measurements made in young healthy non-smokers and patients with mild atopic 
asthma. The inclusion of these additional groups in the second part of this chapter was 
to address the extent to which declines in airway antioxidant status, if seen in COPD 
patients, might be attributed to normal age-related declines in airway defences, as 
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well as a ‘generalised’ inflammatory state: allergic versus chronic. I hypothesised that 
COPD would be characterised by impaired antioxidant defences within the RTLF, 
relative to aged-matched controls, associated with the presence of chronic airway 
inflammation and that this would be apparent irrespective of smoking status. Current 
smoking, I conjectured, would further degrade the antioxidant defences at the air-lung 
interface. Further, I hypothesised that the extent of oxidative stress (more precisely 
defined as altered redox status) in the RTLF would be related to disease severity, the 









2.2.1 Subject demographics  
Subjects for all groups were invited to participate in the present study through 
advertisements in the local media. COPD patients (aged 50-75 years) had moderate to 
severe disease according to the GOLD criteria (FEV1 30-80% of predicted, FEV1/FVC 
less than 0.7) with a smoking history of at least ten pack-years and no evidence of 
other concomitant disease. All patients were required to be non-atopic and clinically 
stable, i.e. without any respiratory tract infection within a six-week period prior to and 
during the study, along with no history of frequent exacerbations during a period of at 
least 3 months prior to inclusion. The only medication permitted was short-acting β2-
agonists and/or anti-cholinergic drugs. Neither long-acting bronchodilators nor 
inhaled corticosteroids were allowed. All subjects were also required to undergo a 
detailed medical consultation with an ECG and chest X-rays prior to inclusion. Healthy 
never-smoking volunteers were age-matched (50-75 years), had normal lung function 
(>80 FEV1 % of predicted) and were all non-atopic. Similarly, aged ‘healthy’ smokers 
were required to have normal lung function, as previously defined, were age-matched 
(50-75 years) and had a smoking history of more than ten pack-years. They were all 
non-atopic and clinically stable. 
 
Subjects recruited to the young healthy control group were required to meet 
the following inclusion criteria: age 18-40 years; never smokers; no history of allergy 
or asthma and normal lung function (FEV1 >80% predicted). All mild asthmatics (FEV1 
>80% of predicted, age range 18-40 years) were required to have a history of allergy 
and at least one positive skin prick test to either Birch or Timothy grass pollen. Mild 
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asthmatics were also required to exhibit bronchial hyper-responsiveness (PC20 
<8mg/ml metacholine). Exclusion criteria were: uncontrolled asthma; any airway 
infection within six weeks prior to the study and current use of medication other than 
inhaled corticosteroids or short-term β2-agonists. Exclusion criteria for all groups were 
the use of any medications other than those specifically stated in the inclusion criteria 
and any use of antioxidant supplementation, including iron supplements. 
 
A total of 57 subjects were recruited into the first part of the study (the aged 
population with and without COPD); 13 healthy aged controls (all never-smokers); 16 
aged smokers (with no evidence of chronic respiratory disease); 17 COPD patients (ex-
smokers) and 11 patients who had continued to smoke following their diagnosis of 
COPD. The second part of the study included 16 young healthy and 16 mild asthmatic 
subjects. All subjects participated following submission of formal consent with study 
approval awarded by the local Ethics Committee of the University of Umeå, in 
accordance with the declaration of Helsinki. A summary of the subject demographics 
is provided in Table 2.2 (aged controls, smokers and COPD patients) and Table 2.3 
(young adults and asthmatics).  
 
2.2.2 Pulmonary function test 
Dynamic spirometry variables (VC, FVC and FEV1) were measured pre and 15-
20 minutes post-bronchodilation with 1mg of terbutalin (Bricanyl® Turbuhaler®; 
AstraZeneca, Södertälje, Sweden) using a Vitalograph spirometer (Buckingham, UK) 
and reversibility calculated. At least three satisfactorily performed and well-
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cooperated measurements of each variable were carried out according to the 
recommendations of the American Thoracic Society. The diffusion capacity of carbon 
monoxide (CO) was obtained by the single breath procedure (Ogilvie et al. 1954).  
 
2.2.3 Collection and preparation of bronchoalveolar lavage samples 
Bronchoscopy was performed on an outpatient basis, following an overnight 
fast, using a flexible video bronchoscope (Olympus BF IT240, Tokyo, Japan) inserted 
through the mouth with the subject in the supine position. Pre-medication with 
atropine (1 mg) was given subcutaneously 30 minutes prior to bronchoscopy to 
reduce airway mucus secretion, with Lidocain (5% and 1%) sprayed onto the airways 
to achieve topical anaesthesia. Bronchial wash (BW) was performed by infusing two 
aliquots of 20 mL sterile sodium chloride (NaCl), pH 7.3 at 37oC into the lingular or 
middle lobe, which was gently sucked back after each infusion. These recovered 
aspirates were kept as separate aliquots on wet ice. Bronchoalveolar lavage (BAL) was 
performed immediately after these small volume infusions by the instillation and 
immediate aspiration of 3 consecutive aliquots of 60 mL saline. The recovered 
aspirates were pooled and placed on wet ice prior to transport to the laboratory for 
processing.  
 
Both BW and BAL fluids were passed through a nylon filter (pore diameter 100 
µM) to remove the mucus and the cellular content was isolated by centrifugation at 
400 rpm for 15 minutes at 4˚C. The obtained pellets were then resuspended in 
phosphate buffer solution (PBS) to a concentration of 106 cells/ml. Total and 
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differential cell counts were carried out on cyto-centrifuge preparations stained with 
May-Grűnwald Giemsa, with a 400 total cell count per slide. Further description of 
these methods is available (Mudway 2001).  The chilled bronchial wash (BW) and 
bronchoalveolar lavage (BAL) fluids were filtered through a nylon filter and 
centrifuged (400 rpm, 15 minutes, at 4˚C). After centrifugation, the cell pellet was 
separated from the supernatant and resuspended in PBS. The total number of cells 
was counted and adjusted to a final concentration of 106 cells/ml. The resultant 
supernatant was treated as follows: an aliquot of lavage fluid (450 μL) was treated 
with 50 μL of 50% metaphosphoric acid (MPA), vortexed for 30 seconds and 
centrifuged at 13,000 rpm for 5 minutes (4oC) to remove protein. The resultant 
supernatant was then stored at -80oC within 30 minutes of BAL collection until 
required for analysis. Samples for GSH and GSSG determination were treated with the 
metal chelator deferoxamine mesylate (DES) and the synthetic antioxidant butylated 
hydroxytoluene (BHT) both at 2 mM, 5 µl of each to 490 µl of lavage, prior to storage 




Table 2.2: Subject demographics for the aged population; with and without COPD, smokers, ex-smokers and never smokers. 
 
 
All data are expressed as medians with either the inter-quartile or full range, as indicated. Significant differences across groups were assumed at the 5% level using 
the Kruskal–Wallis one-way analysis of variance by ranks (significance illustrated in the far right hand column), with post-hoc testing between specified groups 
performed using the Mann-Whitney U Test. Comparison of individual groups were restricted to healthy smokers versus never smokers (a, P < 0.05), healthy 
smokers and COPD current smokers (b, P < 0.05), never smokers versus COPD ex-smokers (c, P < 0.05) and COPD current and ex-smokers (d, P < 0.05). Lung 
function measurements are based on post-bronchodilator values, with evidence of % airway reversibility indicated. Pack years were calculated by multiplying the 
number of packs of cigarettes smoked per day by the number of years the person had smoked. FVC = Forced Vital Capacity; FEV1 = Forced Expiratory Volume in 1 
second; TLC = Total Lung Capacity; IC = Inspiratory Capacity; MEF50 = Maximum Expiratory Flow when 50% of the FVC has been exhaled; TLCOSB = lung carbon 
monoxide diffusing capacity in a Single Breath; % BAL recovery was based on a total instilled saline volume of 180 mLs. 
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Table 2.3: Subject demographics for the young healthy and mild asthmatic groups. 
 
All data are expressed as medians with either the inter-quartile or full range, as indicated. 
 
2.2.4 Differential cell counts 
Cytocentrifuged specimens were prepared by centrifugation at 450 rpm for 5 
minutes. The slides were stained with May-Grünwald Giemsa for cell differential 
counts. 500 cells per slide were counted using a light microscope at 100x 
magnification and the proportion of non-epithelial cells including macrophages, 
neutrophils, eosinophils and lymphocytes was established. Mast cells were analyzed 
on slides stained with basic toluidine blue and counterstained with Mayer´s acid 
haematoxylin, counting a minimum of 12 visual fields at 20x magnification. Based on 
the total cell concentration and the differential cell counts, the concentration of each 








2.2.5 Antioxidant and oxidative damage marker analyses  
2.2.5.1  Ascorbate and urate  
All chemicals used in this and subsequent analyses were obtained from Sigma-
Aldrich Chemical Company Ltd (Poole, UK) unless otherwise stated. Ascorbate (AA) 
and urate (UA) were measured simultaneously by reversed-phase HPLC with 
electrochemical detection (Iriyama, Yoshiura et al. 1984). Pre-acidified and 
deproteinated samples stored at -80oC in 5% MPA were thawed on wet ice. Lipid 
extraction was achieved by transferring 400 µl aliquots of these acidified samples to 
eppendorfs containing 50 µl of 5% MPA and 200 µl of heptane chilled to 4oC, followed 
by vortexing for 60 seconds and centrifugation at 13,000 rpm for 5 minutes (4oC). The 
resultant lower layer was then carefully decanted into amber HPLC vials for analysis. 
All sample processing was performed on wet ice with care taken to protect the 
samples from light at all times. A Gilson 234 auto-sampler was used to inject 20 µl 
aliquots of each sample for analysis on a 5 µm C18 column (4.6 x 150 mm) from 
Phenomenex, eluted with a 0.2 mM K2HPO4-H3PO4 mobile phase containing 0.25 mM 
octanesulphonic acid (pH 2.1) at a flow-rate of 1.5 ml/min. An E&EG amperometric 
electrochemical detector was used for detection with the voltage set at 400 mV and a 
current sensitivity of 0.2 µA. Ascorbate and urate concentrations were determined 
against appropriate standards (AA range: 0-12.5 μM; UA: 0-25 μM). Typical standard 





Figure 2.1: Typical standard curves of ascorbate (upper panel; concentrations: 0, 0.78, 
1.56, 3.125, 6.25 and 12.5 µM; n = 1) and urate (lower panel; concentrations: 0, 1.56, 
3.125, 6.25, 12.5 and 25 µM). 
 
Total vitamin C (dehydroascorbate (DHA) + ascorbate) was also measured by 
pre-treating the 400 µl aliquots of acidified sample with 50 µl of 50 mM Tris(2-
carboxyethyl)phosphine (TCEP) in 5% MPA (Molecular Probes, Eugene, Oregon USA) 
for 15 minutes and then performing the lipid extraction and HPLC analysis as 
described above. The DHA concentration was then calculated by subtracting the 
measured ascorbate concentration from the total vitamin C concentration.  
 






































Representative lavage ascorbate and vitamin C (following sample pre-
treatment with the reductant dithiothreitol (DTT), an alternative to TCEP in un-
acidified samples) traces are illustrated in Figure 2.2. Nasal lavage fluid was used for 
these illustrative chromatograms as the lavage procedure, described by Mudway et al. 
(1999), permits rapid sampling of the nasal epithelial lining fluids and therefore allows 
samples to be processed for analysis within 10-15 minutes, minimising the likelihood 
of artifactual oxidation of ascorbate. Nasal lavage was performed on a healthy male 
subject and the sample was processed for immediate determination of ascorbate and 
vitamin C content at 400 mV. The fresh lavage contained 0.43 µM of ascorbate and 
3.63 µM of vitamin C following sample reduction with DTT (final concentration 5 mM), 
hence 3.2 µM DHA.  The authenticity of this peak was confirmed relative to the 
retention time of a 3.125 µM ascorbate standard prepared in 5% MPA and by spiking a 
400 µL aliquot of the lavage with 50 µL of a 5 µM ascorbate solution prior to the 
addition of 50 µL of 50% MPA. The subsequent concentration in the sample was 1.39 
µM, indicating a 96% recovery of the added ascorbate. Samples were also incubated in 
the presence of ascorbate oxidase for 5 minutes at room temperature (5U/mL final 
concentration), which completely abolished the ascorbate peak. To confirm that the 
increase in the ascorbate peak following DTT reduction could not be attributed to the 
appearance of another signal with an identical retention time, we re-ran the sample at 
810 mV, a potential at which thiols (cysteine, glutathione and homocysteine) are 
readily detectable in this assay. At this potential, following sample reduction with DTT, 
a cysteine peak was apparent, close to, but separate from the ascorbate peak. This 
peak was unaffected by the ascorbate oxidase treatment. To confirm that an 
ascorbate oxidation product other than DHA was not being recycled by DTT we 
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repeated the ascorbate oxidase treatment with the amendment that following the 
initial 5 minute incubation, the sample was transferred to an incubator at 37oC for a 
further 10 minutes to promote the hydrolysis of DHA. Following DTT reduction and 
acidification of this sample no ascorbate was recovered, whilst the cysteine and uric 
acid peaks seen at 810 mV were unaffected.  
 
2.2.5.2  Glutathione determinations  
 Total glutathione concentrations were measured using the GSSG-reductase-
DTNB recycling method developed by Tietze (Tietze 1969) and subsequently modified 
for use on a plate reader by Baker et al. (Baker, Cerniglia et al. 1990). This is based on 
a kinetic assay in which glutathione causes a continuous reduction of 5,5’-dithiobis(2-
nitrobenzoic acid) (DTNB) to TNB. Glutathione reductase and NADPH subsequently 
recycle the oxidised glutathione (GSSG) formed to regenerate reduced glutathione 
(GSH). The product, TNB, is assayed by measuring the absorbance at 405 nm, its 
production being proportional to the total glutathione present, and is expressed as 






Figure 2.2: Typical chromatograms derived from freshly prepared nasal lavage fluid 
obtained from a healthy male subject. Panel ‘A’ illustrates a set of traces at 810 mV, 
with thiols (cysteine and reduced glutathione) and panel ‘B’ at 400 mV, without thiols. 
The ascorbate and urate peaks are highlighted. The trace labelled ‘1’ in both diagrams 
corresponds to a standard containing ascorbate and uric acid at 3.125 and 6.25 µM 
respectively, prepared in 5% MPA. Trace ‘2’ corresponds to the acidified (5% MPA final 
concentration) nasal lavage fluid sample. The inset panels illustrate a magnification of 
the circled section of the main trace with, ‘a’, corresponding to the acidified lavage 
sample; ‘b’, the sample treated with ascorbate oxidase; ‘c’, the sample treated as 
outlined previously, but subsequently incubated at room temperature for 10 minutes 
prior to sample reduction with 0.1% DTT (final concentration); ‘d’, the lavage fluid 
spiked with ascorbic acid; and ‘e’, the lavage fluid immediately reduced with DTT, 







50 µl aliquots of DES/BHT-treated samples were added to a 96-well ELISA 
microplate (Greiner Bio-one, Stonehouse, UK) and 100 µl of DTNB reaction mix added 
to achieve final concentrations of 0.15 mM DTNB, 0.2 mM NADPH and 1 U glutathione 
reductase (from baker’s yeast) in phosphate buffer (100 mM sodium phosphate 
containing 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.5) in each well. The 
plate was then transferred to a plate reader (SpectraMAX 190, Molecular Devices) and 
the immediate rate of change of absorbance at 405 nm followed for two minutes at 
30°C, with absorbance measurements made every 10 seconds with mixing between 
measurements. Glutathione concentrations in samples were measured by comparison 
with a set of standards (GSSG: 0-6.6 μM). A typical standard curve for total glutathione 
is illustrated in Figure 2.3. 
 
The GSSG concentration was measured by pre-treating samples with 2-vinyl 
pyridine for 1 hour. This reagent forms a conjugate with GSH and prevents it from 
reacting with the DTNB. Treated samples were analysed as outlined above. GSSG 
produces two molecules of TNB when it reacts with DTNB whereas reduced GSH 
produces only one molecule of TNB. Consequently, the reduced GSH concentration 
was calculated as: 
Total glutathione – (2 x GSSG) 
 
GSSG concentrations in samples were again measured by comparison with a set of 
standards (GSSG: 0-3.3 μM) also treated with 2-vinyl pyridine. A typical standard curve 
for GSSG ran with and without 2-vinyl pyridine treatment is shown in Figure 2.3. The 
sensitivity of this glutathione assay has been determined to be 0.025 μM and 0.01 μM 
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for GSH and GSSG respectively. Intra- and inter-assay variability for GSH was 





Figure 2.3: Typical standard curves of total glutathione (upper panel; concentrations: 
0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300 and 330 ρmol/50 µl; n = 2) and 
glutathione disulphide (lower panel; concentrations: 0, 15, 30, 45, 60, 75, 90, 105, 120, 
135, 150 and 165 ρmol/50 µl). 
 
2.2.5.3  Total protein determinations 
Total protein was measured by reaction with bicinchoninic acid (BCA) and 4% 
copper (II) sulphate against a set of bovine serum albumin (BSA) standards (Smith, 












Total glutathione (pmol / 50uL) 














GSSG (pmol / 50uL) 
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Krohn et al. 1985). This method is based on the reduction of Cu2+ by proteins in an 
alkaline medium, with the highly sensitive and selective colourimetric detection of Cu+ 
using BCA. The chelation of two molecules of BCA with each Cu+ ion forms a purple 
coloured product that exhibits a strong absorbance at 562 nm. A typical standard 
curve is illustrated in Figure 2.4. 
 
Figure 2.4: Typical standard curve of total protein concentration with BSA standard 
concentrations of 0, 0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml. 
 
 
2.2.5.4  Endogenous protein chelator measurements  
 Metal handling proteins were measured in untreated lavage using a variety of 
commercially available ELISA kits. Human transferrin (diluted 50-fold in the supplied 
assay buffer) and ferritin (undiluted) were quantified in BAL fluid samples with the use 
of ELISA kits from Alpha Diagnostic International, Inc., San Antonio, TX, USA. Human 
lactoferrin (undiluted) was quantified by ELISA kits from OXIS Research International, 
Inc., Portland, OR, USA.  
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2.2.5.5  Determination of protein bound 4-HNE  
HNE-His protein adducts were quantified using the OxiSelect HNE-His Adduct 
ELISA Kit (Cell Biolabs, Inc., San Diego, CA) according to the manufacturer’s 
instructions.  HNE-His adduct concentrations in the lavage samples were established 
by comparing the sample absorbance against a known HNE-BSA standard curve: 0-10 
µg/ml. 
 
2.2.6 Statistics  
 Data were not normally distributed (Shapiro-Wilks test) and are therefore 
expressed throughout as medians with the 25th and 75th percentiles. Comparison of 
inflammatory cell numbers, antioxidant and oxidative damage markers concentrations 
across the various subject groups were performed using the Kruskal–Wallis one-way 
analysis of variance by ranks, with post-hoc testing between specific groups 
performed using the Mann-Whitney U test. In all cases significant differences were 
assumed at the 5% level. Correlation analysis for each individual group, plus compiled 
groups of COPD patients (current and ex-smokers) and smokers (both aged ‘healthy’ 
smokers and COPD smokers) were performed using the Spearman Rank Order 
Correlation. These analyses were restricted parameters that had been shown to differ 
significantly between groups to limit the likelihood of reporting spurious associations. 
All analyses were performed using SPSS, version 17.0 (SPSS Inc., Chicago, IL). 
 
2.3 Results and Discussion 
To investigate whether COPD patients exhibit oxidative stress at the surface of 
their airways, I performed measurements of the major low molecular weight 
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antioxidants and chelator proteins in airway lavage fluids recovered from current and 
ex-smoking patients, as well as age and smoking-history matched controls (details 
provided in Table 2.5). In addition, I examined the concentration of the lipid oxidation 
marker, 4-hydroxynonenal (as protein adducts), which had previously been reported 
to be elevated in lung tissue specimens obtained during lung resections of patients 
with COPD (Rahman et al. 2002). This is the first comprehensive study to examine 
RTLF antioxidant defences in lavage samples from COPD patients, as reviewed in 
section 2.1, and complements earlier work examining cellular antioxidant defences in 
airway leukocytes recovered by BAL in these subjects (Behndig et al. 2009). Data 
arising from these subject groups on lymphocyte subsets have been published 
previously by our collaborators at the University of Umeå (Roos-Engstrand et al. 2009, 
2010 and 2011).  
 
Of the subjects recruited into the study, bronchoscopy with bronchoalveolar 
lavage was successfully performed on 9/11 COPD smokers, 15/17 COPD ex-smokers, 
13/13 healthy aged never-smokers and 16/16 ‘healthy’ aged smokers, with recovery 
being significantly lower (36%) in the COPD ex-smoking group relative to the aged 
match never-smokers (50%, P<0.05) – Table 2.2.  Overall recoveries were markedly 
lower than has previously been reported in younger populations of healthy volunteers 
and asthmatics, where in excess of 70-80% of the instilled volume is typically 
recovered (Mudway et al. 2001). Differential cell counts are presented for both BW 
and BAL fluid in Table 2.4 and were performed by colleagues at the Division of 




2.3.1 Differential cell counts 
An increase in total airway leukocytes of smokers compared to never-smokers 
was observed, predominantly reflecting a 2.6 and 2.1-fold expansion in BAL fluid 
macrophage numbers in aged healthy and COPD smokers compared with their 
corresponding never-smoking or ex-smoking controls (P<0.001 in both cases – Table 
2.4). These data therefore accord with other published studies showing an increase in 
total leukocytes in the airways of smokers with normal lung function (Wallace et al. 
1992; Barcelo et al. 2008); with a similar expansion in airway macrophage numbers 
reported in the lungs of young smokers (Ohnishi et al. 1998). A similar smoking-
related increase in macrophage numbers was not apparent in the more proximal BW 
sample. No increase in macrophage numbers was observed in the COPD patients, 
current or ex-smokers compared with their relevant control groups. This result is 
somewhat at odds with the literature reports of increased macrophage numbers in 
the bronchial sub-mucosa (Rutgers et al. 2000; Di Stefano et al. 1996; Saetta et al. 
1993), bronchial glands (Saetta et al. 1997) and airway epithelium (Turato et al. 2002) 
of COPD patients. Furthermore, there is some evidence supporting a positive 
association between alveolar macrophage numbers and the severity of COPD 
(Finkelstein et al. 1995; Gorska et al. 2008). It is important to state that the COPD 
patients in the current study were all clinically stable, with no airway infection for a 
period of 3 months prior to the bronchoscopy, no recent exacerbations and were not 
taking anti-inflammatory medications. These tight recruitment criteria were adopted 
to minimise the influence of recent exacerbations and medication usage. Other 
studies examining airway inflammation in COPD have often provided limited 
information on the patient’s recent history of infection, medication usage or smoking 
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history (examples being, Smyth et al. 2007; Saetta et al. 1993; Costabel et al. 1992), 
which makes a simple comparison of observations between studies difficult. This 
theme will be discussed in greater detail in the later section examining the absence of 










Table 2.4: Differential white blood cell counts in BW and BAL fluids from COPD patients and aged and smoking matched controls. Cell numbers 
are presented as cell/mL*104. 
 
All data are expressed as medians with either the inter-quartile or full range, as indicated. Significant differences across groups were assumed at the 5% level using the 
Kruskal–Wallis one-way analysis of variance by ranks (significance illustrated in the far right hand column), with post-hoc testing between specified groups performed using 
the Mann-Whitney U Test. Comparison of individual groups were restricted to healthy smokers versus never smokers (a, P < 0.05), healthy smokers and COPD current 
smokers (b, P < 0.05), never smokers versus COPD ex-smokers (c, P < 0.05) and COPD current and ex-smokers (d, P < 0.05). Subject numbers given in parenthesis represent 
the subjects recruited, plus the number of subjects from which BW or BAL was recovered for differential cell counts. 
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Whilst I observed no evidence of increased macrophage numbers associated 
with COPD, the smoking related increase was clear cut. It was also notable at the gross 
level that the aspirates obtained from the lungs of smoking subjects were discoloured 
(Figure 2.5), with corresponding cytospin preparations demonstrating the presence of 
carbon inclusions in many of the macrophages, consistent with previous observations 
(Brody et al. 1975). This increase in macrophage numbers in the distal lung in 
response to cigarette smoke could reflect increased recruitment or proliferation 
within the lung, or reduced cell death. In support of the first of these options, 
monocyte-selective chemokine (MCP-1) and  GRO-α  have been shown to be  
increased in induced sputum and BAL samples from COPD patients, including current 
smokers (Traves et al. 2002; Capelli et al. 1999), associated with increased alveolar 
and airway macrophage numbers (de Boer et al. 2000). Evidence of increased 
macrophage proliferation or reduced cell death has been inferred from the 
observation that inclusion bodies containing particles from cigarette smoke can be 
detected within the airway macrophages at least 2 years after smoking cessation 
(Marques et al. 1997). Macrophages themselves appear to have relatively low 
proliferative capacity within the lung, though some evidence of proliferation has been 
noted in the lungs of smokers relative to healthy and asthmatic subjects (Tomita et al. 
2002; Bitterman et al. 1984; Barbers et al. 1991). There is however, increasing 
evidence that alveolar macrophages from smokers exhibit a reduced rate of cell death 
(Tomita et al. 2002) related to increased expression of anti-apoptotic proteins, such as 
Bcl-xL and redox sensitive induction of p21CIP1/WAF1, a key regulator of the cell cycle 
(Yin et al. 1999). Recently, a significant reduction in the proportion of sputum 
92 
 
neutrophils undergoing spontaneous apoptosis has also been reported in healthy 
smokers and individuals with COPD compared with non-smokers (Brown et al. 2009). 
 
Cigarette smoke has also been reported to activate alveolar macrophages 
stimulating the release of inflammatory mediators such as tumour necrosis factor 
(TNF)-[alpha], IL-8, LTB4 and interleukin-1 (IL-1) (Sarir et al. 2009; Ito et al. 2000) as 
well as reducing their capacity to phagocytose apoptotic epithelial cells (Hodge et al. 
2003), Escherichia coli (Prieto et al. 2001) and H. influenzae (Berenson et al. 2006). 
Whilst I did not explore cellular function in this thesis in relation to disease severity or 
smoking status, it is significant that there is increasing evidence of aged and 
functionally impaired macrophages in the lungs of aged smokers. Previous work by 
Behndig et al. (2009) examining the antioxidant enzymes in airway leukocytes 
(predominately alveolar macrophages) harvested from the same subjects as employed 
in this analysis demonstrated an apparent age related decline in their activities, which 
appeared independent of disease state or smoking status. Given that many of the 
non-smoking COPD patients were recent quitters, it is tempting to speculate that the 
presence of aged cell macrophages in the lung with degraded defences may 
contribute to the pathology of COPD, though one would want to see evidence of 





Figure 2.5: Bronchoalveolar lavage aspirates from a healthy never-smoker (upper left 
hand panel), and a current smoker (lower left hand panel) from the aged control 
groups of the current study. The corresponding May-Grűnwald Giemsa stained 
cytospins are illustrated to the right, illustrating the preponderance of macrophages, 
and in the lower panel the presence of carbon inclusions in the darkly stained cells. 
 
No evidence of neutrophilia in COPD smokers and ex-smokers was observed 
relative to their control groups (Table 2.4). This observation differs markedly from the 
published literature where increased BAL neutrophils have been reported in both 
smoking and ex-smoking COPD patients (Babusyte et al. 2007; Barnes et al. 2003). 
Moreover, this increase in neutrophil numbers has been reported to persist even after 
smoking cessation (Louhelainen et al. 2009). The basis for this cellular recruitment to 
the airways has been associated with the increased release of chemotactic factors 
such as interleukin 8 (IL-8) and leukotriene B4 (LTB4), which have been shown to be 
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elevated in the airways of patients with COPD (Corhay et al. 2009; Sarir et al. 2009). 
Again, the discrepancy between the absence of overt inflammation in the COPD 
patients in the current study versus the existing literature may reflect the clinical 
status of the mild to moderate COPD patients examined in the present study. Previous 
studies have reported increased airway neutrophilia to be associated with more 
severe disease (Hodge et al. 2004) or exacerbations (Fiorini et al. 2000). 
 
 Increases in BAL mast cell numbers were also observed in aged ‘healthy’ 
smokers (0.06 (0.03-0.10) cell/mL*104) relative to the aged non-smokers (0.01 (0.01-
0.02) cell/mL*104, P=0.002), with a similar increase also apparent in the more 
proximal BW sample (P=0.017). A similar increase was not observed in the COPD 
smokers relative to the ex-smoking patients. Recently, it has been demonstrated that 
the numbers of mast cells were significantly increased in the sputum of smokers 
compared to ex-smokers (Wen et al. 2010). Moreover, CXCL-10, which has recently 
been implicated in mast cell migration to the airway smooth muscle cells bundles 
(Brightling et al. 2005) has been shown to be elevated in the airways of smokers 
compared to control groups (Clarke et al. 2010). Mast cell activation has also been 
demonstrated in the distal lung of smokers, with increased concentrations of 
histamine and tryptase reported in bronchoalveolar lavage fluid recovered from these 
subjects (Yamamoto et al. 1997). Overall therefore, I observed little evidence of upper 
or lower airway inflammation in relation to the presence of COPD itself, rather the 





2.3.2 Low molecular weight antioxidants 
Consideration of the antioxidant defences within the respiratory tract lining 
fluids of the volunteers was restricted to the major low molecular weight antioxidants 
(glutathione, urate and ascorbate) and chelator proteins (transferrin, lactoferrin and 
ferritin). Due to the limited recovery of lavage samples from the bronchial airways, 
especially from the COPD patients, these analyses were restricted to the more distal 
bronchoalveolar lavage fluid samples. These data are summarised in Table 2.5.  
Significantly increased concentrations of GSH were noted in both the aged ‘healthy’ 
(5.1-fold increase, P<0.001) and COPD smokers (2.3-fold increase, P=0.019) relative to 
their non-smoking control groups (Figure 2.6). These increases were not associated 
with enhanced concentrations of glutathione disulphide in the smoking subjects. In 
addition, I observed no evidence of increased GSH or GSSG concentrations related to 
the presence of COPD. The observation of an increase in respiratory tract lining fluid 
GSH concentrations following acute smoking, or in active smokers, accords with 
previous observations (Cantin, North et al. 1987; Linden, Hakansson et al. 1989; 
Morrison, Rahman et al. 1999; MacNee 2000). Similar increases in GSH at the air-lung 
interface have also been reported in human subjects following inhalation of gaseous 
oxidants (nitrogen dioxide - Kelly et al. 1996; ozone -Mudway et al. 2006), or diesel 
exhaust (Mudway et al. 2004) suggesting that the transient up-regulation of GSH 
following acute exposures to these aerosols may act to counteract the increased 




Figure 2.6: Total and reduced glutathione, plus glutathione disulphide concentrations 
in bronchoalveolar lavage fluids recovered from COPD patients (both current and ex-
smokers) and aged matched controls (current and never smokers). Data are 
summarised as box plots, with the central line illustrating the median values, the 
upper and lower boundaries of the box, the 75th and 25th percentiles respectively, and 
the whiskers, the 95% confidence intervals. Comparisons between groups were 
performed using the Mann-Whitney U Test, with P-values illustrated. NS = no 
significant difference between the indicated groups. 
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Table 2.5: Antioxidant and oxidative damage marker concentrations on BAL fluid from COPD patients and age-match controls. 
 
All data are expressed as medians with inter-quartile range. Significant differences across groups were assumed at the 5% level using the 
Kruskal–Wallis one-way analysis of variance by ranks (significance illustrated in the far right hand column), with post-hoc testing between 
specified groups performed using the Mann-Whitney U Test. Comparison of individual groups were restricted to healthy smokers versus never 
smokers (a, P < 0.05), healthy smokers and COPD current smokers (b, P < 0.05), never smokers versus COPD ex-smokers (c, P < 0.05) and COPD 
current and ex-smokers (d, P < 0.05).
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It remains unclear from the literature, as reviewed in Chapter 1 (section 
1.6.2.3) whether this is a transient or sustained increase, or indeed whether it reflects 
a regulated export mechanism that could be defined as an adaptation or passive 
release from dying cells, hence reflecting injury. For example, it is long established 
that cells induced to undergo apoptosis demonstrate a rapid and specific efflux of GSH 
(van den Dobbelsteen et al. 1996) that can be delayed by the provision of GSH-
diethylesters to boost intracellular GSH concentrations. This export process appears to 
involve multidrug resistance-associated protein 1 (MRP1), with export retarded by 
knocking down the expression of this transporter by RNA interference (Hammond et 
al. 2007). This channel also appears to play a role in the basal export of glutathione to 
the extracellular environment (Marchan et al. 2008), though it remains unclear from 
the existing literature how its expression is affected by oxidative stress. In addition to 
MRP1, multidrug resistance-associated protein 2 (MRP2) and the cystic fibrosis 
transmembrane conductance regulator (CFTR) have been demonstrated to play a role 
in GSH export (Gao et al. 1999; Ballatori et al. 2005), though once again their 
regulation in response to oxidative stress is poorly defined. This discussion on the 
potential source of the GSH moving into the RTLFs in smokers will be developed later, 
following consideration of the other antioxidants and relation of these findings to 
those obtained in young adults and asthmatic subjects. 
 
Vitamin C (ascorbate, plus dehydroascorbate) concentrations were also found 
to be significantly augmented in healthy smokers, compared with the aged-matched 
non-smoking controls (1.8-fold, P=0.025 – Table 2.5, Figure 2.7).  An increase (2.1-
fold) was also observed in the COPD smoking group compared with the ex-smokers 
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but this failed to attain statistical significance (P=0.06). These increases again only 
appeared to relate to the subjects smoking status and not the presence of COPD. In 
the COPD patients the significant increase in BAL fluid vitamin C concentrations with 
smoking, reflected  an increase in ascorbate (P=0.016) though it was notable that 
ascorbate itself contributed only a small fraction of the measured vitamin C pool and 
was often not measureable in the ex-, or never-smoking subjects.   
 
 
Figure 2.7: Total Vitamin C, ascorbate and dehydroascorbate concentrations in 
bronchoalveolar lavage fluids recovered from COPD patients (both current and ex-
smokers) and aged matched controls (current and never smokers). All other data 




The presence of high concentrations of dehydroascorbate (DHA) in the BAL 
fluid samples is a contentious observation. DHA is inherently unstable under 
physiological conditions and rapidly hydrolyses to a variety of irreversible oxidation 
products including 2,3-diketo-L-golonic, oxalic and threonitic acids (Deutsch, 2000). Its 
presence at baseline therefore raises numerous conceptual problems; if ascorbate 
within airway RTLFs were inherently unstable this would constitute a significant drain 
on the body’s vitamin C reserves. Thus one has to first address the question of 
whether erroneous oxidation has occurred in the samples. All lavages were performed 
with unbuffered saline (pH 5.4) to limit oxidation during the collection and then 
immediately acidified with metaphosphoric acid after the isolation of the cell free 
fraction (see section 2.2.3). These precautions, together with rapid sample processing 
at 4oC and storage at -80oC would be considered sufficient to preserve the in vivo ratio 
of ascorbate to DHA. It should also be noted that conditions likely to promote the 
oxidation of ascorbate would also result in hydrolysis of DHA, and that the ratio of 
GSH to GSSG (Table 2.5) in the samples did not support the view that there was 
generic oxidation of lavage aspirates. 
 
In contrast to the intracellular environment, which is maintained in a reducing 
state, there is increasing evidence that the respiratory tract lining fluids of the lung 
may represent a more oxidising environment. Studies have demonstrated that 
ascorbate is rapidly oxidised by induced sputum in an azide inhibitable manner 
suggesting that endogenous peroxidases may contribute to the oxidative losses 
observed (Schock, 2004). The RTLF has also been shown to contain appreciable 
concentrations of non-transferrin bound iron, especially in chronic inflammatory 
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diseases (Gutteridge, 1996). Thus, if substantial losses of vitamin C from the RTLF are 
to be prevented, either regenerative pathways must exist to reduce DHA back to 
ascorbate, or the half-life of DHA in this compartment must be sufficient to permit its 
uptake by epithelial or resident inflammatory cells with its subsequent reduction back 
to ascorbate. Whilst the high concentrations of GSH within the RTLF will reduce a 
small fraction of the DHA back to ascorbate (Winkler et al. 1994), the rate at which 
this occurs over the RTLF concentration range, 200-400 µM, is insufficient to prevent 
substantial hydrolysis of DHA. There is also no solid evidence of dehydroascorbate 
reductase activity within this extracellular compartment to catalyse such a reduction. 
In contrast, the rapid uptake of DHA into a variety of cell types (neutrophils, 
lymphocytes, epithelial cells) via facilitated glucose transporters GLUT1, GLUT3 and 
GLUT4 has been demonstrated (Vera et al. 1993; Rumsey et al. 1997; Liang et al. 
2001), with evidence that once internalised the DHA is rapidly reduced to ascorbate by 
NADPH-dependent dehydroascorbate reductases (Park et al. 1996; Wilson et al. 2002).  
 
The major route of ascorbate uptake into cells occurs through the high affinity 
Na+-dependent vitamin C transporters, SVCT1 and SVCT2 (Tsukaguchi et al. 1999). It 
has been argued that the uptake of DHA is only likely to be significant during episodes 
of oxidative stress where high local concentrations of DHA occur near to cells 
producing reactive oxygen species (ROS). This DHA may be taken up by the ROS 
producing cells, as is the case for neutrophils (Wang et al. 1997) as well as by other 
cells near the site of production (Nualart et al. 2003). This view is based on a number 
of assumptions: that vitamin C is maintained in its reduced state in vivo through the 
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action of DHA-reductases and the effective chelation of iron, and that glucose will 
block DHA transport.  
 
Little is known about the regulation of vitamin C at the lung surface. 
Traditionally it has been assumed that RTLF ascorbate is derived by passive diffusion 
from the plasma pool, but there is little experimental evidence to support this view. 
Attempts to correlate basal human plasma and RTLF ascorbate concentrations have 
proven inconclusive (Behndig et al. 2009). Assuming that diffusion from the blood 
does contribute to RTLF levels it is tempting to speculate that the rapid oxidation of 
ascorbate not only provides DHA for cellular uptake, but also promotes further 
movement of ascorbate into this compartment down its concentration gradient.  If 
ascorbate is not derived directly from the plasma pool, it might be assumed that an 
export mechanism exists from respiratory epithelial cells. Whilst a considerable body 
of work has investigated ascorbate and DHA uptake, relatively little is known about 
cellular export. Both the addition of ascorbate to cells and intracellular reduction of 
DHA to ascorbate have been shown to stimulate efflux (Wilson, 2005), though the 
transporters involved have not been characterised. In addition, volume sensitive anion 
channels have been shown to be permeable to ascorbate (Furst et al. 2002) but again 
the molecular identities of these channels are not known.  Whilst there is little data on 
ascorbate exporters, the airway epithelium has been shown to express both SVCT1 
and 2 (Tsukaguchi et al. 1999) in the apical membranes of tracheal, bronchial and 
alveolar epithelium (Jin et al. 2005). Thus it would seem that rather than exporting 
ascorbate into this compartment, the epithelium may actively take up this antioxidant. 
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This, coupled to the instability of ascorbate within this compartment, may partially 
explain why the measured ascorbate concentrations were low in the current study. 
The basis for the relatively small increase observed in the smoking subjects, as with 
the GSH response, remain elusive and will be considered later in this chapter. 
Urate represents one of the major low molecular weight antioxidants within 
the RTLF (reviewed in section 1.6.2.1). Whilst previous studies have demonstrated low 
plasma urate concentrations to be associated with COPD severity (Nicks, 2011), in the 
present study I observed no evidence of altered BAL fluid urate concentrations 
associated with either smoking status or the diagnosis of COPD (Table 2.5). This 
accords with the only other published study addressing lavage urate concentrations in 
COPD, which demonstrated elevated concentrations in saliva but not BAL fluid from 
COPD smokers and ex-smokers relative to aged and smoking status matched controls 
(Yigla, 2007). 
 
2.3.3 Chelator proteins 
In addition to the low molecular weight antioxidants, I also considered the 
concentration of transferrin, lactoferrin and ferritin within the lavage returns. These 
data (summarised in Table 2.5 and Figure 2.8) demonstrated a marked smoking-
related increase in ferritin concentrations in both the aged healthy and COPD smokers 
relative to their non-smoking controls. This response appeared to parallel the 
increased concentrations of glutathione and vitamin C reported in the smoking 
groups. As ferritin is predominately an intracellular Fe storage protein, one 
explanation of this finding is that ferritin is being released into the respiratory tract 
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lining fluids as a function of cell death, with an associated release of intracellular 
antioxidants which possibly suggests that the response is not a regulated adaptation, 
as discussed previously. A previous study by Ghio et al. (1998) demonstrated a similar 
increase in ferritin in human volunteers following instillation of an iron-containing 
particle. In contrast to the present study however, Ghio also observed a parallel 
increase in lavage lactoferrin and decreased transferrin concentrations. In the present 
study, the concentration of these proteins was equivalent across the considered 
groups. Similar increases in ferritin have been reported in rat and human respiratory 
epithelial cells exposed to cigarette smoke and/or condensate with ferritin also 
reported to be elevated in airway lavage samples from smokers and patients with 





Figure 2.8: Ferritin, transferrin and lactoferrin concentrations in bronchoalveolar 
lavage fluids recovered from COPD patients (both current and ex-smokers) and aged 
matched controls (current and never smokers). All other data details are as outlined in 
the legend to figure 2.6. 
 
2.3.4 Protein bound 4-HNE 
In addition to respiratory tract lining fluid antioxidant concentration, I also 
examined the concentration of 4-hydroxy-2-nonenal (4-HNE) protein adducts Table 
2.5, Figure 2.9 (data are expressed per unit volume of recovered BAL, or per unit 
protein). The focus on this oxidative post-translational modification was based on 
previously published data in which increased staining for 4-HNE-modified proteins was 
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observed in the airway epithelium, endothelium and neutrophils in lung tissue 
specimens obtained during lung resections, from patients with and without COPD 
(Rahman, et al. 2002). I observed no evidence of increased adduct concentrations in 
the lavage samples in relation to subject smoking status, or the presence of COPD 
(Figure 2.9). Rather, there was evidence of decreased concentration of 4-HNE-
modified proteins in COPD ex-smokers relative to their aged-matched non-smoking 
controls, though this failed to attain statistical significance (P=0.06) unless the 
comparison was performed between the combined groups of smoking and non-





Figure 2.9: Protein bound 4-hydroxynonenal concentrations in bronchoalveolar lavage 
fluids recovered from COPD patients (both current and ex-smokers) and aged matched 
controls (current and never-smokers). Data are expressed per volume of recovered 








2.3.5 Correlation data 
 Correlation analysis was performed between those antioxidant and oxidative 
damage marker concentrations which had been shown to differ between the patient 
groups and selected clinical endpoints related to impaired pulmonary function (FEV1 
and reversibility), gas exchange (TLCOSB) and inflammation (BAL macrophage and 
neutrophil numbers). The results of these analyses are summarised in Tables 2.6 – 2.9 
for healthy never-smokers, healthy smokers, COPD ex-smokers and COPD current 
smokers respectively. Further correlation matrices related to all smoking subjects and 
all COPD patients are subsequently illustrated in Tables 2.10 and 2.11. Overall these 
analyses failed to show any coherent pattern of associations related to smoking status 
or the severity of COPD. Whilst there was evidence of a statistically significant 
association between BAL GSH and predicted FEV1 (Spearmans rho (ρ)=0.74, P=0.003) 
and airway reversibility following bronchodilation with 1mg of terbutalin (ρ=0.62, 
P=0.019) in the COPD ex-smokers (Table 2.8), similar associations were not apparent 
following smoking continuation in these subjects (Table 2.9) or when all COPD 





Table 2.6: Correlation (Spearman Rank Order Correlations) matrix for healthy aged never-smokers. 
 
Significant associations (Spearman rho and P-value, n=8-13) are highlighted in red text. Grey cells illustrate that one or both pairs of variable 




Table 2.7: Correlation (Spearman Rank Order Correlations) matrix for ‘healthy’ aged smokers. 
 
Significant associations (Spearman rho and P-value, n=14-16) are highlighted in red text. Grey cells illustrate that one or both pairs of variable 
were not determined in this particular group. 
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Table 2.8: Correlation (Spearman Rank Order Correlations) matrix for COPD ex-smokers. 
 
Significant associations (Spearman rho and P-value, n=11-17) are highlighted in red text. Grey cells illustrate that one or both pairs of variable 




Table 2.9: Correlation (Spearman Rank Order Correlations) matrix for COPD smokers. 
 
Significant associations (Spearman rho and P-value, n=8-11) are highlighted in red text. Grey cells illustrate that one or both pairs of variable 




Table 2.10: Correlation (Spearman Rank Order Correlations) matrix for all aged smokers. 
 
Significant associations (Spearman rho and P-value, n=22-25) are highlighted in red text. Grey cells illustrate that one or both pairs of variable 
were not determined in this particular group. 
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Table 2.11: Correlation (Spearman Rank Order Correlations) matrix for all COPD patients. 
 
Significant associations (Spearman rho and P-value, n=19-28) are highlighted in red text. Grey cells illustrate that one or both pairs of variable 
were not determined in this particular group. 
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Overall these results, similar to the inflammatory cell data, failed to provide 
any clear evidence of antioxidant perturbation or oxidative stress within the 
respiratory tract lining fluids of patients with COPD. Rather the responses observed 
were increased GSH, vitamin C and ferritin related to smoking status, though there 
was very little evidence that this was quantitatively associated to the subjects’ 
reported smoking history (pack years) or clinical indices of pulmonary health.  
 
2.3.6 Alternative control subjects (healthy young and mild asthmatics) 
 To further explore how the combination of COPD and smoking related 
inflammation and age impacted on the endogenous antioxidant defences in these 
subjects, further subject groups of healthy young and mild asthmatic non-smokers 
were recruited for bronchoscopy. The demographics of these subjects are provided in 
Table 2.3, with information on total and differential cell counts in recovered bronchial 
wash and bronchoalveolar lavage in Table 2.12. Inclusion of these subjects allowed me 
to address two supplementary issues in relation to COPD antioxidant defences at the 
air-lung interface: first, whether there was a degradation of antioxidant defences with 
evidence of increased oxidative stress with age, and second, whether general airway 
inflammation and acute allergic inflammation, as opposed to the more chronic pattern 
associated with COPD, was characterised by antioxidant adaptation to protect against 
oxidative stress. The former issue has recently gained prominence due to the 
accelerated ageing hypothesis of COPD that was proposed by the group of Barnes 
(reviewed in section 1.8), supported by evidence of shortened telomeres in alveolar 
type II and endothelial cells (Tsuji, 2006), peripheral mononuclear blood cells (Morla, 
2006) and fibroblasts (Muller, 2006) from the lungs of COPD subjects. In addition, 
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antioxidant enzymes such as superoxide dismutase have also been reported to be 
lowered in aged smokers and stable COPD patients (Kirkil, 2008). To date, no 
comprehensive studies addressing human respiratory tract lining fluid antioxidant 
status with age have been published, though degradation of these defences has been 
speculated upon as potentially increasing the vulnerability of the aged lung to inhaled 
xenobiotics (Kelly et al. 2003). 
Table 2.12: Differential white blood cell counts in BW and BAL fluids from healthy 
young and mild asthmatic subjects. Cell numbers are presented as cell/mL*104. 
 
All data are expressed as medians with inter-quartile. Significant differences across 
groups were assumed at the 5% level the Mann-Whitney U Test. Significant P values 
for ‘a’ are 0.0012 (eosinophils) and 0.012 (mast cells). 
 
Figures 2.10 (macrophages, neutrophils and lymphocytes) and 2.11 
(eosinophils and mast cells) illustrate how the inflammatory cell populations observed 
in the young healthy and asthmatic populations relate to the previous observations in 
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the aged smokers and COPD patients. Macrophage numbers did not differ between 
the young healthy and asthmatic patients in either of the sampled compartments, but 
numbers in bronchial wash were significantly reduced (P<0.001) in the aged versus 
young healthy non-smokers. A similar contrast was not apparent in the more distal 
BAL fluid sample. In contrast, macrophage numbers were elevated above those seen 
in the young asthmatics in the aged smoking groups in both the BW and BAL samples. 
Neutrophil numbers in both the BW and BAL samples were broadly equivalent in the 
young healthy and asthmatic groups in contrast to previous studies that have reported 
neutrophilia in mild asthmatic subjects (Mudway et al. 2001). Indeed there was a 
trend suggesting decreased neutrophil numbers in the BW of asthmatics, which failed 
to attain statistical significance (P=0.06). Comparison of neutrophil numbers in BW 
and BAL between the young asthmatics with aged smokers and COPD patients 
produced mixed results with only a statistically significant increase in COPD smokers 
occurring in both compartments. Lymphocyte numbers were equivalent between 
young healthy and asthmatic subjects, and young healthy and aged non-smoking 
controls in both BW and BAL, with evidence of a significant depression in numbers in 
COPD patients (independent of smoking status) compared with the asthmatics. As 
expected, both eosinophil and mast cell numbers were increased in the BW of atopic 
mild asthmatics (Figure 2.11). Evidence of allergic inflammation was not apparent in 
the distal BAL fluid sample. Interestingly, there was some evidence of an expansion in 




Figure 2.10: BAL fluid cell populations in young and aged adults (smokers and non-smokers), young mild asthmatics and COPD patients 
(smokers and non-smokers). Data are illustrated as box plots as outlined in the legend to figure 2.6. Statistical comparison (Mann-Whitney U 
tests) were restricted to young vs. aged adults; young health and mild asthmatic volunteers, and the asthmatic population vs. all COPD groups, 




Figure 2.11: Eosinophil and mast cell numbers measured in BAL fluid recovered from 
young and aged adults (smokers and non-smokers), young mild asthmatics and COPD 
patients (smokers and non-smokers). All other details are as outlined in the legend to 
figure 2.10. 
 
The concentration of BAL fluid antioxidants measured in the young healthy and 
mild asthmatic subjects are summarised in Table 2.13. Ferritin was not considered in 
these analyses as the previous results had demonstrated increases only in smokers 
and all of the subjects in these tow groups were never-smokers. Overall no significant 
differences were noted in any of the low molecular weight antioxidants or in 
transferrin concentration between the two groups. This contrasted significantly with 
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previous reports of compromised ascorbate concentrations within bronchial wash 
(Kelly et al. 1999), bronchoalveolar lavage (Kelly et al. 1999) and induced sputum 
(Kongerud et al. 2003) of asthmatic subjects. In these papers and others addressing 
antioxidant responses to inhaled xenobiotics (Mudway et al. 2004; Mudway et al. 
2001), low basal ascorbate in the respiratory tract lining fluids of asthmatics was 
associated with increased GSH and GSSG concentrations, again absent in the present 
samples. 
 
Table 2.13: Antioxidant and oxidative damage marker concentrations on BAL fluid 
from young atopic mild asthmatic and aged matched healthy controls. 
 
All data are expressed as medians with inter-quartile. No significant differences were 
noted in the quoted parameters between the two groups. 
 
A review of these earlier papers reveals that in all cases where ascorbate was 
depressed and glutathione augmented, basal neutrophilia was present in the airways 
of the asthmatic subjects. Thus the argument developed in these papers, that 
compromised antioxidant defences at the air-lung interface of asthmatics were 
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characteristic of the disease, may be incorrect and the level of airway ascorbate may 
simply be a function of the degree of neutrophilic inflammation. Such a view would 
chime well with the DHA uptake model in which activated neutrophils oxidize 
ascorbate in their immediate vicinity to enable rapid uptake of DHA and subsequent 
reduction back to ascorbate to augment their intracellular concentrations (Wang et al, 
1997). It was notable that in contrast to the aged subjects, the contribution of DHA to 
the measured vitamin C concentration was much reduced in the young subject groups.  
 
 The glutathione responses observed in the young healthy and mild asthmatic 
subjects are compared against the previous data obtained from the aged smokers and 
COPD patients in Figure 2.12. No evidence was observed of an age-related increase in 
either GSH or GSSG in the young versus aged never-smokers, or between the young 
asthmatics and the aged COPD ex-smokers. This contrasted markedly with the results 
obtained for ascorbate and dehydroascorbate, where there was a clear age-related 
decrease in the former (P<0.001) and elevation in the latter (P<0.001), Figure 2.13. 
This age-related increase in ascorbate oxidation within the asthmatic respiratory tract 
lining fluids was paralleled by a significant increase (P<0.001) in 4-HNE protein adducts 
with age, with no difference observed in concentrations between the young healthy 
and mild asthmatic subjects, Figure 2.14. To our knowledge, this is the first evidence 




Figure 2.12: Reduced glutathione and glutathione disulphide concentrations in 
bronchoalveolar lavage fluids recovered; young never-smokers, mild asthmatics 
(never-smokers), aged never and ‘healthy’ smokers, plus COPD patients (current and 
ex-smokers). All other details are as outlined in the legend to figure 2.6. Comparisons 
between groups (restricted to young vs. asthmatic adults, young vs aged controls, and 
asthmatics vs. all aged COPD and smoking groups) were performed using the Mann-







Figure 2.13: Ascorbate and dehydroascorbate concentrations in bronchoalveolar 
lavage fluids recovered; young never-smokers, mild asthmatics (never-smokers), aged 
never and ‘healthy’ smokers, plus COPD patients (current and ex-smokers). All other 




Figure 2.14: Protein bound 4-hydroxy-2-nonenal concentrations in bronchoalveolar 
lavage fluids recovered; young never-smokers, mild asthmatics (never-smokers), aged 
never and ‘healthy’ smokers, plus COPD patients (current and ex-smokers).  All other 







In the present study I sought to address whether increased inflammation and 
associated oxidative stress at the air-lung interface was associated with the presence 
and clinical severity of COPD. To achieve this I investigated the concentration of a 
range of antioxidants (both low molecular weight antioxidants and metal chelators) in 
lavage samples obtained from COPD patients, both current and ex-smokers, and 
compared these concentrations with those observed in aged and smoking history 
matched controls. I hypothesised that patients with COPD would have depressed 
concentrations of antioxidants at their air-lung interface, reflecting the presence of 
chronic inflammation and consistent with the sensitivity of this group of patients to 
inhaled xenobiotics. 
 
In contrast to my expectations, I failed to show any evidence for oxidative 
stress or perturbed antioxidant status in the airways of COPD patients. Rather the 
changes in antioxidant concentrations observed were either related to smoking status 
or age-related changes in respiratory tract lining fluid redox, i.e. increased ascorbate 
oxidation and the presence of 4-HNE protein adducts. It also appeared likely that the 
increased concentrations of vitamin C and glutathione at the air-lung interface 
occurred as a consequence of cell lysis, based on the release of intracellular ferritin, 
though this would need further confirmation through the quantification of other 
wholly intracellular proteins within the extracellular compartment. This does not infer 
that oxidative stress does not play a role in the aetiology and progression of COPD, for 
example its relationship to cigarette smoking clearly demonstrates that this is the 
case, but in stable patients, in the absence of an inhaled oxidant challenge or 
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exacerbation, it appears extracellular defences are no worse than would be observed 
in a healthy aged subject. This study did not specifically address the extent to which 
adaptive mechanisms may be impaired in COPD, and clearly there is an increasing 
body of evidence supporting this view (Goven et al, 2009).  
 
Therefore, with evidence of oxidative stress directly related to age and 
smoking status, I hypothesised that smoking and age-related responses could be 
related to the presence of an increased catalytic metal pool (predominately Fe and Cu) 
within the RTLF, either arising from the inhalation of a metal-rich cigarette smoke 
aerosol or dysregulation of metal handling at the air-lung interface which is explored 


















In the previous chapter I investigated whether COPD was associated with an 
impaired antioxidant defence network in the RTLFs of the distal lung. Contrary to my 
original hypothesis I found no evidence supporting the presence of oxidative stress in 
patients with COPD. The alterations observed in the RTLF antioxidant network were 
either related to smoking status (elevated glutathione and ferritin concentrations), or 
the age of the volunteers, with clear evidence of increased oxidative stress in the older 
patients/volunteers (increased dehydroascorbate and 4-HNE concentrations). To 
further explore these observations in this chapter, I hypothesised that the smoking 
and age-related responses were related to the presence of an increased catalytic 
metal pool (predominately Fe and Cu) within the RTLF, either arising from the 
inhalation of a metal-rich cigarette smoke aerosol (Pappas, 2011), or dysregulation of 
metal handling at the air-lung interface (Ghio, 2009). Under normal conditions Fe 
released into the RTLF from dying cells (Ghio, 2009), or incident from inhaled air 
(Gilmour, 1996; Happo, 2008), is rapidly bound by the extracellular protein transferrin 
and transported into cells via receptor-mediated endocytosis for storage in ferritin 
(Syed, 2006). In addition, Fe as well as other metal cations including Cu and Zn can be 
taken up into cells by the divalent metal transporter 1 (DMT1) (Wang, 2002), which 
has been shown to be expressed on both alveolar macrophages (Nguyen, 2006) and 
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airway epithelial cells in vitro (Wang, 2002) and in vivo (Ghio, 2003). Neutrophils also 
release secondary granules containing the glycoprotein lactoferrin which complexes 
with ferric iron, which can then be taken up by respiratory epithelial cells and 
macrophages for storage within ferritin (Markowetz, 1979). This emphasis on the 
rapid cellular sequestration of Fe, as well as other catalytically active metals in the 
lung, reflects both their deleterious effects promoting oxidative reactions in the lung 
(Jomova, 2011), as well as the need to limit the availability of these metals to bacteria, 
which require Fe for growth and proliferation (Oppenheimer, 2001; Fischbach, 2006). 
Correspondingly, transferrin levels expressed as a percentage of total protein, are 
significantly higher in RTLFs (4-5.6% of the total protein) than in plasma (Mateos and 
Brock 1998). In addition, there would appear to be a considerable functional Fe 
binding reserve in healthy individuals, with transferrin usually only 20-30% loaded 
with iron (Halliwell and Gutteridge, 2007).  
 
The lung has therefore clearly evolved an array of mechanisms to prevent the 
accumulation of Fe as well as other divalent metals at the air-lung interface. One 
might therefore imagine that with the reserve metal binding capacity of transferrin, 
there would be a sufficient buffer against the appearance of ‘free’ unbound and hence 
catalytically active metals. There are a number of caveats however, that need to be 
considered: first, it is now clear that pools of non-transferrin bound iron can exist, 
even in the presence of unsaturated transferrin (Gutteridge, 1995; Aruoma, 1999; 
Gosriwatana, 1999); second, reductions in pH can significantly impact on the Fe 
binding capacity of transferrin (Wally, 2007); and finally, there is clear evidence of 
both up– and down-regulation of components of the metal sequestration system in a 
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variety of acute and chronic lung diseases:  lung transplantation (Pugh, 2005); acute 
respiratory distress syndrome (Ghio, 2003); idiopathic pulmonary alveolar proteinosis 
(Ghio, 2008); and cystic fibrosis (Stites, 1999).   
 
For metals to promote damaging oxidations at the air-lung interface they must 
therefore be unbound to any of the endogenous chelators (lactoferrin, transferrin) 
within the RTLF. These pools of unbound, or ‘free’ metals, usually assumed to be Fe 
only, have been given the name ‘the non-transferrin iron (NTBI) pool.’ For Cu, the 
term ‘the caeruloplasmin-bound pool’ has recently been proposed (Walshe, 2012). It 
is however, misleading to refer to ‘free’ pools of metals in vivo as they are never truly 
unbound in body fluids, where they exist complexed to a variety of molecules 
including albumin, citrate, DNA and phosphate (Nilsson, 2002). Thus, the central 
question is not whether it is ‘free’, but rather whether the bound form retains the 
capacity to catalyse free radical reactions. Numerous assays have been developed to 
quantify these ‘catalytically’ active metal pools, including the highly sensitive 
bleomycin and nitrilotriacetic acid assays (Gutteridge, 1981; Gosriwatana, 1999). 
These assays were first employed to demonstrate the presence of a NTBI pool in 
patients with thalassaemia (Graham, 1979) or haemochromatosis (De Valk, 2000). 
There is however, evidence of a non-transferrin bound iron (NTBI) pool at the lung 
surface in both healthy subjects and subsets of patients with adult respiratory distress 
syndrome (Gutteridge, 1996). This observation has never been followed up in the 
literature and has been widely questioned. This in part reflects the technical difficulty 
in making these measurements in dilute lavage returns, as opposed to in plasma, but 
also the apparent measurement of an unchelated Fe pool in healthy adults.  
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To address the hypothesis that the age-related increase in oxidation markers in 
the lavage returns might be related to altered metal homeostasis at the air-lung 
interface, I examined both the concentration of Fe and Cu in the recovered samples 
using ICP-MS, as well as the pro-oxidant status of the lavage samples. The later assay 
was based on a method designed to quantify contaminating Fe in biological buffers 
(Welch, 2002). This method, based on the capacity of metals to catalyse the oxidation 
of ascorbate, was preferred over a direct quantification of the NTBI pool as it provided 
a direct measure of catalytically active metals and is highly sensitive and suitable for 
use with dilute samples. In addition, through the use of selective chelators, either to 
augment (NTA) or inhibit (DTPA) the oxidation of ascorbate, it was possible to 
proportion pro-oxidant activity to metal and non-metal sources and through the 









All chemicals used were obtained from Sigma Chemical Company Ltd. (Poole, 
U.K.), Fluka (Dorset, U.K.) or Laboratory Supplies (Poole, U.K.) and were of analytical 
grade or better quality. 
 
3.2.2 Chelex water preparation 
Ultra pure water was employed to decrease background metal contamination 
when assessing the endogenous pro-oxidant activity of the lavage samples. Each litre 
of deionised Elga-stat water (18 Ώ) was treated with 30 grams of Chelex 100 resin 
(iminodiacetic acid-coated polystyrene beads). This solution was prepared in a 
polycarbonate beaker and after mixing for 24 hours at room temperature, the Chelex 
100 resin was removed by vacuum filtration through a 0.45 μm cellulose nitrate 
membrane. The pH of the purified water was subsequently adjusted to 7 using 1M 
sodium hydroxide and 1M hydrochloric acid, both previously prepared in ultra pure 
water and stored at 4 °C for a maximum of one month.  
 
3.2.3 Subject demographics 
The subject demographics were as described in section 2.2.1 with 





3.2.4 Determination of BAL metal concentrations 
Trace metal concentrations (Fe, Cu, Zn, As, Cd and Y) in BAL fluid samples were 
established by inductively coupled plasma mass spectroscopy (ICP-MS) following an 
acid digestion in dilute nitric acid. Each lavage sample (0.5 mL) was added to 1.5 mL of 
6.5% HNO3 (10.83 ml of 60% HNO3 + 89.17 ml of ultra pure Chelex resin treated water) 
and spiked with 20 µl of a 1 ppm yttrium solution (prepared in 6.5% HNO3 from a 100 
ppm yttrium stock (Lleeman Lab, Inc – Lowell, MA, USA). All digestions were 
performed in acid washed (2% HNO3) Teflon vials following extensive rinsing in ultra 
pure water. The acidified samples were then vortexed for two minutes prior to 
heating in a hot water bath at 90 ºC for 90 minutes. All samples were ran in parallel to 
digestion blanks, at least 8 per run, containing 1500 µl of 6.5% Nitric acid and 20 µl of 
internal standard, plus 0.5 mL of Chelex 100  resin treated ultra pure water. The 
resultant digests were then allowed to cool to room temperature overnight in a fume 
cupboard prior to centrifugation at 4,000 rpm for 10 minutes. Where a precipitate was 
apparent (this was not observed with any of the digests) the resultant supernatant 
was transferred to a new tube prior to analysis. Samples were analysed (63Cu (natural 
abundance 69.15%), 56Fe (91.72%), 89Y (100%), 111Cd (12.80%), 75As (100%),  66Zn (66; 
27.90%)) by ICP-MS using an ELAN DRC ICP-MS (MSF008) at the King’s College London 
mass spectrometry facility. The selected isotopes were chosen to avoid known 
potential isotopic interferences. The potential ArO+ interference for the major isotope 
of iron (56Fe) was removed using the dynamic reaction cell, through its reaction with 
ammonia. Trace metal calibrations were conducted using dilutions of a certified multi-
elemental standard solution (VI CertiPUR Merck, Lot. No.OC529648). Typical 7 point 
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standard curves are illustrated in Figure 3.1. In addition to the digestion blanks, repeat 
digestions of a single BAL fluid sample recovered from a healthy adult (24 year old 
male) were ran throughout each run to assess the intra-assay variability. The results of 
these analyses versus the background intensity measurements in the digestion blanks 
are illustrated in Figure 3.2. 
 
 
Figure 3.1: Typical elemental standard curves. Data points represent the mean 




Figure 3.2: Raw concentrations (*corrected for the internal standard, not the final 
dilution, but equivalent for blanks and lavage samples) of the indicated elements in 
repeat lavage and blank digests. The number of repeat incubations and analyses are 
indicated, as is the coefficient of variation  (standard deviation/mean x 100) for the 
measured concentrations in the BAL digests. Note: In the case of Fe, the values from 
the BAL digests were always less, or near equivalent to the concentrations measured 
in the blanks. Cd was below the detection limit of the assay:  nd, not detected.  
 
 
3.2.5 Ascorbate depletion assay 
The pro-oxidant activity of the recovered BAL fluid samples was assessed with 
respect to their capacity to deplete ascorbate (AA) from a single 200 μM antioxidant 
solution. In this assay, greater ascorbate depletion rates were expected to occur in 
samples containing unchelated catalytic metals, predominately Fe or Cu. A stock AA 
solution was prepared at a concentration of 4 mM in Chelex treated water and 
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adjusted to pH 7.0. An aliquot of each lavage sample (90 μL) was diluted with 5 μL of 
Chelex-treated water and then incubated with the stock antioxidant solution (5 μL) at 
37 °C for two hours in a plate reader (Spectra Max 190). Lavage fluid incubations with 
AA were performed in triplicate in UV 96-well flat-bottom plates (Greiner bio-one). 
The concentration of AA remaining in each well was quantified by measuring the 
absorbance at 265 nm every two minutes over the two hour incubation period. 
Duplicate blanks and standards (25 – 200 μM AA) were run in parallel with samples on 
the 96-well plate, such that a calibration curve was constructed for each two minute 
measurement; calibration curves are shown for a selection of the measurement time 
points in Figure 3.3.  
 
Figure 3.3: Example of a typical AA calibration curve for quantifying depletion in a 
single antioxidant solution. Note: the absorbance values at each concentration fall 
with time reflecting the auto-oxidation of ascorbate from the standard. 
 
The AA concentration in sample wells at each time point was determined 
against its respective calibration curve and corrected for AA losses by auto-oxidation 
measured in the blank controls. The rate of AA depletion was determined over the 
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two hour incubation and expressed as µM second-1.  As the decline of this antioxidant 
was assumed to follow first order kinetics, only the linear portion of the measurement 
time course was considered. Rates were derived using Microcal Software Limited’s 
OriginLab (version 5.0). To determine the influence of metals in the measured rate of 
AA depletion, samples were incubated with the metal cation chelators DTPA and NTA 
(structures illustrated in Figure 3.4). Incubations were conducted in a similar 
procedure as previously described above, however, instead of diluting the nasal lavage 
samples with 5 μL Chelex-treated water, samples were spiked with 4 mM DTPA (5 μL). 
The likely impact of these chelators on the observed rates is described in Figure 3.4. 
 
3.2.6 Statistics 
Data were not normally distributed (Shapiro-Wilks test) and are therefore 
expressed throughout as medians with the 25th and 75th percentiles. Comparisons of 
the ascorbate depletion rates and metal concentrations across the patient groups 
were performed using the Kruskal–Wallis one-way analysis of variance by ranks, with 
post-hoc testing between specific groups performed using the Mann-Whitney U test. 
In all cases where ascorbate depletion rates were compared in a given subject group 
with or without co-incubation with metal chelators, post hoc testing was performed 
using the Wilcoxon-Signed Rank Test. In all cases significant differences were assumed 
at the 5% level. Correlation analysis for each individual group, plus compiled groups of 
COPD patients (current and ex-smokers) and smokers (both aged ‘healthy’ smokers 
and COPD smokers), were performed using the Spearman Rank Order Correlation. 
These analyses were restricted to parameters that had been shown to differ 
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significantly between groups to limit the likelihood of reporting spurious associations. 




Figure 3.4: An illustration of the principle of the ascorbate depletion assay. Lavage 
samples are spiked with ascorbate to achieve a starting concentration of 200 µM. The 
loss of ascorbate is then monitored at 265 nm every 2 minutes for 2 hours. A typical 
profile for a lavage sample is shown above using the red line. All incubations are also 
performed parallel to a water blank, which accounts for the background rate of auto-
oxidation occurring due to trace metal contamination (black line). Addition of the 
chelator DTPA in excess should completely abolish any metal dependent catalysis, 
including that contributing to the background oxidation (purple line). Co-incubation, 
conversely, may act to accelerate the oxidation of ascorbate, specifically in relation to 
the formation of Fe-NTA, as it is able to mobilise Fe from other biologic chelators in 





3.3 Results and Discussion 
 To address the basis for the age-related increase in markers of oxidative 
damage (DHA and 4-HNE) observed in the previous chapter, I investigated the 
concentrations of the redox active metals Fe and Cu within the recovered BAL fluid 
samples. Direct measurements of these metals were made after a nitric acid digest by 
ICP-MS. Indirect assessment of their capacity to catalyse oxidation reactions was 
obtained using an ascorbate depletion assay, through the use of selective chelators, 
either to augment (NTA) or inhibit (DTPA) catalysis related to the non-transferrin 
bound Fe-pool i.e. that bound to low molecular weight anions, such as citrate and 
acetate, or associated with albumin (Hider, 2002). I hypothesised that ageing would be 
associated with a more pro-oxidant status within the airway lining fluids, 
characterised by an increase in catalytically active metals i.e. unchelated Fe and Cu 
concentrations. As a secondary hypothesis, I also tested the assumption that the 
concentration of these metals, as well as As and Cd, would be elevated in current 
smokers due to their presence in the cigarette smoke aerosol (See, 2007). Zinc was 
also examined in the lavage digests, both as a non-redox active metal but also due to 
its 1:1 stoichiometry with Cu in extracellular superoxide dismutase, which is known to 
be present in the airway lining fluids (Mudway, 2001). It was assumed that 
equivalence between Cu and Zn concentrations would therefore reflect their presence 
within this critical antioxidant enzyme, and deviation from this relationship due to 
alternate sources.  
 
As outlined in the methods section, I was unable to obtain a valid measurement 
for BAL fluid Fe after the subtraction of the digestion blanks in any of the samples. 
139 
 
Previous studies have reported total and non-haem Fe concentrations to be broadly 
equivalent in lavage fluids harvested from healthy never-smokers, in the range of 
0.01-0.03 µg/mL, with evidence of substantial increases in lavage samples obtained 
from patients with adult respiratory distress syndrome (Ghio, 2003) and pulmonary 
alveolar proteinosis (Ghio, 2008). Clearly, given the content of heam (catalase (Ulker, 
2008), lactoperoxidase (Ratner, 2000), myeloperoxidase (Mudway, 1999), eosinophil 
peroxidase (Erpenbeck, 2003)) and non-haem Fe (transferrin, lactoferrin (Ghio, 2009)) 
proteins with the RTLF, the failure to detect measurable Fe was methodological. In the 
previous reports of non-haem Fe (Ghio, 2003; Ghio, 2008), quantification was 
achieved using inductively coupled plasma atomic emission spectroscopy following a 
somewhat more robust digestion protocol than I employed in the present analysis: 6 N 
HCl/20% trichloroacetic acid to 1.0mL of lavage supernatant, heating to 70°C for 
18hrs. Whilst there is an acknowledged problem in quantifying the most abundant 
isotope of Fe (56Fe) by ICP-MS, due to the polyatomic interference from ArO+, this 
should not have been a problem as I employed the dynamic reaction cell with NH3 to 
eliminate this species. Therefore, most likely the failure to detect Fe reflected 
advantageous metal contamination, either during the bronchoscopy, or during the 
digestion protocol.   
 
Whilst Fe and Cd were not possible to quantify, following the digestion blank 
subtraction, measureable concentrations of Cu, Zn and As were achieved in all of the 
analysed samples. The Cu concentrations measured in the lavage returns from each of 
the subject groups investigated are illustrated in Figure 3.5. Considering the COPD 
patient groups relative to their age and smoking status matched controls, I observed 
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no significant differences in total Cu. In contrast, the concentration of Cu was 
significantly lower in the lavages obtained from the young healthy adults and mild 
asthmatics, relative to all of the aged groups, irrespective of smoking or disease 
status. No difference in Cu concentrations was noted between the young asthmatic 
and control subjects. A similar pattern was observed with respect to the total Zn 
determinations in the lavage digests, with clearly elevated concentrations apparent in 
the aged groups (Figure 3.6). Notably, the concentration of Zn measured across all 







Figure 3.5: Total copper concentrations in BAL fluids samples obtained from COPD and 
asthmatic patients, plus aged and smoking history matched controls. Data are 
presented as box plots, with the central line indicating the median, the lower and 
upper boundaries of the box, the 25 and 75th percentiles and the whiskers the 95% 
confidence interval. Comparisons of the Cu concentrations between the patient 
groups were performed using the Kruskal–Wallis one-way analysis of variance by 
ranks, with post-hoc testing between specific groups performed using the Mann-







Figure 3.6: Total Zn concentrations in BAL fluids samples obtained from COPD and 
asthmatic patients, plus aged and smoking history matched controls.  All other details 
are as outlined in the legend to Figure 3.5. 
 
An examination of the RTLF proteome (Magi, 2006; Noël-Georis, 2002), 
indicates that the major Cu containing proteins within this extracellular compartment 
are extracellular Cu,Zn superoxide dismutase (ECSOD) and caeruloplasmin. The 
tetrameric metalloenzyme ECSOD contains 4 atoms of both Cu and  Zn (Marklund, 
1982), while the Cu transport protein and ferroxidase caeruloplasmin contains 6 six 
cupredoxin-type domains (Bento, 2007), plus a 7th labile surface copper binding site 
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that has been argued to attribute the protein a pro-oxidant state (Mukhopadhyay, 
1997). Albumin has also been shown to loosely bind Cu and Zn at histidine residues 
(Masuoka, 1994). A comparison of the relative abundance of Cu and Zn in the lavage 
returns from each of the patient groups (Figure 3.7) clearly demonstrates a 
relationship between the two metals, but seems to support additional Zn sources. As 
the published proteome doesn’t indicate any obvious candidates, it is probable that 




Figure 3.7: Association between the measured total (acid digested) BAL fluid Cu and 
Zn concentrations from all subjects, as well as broken down by each patient group (as 
illustrated in the above key). The strength of association was assessed using the 
Spearman Rank Order Correlation (Spearman’s rho (ρ) and the associated P-values are 
illustrated). The red line represents the line of identity, with the data groups toward 




 It was notable that neither Cu nor Zn was elevated in the lavage returns of 
current smokers. Similarly, As concentration was not enhanced in smokers relative to 
non-smokers (6.3 (5.3-7.2), n= 22 versus 7.9 (7.0 – 8.5) µg L-1, n=26) and there was no 
evidence of an age-related increase, similar to that observed for Cu and Zn (data not 
shown).  
 
 To further explore whether the lavage returns from the aged subjects had a 
more pro-oxidant status, consistent with the increased concentration of oxidation 
markers reported in these subjects in chapter 2, I made use of the ascorbate depletion 
assay. In this assay the presence of an oxidant or redox catalyst, such as Fe or Cu 
promotes the oxidation of exogenous ascorbate added to the lavage samples (Welch, 
2002). As the measured rate of ascorbate oxidation reflects the potential contribution 
of multiple oxidant/redox catalysts I employed selective synthetic chelators to isolate 
metal versus non-metal contributions to the observed oxidation rates, as well as to 
attempt to quantify the contribution of Fe and Cu. The ascorbate depletion rates 
observed in each of the patient groups, with and without co-incubation with DTPA or 
NTA are illustrated in Figure 3.8. Considering the total ascorbate depletion rate, 
illustrated in the uppermost panel, it was clear that the observed rates observed in 
the young volunteers (both healthy and mild asthmatic subjects) were significantly 
less than those seen in the aged groups, irrespective of COPD or smoking status, 
mirroring the earlier metal results. Perhaps counter-intuitively there was some 
evidence of a reduced rate of ascorbate depletion in the healthy current versus never-




Figure 3.8: Ascorbate depletion rates, with and without chelators (DTPA and NTA), 
observed in lavage fluids obtained from young asthmatics, aged COPD patients, as well 
as age and smoking history matched controls. Data are presented and group 





Figure 3.9: Fold change in the ascorbate depletion rate following co-incubation with 
DTPA (white boxes) or NTA (black boxes) relative to untreated rates. Paired 
comparisons between the DTPA and NTA treatments for each group were performed 
using the Wilcoxon-Signed Rank Test. P values are indicated where they were <5%. 
 
The difference between the rates observed between the aged and young 
adults were maintained after DTPA (central panel, Figure 3.8), despite a significant 
decrease in the measured rate (Figures 3.9 and 3.10), as well as after NTA, which 
decreased the ascorbate depletion rate in the young adults but increased them in the 
aged populations (Figure 3.9). DTPA is a polyamino carboxylic acid consisting of a 
diethylenetriamine backbone with five carboxymethyl groups with the ability to bind 
to and fully redox-inactivate transition metals such as Fe and Cu. As such, any residual 
oxidation apparent after co-incubation with an excess of DTPA must reflect the 
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presence of other pro-oxidants, most likely peroxide species such as hydrogen 
peroxide, or lipid and protein peroxides. Hence, the data presented suggests both an 
increased content of catalytic metals within the RTLF with age but also implies that 
other pro-oxidant species are also increased in these groups. NTA has been shown to 
remove virtually all Fe from oligomeric iron complexes and albumin/low molecular 
weight ligand bound iron and therefore has the converse action of increasing the 
catalytic Fe pool, consistent with the evidence that Fe-NTA actually promotes the 
oxidation of biomolecules (Iqbal, 2009; Morel, 1997). As the Fe binding affinity of NTA 
does not permit it to remove bound Fe from ferritin, transferrin or lactoferrin it 
therefore has the effect of promoting oxidation in direct relation to the size of the 
NTBI pool.  
 
A paper by Joyner et al. (2011) recently examined the influence of a panel of 
chelators (including NTA and DTPA) on the oxidative activity of redox active metals 
(Fe, Cu, Co and Ni) on the rate of ascorbate oxidation. These studies demonstrated 
that incubation with an excess of DTPA effectively prevented ascorbate oxidation by 
either Fe or Cu, consistent with the observations presented in this chapter. Notably, 
the rate of ascorbate oxidation by Fe (ferrous sulphate heptahydrate) in the absence 
of hydrogen peroxide was negligible, with the rate observed in the presence of H2O2 
approximately 10-fold less than with Cu (cupric chloride dihydrate). This result 
highlights the importance of Cu as a redox catalyst in biological systems. They further 
observed that Cu catalysed oxidation of ascorbate was reduced 4-fold by NTA-
chelation. This finding suggests that NTA can be used to discriminate between Fe and 




Figure 3.10: Individual ascorbate depletion rates, with and without chelation in each of the patient groups.  Paired comparisons between the 
observed ascorbate depletion rates, with and without DTPA or NTA treatment for each group were performed using the Wilcoxon-Signed Rank 




Figure 3.11: Associations between the observed ascorbate depletion rates (with and 
without chelators) with the measured total Cu concentrations in the lavage fluid 
samples. The strength of association was assessed using the Spearman Rank Order 
Correlation, with the Spearman’s rho (ρ) and the associated P-values illustrated for all 
of the subject groups combined. The associations for each separate patient group are 
illustrated in Table 3.1.  
 
Thus, the reduced rates of ascorbate oxidation observed in the young healthy 
and asthmatic groups following NTA treatment suggests the presence of a catalytically 
active Cu pool. Conversely, the increased oxidation rates observed with NTA co-
incubation in the lavages from the aged groups (healthy, COPD and smokers) 
demonstrates the presence of a catalytically active NTBI pool. These data therefore 
represent the first evidence of an increased catalytic Fe pool in aged subjects and 
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though consistent with my previous observations on lavage metals and oxidation 
markers, this was not related to the presence of COPD or current smoking.  
 
Table 3.1: Spearman correlation coefficients for BAL fluid total Cu and Zn content with 




Correlation analysis demonstrated that the rates of ascorbate oxidation 
observed in the lavage returns from all subjects were significantly associated with the 
measured total Cu; with the association maintained with NTA co-incubation, but 
somewhat attenuated with DTPA (Figure 3.11). When these associations were 
examined on an individual group basis (Table 3.1) it was clear that only the overall 
rate was consistently associated with the pro-oxidant status of the lavage samples. 
Due to the underlying association between Zn and Cu (Figure 3.7), similar significant 
correlations were observed with the ascorbate depletion rate when all subjects were 
considered, but these associations were not robust across the individual groups (Table 
3.1). Additional correlation analyses were performed between the measured lavage 
Cu content and the oxidation marker concentrations (GSSG, DHA and 4-HNE) reported 
in chapter 2 (Figure 3.12). In all cases significant associations were noted when all 
subjects were considered, most strongly for the measured DHA concentration. The 
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analysis by sub-group presented in Table 3.2 was somewhat less consistent, with the 
most consistent associations observed in the aged current smokers and COPD ex-
smokers. It should be noted however that the sub-group analysis was limited by the 
small group size in the COPD current smokers. Nevertheless, these data suggest that 
increased catalytic metal content at the surface of the lung related to age, gives rise to 
an increased pro-oxidant environment supported by evidence of antioxidant and lipid 
oxidation. 
 
Figure 3.12: Associations between the measured total Cu concentrations in the lavage 
fluid samples with markers of oxidative stress. The strength of association was 
assessed using the Spearman Rank Order Correlation, with the Spearman’s rho (ρ) and 
the associated P-values illustrated for all of the subject groups combined. The 
associations for each separate patient group are illustrated in Table 3.2.  
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Table 3.2: Spearman-Rank order correlations between BAL fluid total Cu and Zn, with glutathione (total, reduced and glutathione disulphide), 






The results from the previous chapter did not support the presence of increased 
oxidative stress in the airways of patients with COPD, either current or ex-smokers. 
This was argued to reflect the fact that the studied COPD patients were well 
controlled, supported by the absence of neutrophilic inflammation. I did, however, 
note an increase in markers of oxidation in all of the aged groups (COPD ex- and 
current smoker, plus their aged matched controls) relative to the young healthy and 
asthmatic subjects. In this chapter I sought to investigate the basis for this age-related 
increase in oxidation at the air-lung interface, focusing on possible alterations in the 
airway handling of catalytic metals (Fe and Cu). As expanded upon in this chapter, the 
lung has evolved numerous mechanisms to limit the availability of ‘free’ unchelated 
metals, which would otherwise promote damaging biological oxidations or support 
bacterial growth. To achieve this, I attempted to quantify RTLF metals in lavage using 
ICP-MS and developed a novel method for assessing the pro-oxidant status of the 
recovered lavages. The use of this simple ascorbate oxidation assay, coupled to co-
incubation with NTA and DTPA to isolate metal dependent oxidative catalysis and 
further define the relative contributions of Fe and Cu, is novel. The results obtained 
demonstrate for the first time an age-related increase in the NTBI pool in the lung. 
They are also suggestive of a labile and catalytically active Cu pool in young adults. 
 
These observations are interesting not only because they provide a new 
explanation for the increased oxidation observed in numerous tissues with age, but 
also because they imply that the aged airway would display an increased sensitivity to 
oxidative injury, either due to the inhalation of oxidant gases/particulates, or acute 
154 
 
inflammation. In these scenarios, the presence of labile Fe or Cu pools would promote 
Fenton-like chemistry with the production of damaging hydroxyl radicals, as well as 
catalyse ongoing protein and lipid oxidation processes. This hypothesis needs to be 
tested, preferably in patients undergoing exacerbations, or of a more severe clinical 
state. The relationship of these endpoints with normal physiologic ageing also requires 
further exploration. In the present study, I did not examine the association between 
subject age and the endpoints studied due to the lack of subjects of intermediate age 
between the young controls and asthmatics. Given the nature of these observations, I 
believe there would be merit in examining a more complete age range to fully define 


















Chapter 4:  
Developing a novel Mass Spectrometry-based method for the 
quantification of 4-HNE adducts in complex biological fluids 
 
4.1 Introduction 
Oxidative stress reflects an oxidant–antioxidant imbalance, resulting from an 
excess oxidant production or depletion of antioxidants. Whilst there is a body of 
published evidence demonstrating increased markers of oxidative stress in the 
airspaces, breath and urine of patients with COPD, much of this is based on indirect 
measures and there is considerable inconsistency between various studies (reviewed 
in Chapter 2).  In the previous two experimental chapters, I investigated whether 
there was evidence of oxidative stress or increased redox active metal concentrations 
in the alveolar lung lining fluids of COPD patients in BAL fluid samples.  The data in 
these previous two chapters failed to demonstrate marked antioxidant deficiencies or 
altered metal concentrations in this extracellular compartment in patients with COPD, 
relative to age and smoking-history matched controls. Rather, the changes in these 
indices that were noted appeared to be a function either of smoking status, or the age 
of subjects. 
 
 Given the absence of global markers of oxidative stress the decision was made 
to focus on more subtle manifestations of increased ROS production, namely oxidative 
post-translational modifications to functionally important proteins. Previous studies 
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have demonstrated oxidations (cysteine and methionine oxidations, carbonylations, 
nitrations and adduct formation with reactive electrophiles) to specific proteins 
(plasma, airway lining fluid and in airway cells) in a range of airway diseases, resulting 
in altered protein function relevant to disease progression  (Li, 2009; Wang, 2007; 
Starosta, 2006; Rottoli, 2005; Gole, 2000). In this study I decided to focus on 4-HNE 
adduct formation, as the concentrations of 4-HNE modified proteins have been shown 
to be increased in biopsies obtained from COPD patients, using immunohistochemical 
techniques (Rahman, 2002).  
  
Michael adducts in proteins are yielded through the reaction of 4-HNE with 
sulfhydryl groups of cysteine residues, the ε-amino group of lysine residues and the 
imidazole moiety of histidine residues (Mendez, 2010). Previous publications have 
measured 4-HNE modifications most commonly through the use of immunological 
methods including: immunohistochemical staining using 4-HNE monoclonal antibodies 
(Toyoda, 2007; Waeg, 1996; Yoritaka, 1996); immunochemical detection (Hartley, 
1999; Uchida, 1993); immunoblotting and SDS-PAGE electrophoresis (Mendez, 2010; 
Chen, 2007; Carbone, 2005; Li, 1997). Whilst immunological techniques offer rapid 
detection and kits are commercially available, the disadvantages are that they are 
expensive, some protocols require enrichment which prolongs analysis, specificity is 
only to the antibody/antigen that has been selected and false positives/negatives may 
occur. In addition, immunological approaches do not provide information on the 
chemical structure of the 4-HNE-protein adducts, nor do they allow absolute 
quantification of such derivatives in biological matrices. Alternative approaches have 
included the use of derivatising agents such as 2,4-dinitrophenylhydrazine (DNPH) 
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which reacts with carbonyl groups to generate 2,4-dinitrophenylhydrazones that are 
then characterised using UV spectroscopy (Levine, 1990). Limitations are also found 
with this technique as DNPH is not specific for 4-HNE and can react with any other 
carbonyl-modified proteins that have resulted from alternative oxidative pathways 
such as the metal-catalysed oxidation of amino acid side chains and covalent 
modification of protein by alternative reactive alkenals e.g. malondialdehyde and 4-
oxononenal.  
 
With proteins being one of the major targets of oxidative damage within the 
body, there is an urgent need for reliable and robust analytical methods that are 
capable of yielding absolute quantitative data, with particular emphasis on the 
accurate quantification of the extent of protein modification by 4-HNE (Hawkins, 
2009). Many methods provide qualitative or semi-quantitative assessments on the 
degree of protein modification without unequivocally ascertaining the sites of 
modification or an absolute measurement. In the last 15 years, advances in ionisation 
and increases in the accessible mass ranges of modern mass spectrometry 
instruments have led to the fundamental improvements in the analysis of 4-HNE-
modified proteins. Mass spectrometry-based proteomic techniques have sought to 
overcome the difficulties associated with specificity. These approaches include: GC-MS 
(Véronneau, 2002; Requena, 1997); MALDI-TOF (Mendez, 2010; Siegel, 2007; 
Bennaars-Eiden, 2002); LC-ESI-MS/MS with collision induced dissociation (Mendez, 
2010; Zhu, 2007; Aldini, 2006; Carbone, 2005; Liu, 2003) and LC-ESI-MS/MS with 




Mass spectrometry-based proteomics is a major tool used in the identification 
of proteins. Using the mass-to-charge ratio of analytes, a plethora of information can 
be gained including the measurement of: intact proteins and protein complexes; 
fragment ions produced from protein ions (known as top-down sequencing); peptides 
produced following enzymatic or chemical digestion of proteins (referred to as mass 
mapping) and fragment ions produced from mass-selected peptide ions (known as 
bottom-up sequencing) (Wysocki, 2005). Fragmentation can occur either “in-source” 
during the ionisation process or through purposeful induction of increased potential at 
the spray tip (usually by sources such as ESI) or “post-source” in a tandem mass 
spectrometry instrument (MS/MS by CID (collision-induced dissociation), ECD 
(electron-capture dissociation) or ETD (electron-transfer dissociation)). There is a 
continual expansion of genome and protein sequence data that is stored in databases 
and the application of mass spectrometry and MS/MS takes full advantage of this. 
Following digestion of a protein (either a model protein or complex matrix) and LC-
MS/MS analysis, the resultant data of product ion peak intensities and their mass-to-
charge ratios are compared with sequence data generated by the theoretical digestion 
of a protein. In the case of post-translational modifications, it is possible to define the 
instrument used, the protein that was digested, the type of digestion and the 
expected modifications to generate theoretical data.  
 
As demonstrated in chapters 2 and 3, global measurements of oxidative stress 
are possible in relation to antioxidants and metals but do not evidence an increased 
level of oxidative stress that is directly related to disease severity and independent of 
smoking status. Therefore, the next logical step was to assess the extent of oxidative 
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stress at the molecular level. In order to achieve this, experiments were performed to 
demonstrate that Michael additions can be formed between 4-HNE and short-chain 
peptides followed by analysis of these adducts in a model protein and subsequently 
within a complex biological matrix (bronchoalveolar lavage samples). A novel 
approach was utilised to achieve this; LC-ESI-MS/MS (neutral-loss driven) with both 
CID and ETD. This approach is similar to that demonstrated by Rauniyar et al. (2009) 
but utilises ETD instead of ECD, which has previously been used to identify sites of 





4.2.1 Synthesis of 4-hydroxy-2-nonenal 
Reference 4-HNE material certified to a given purity is expensive and 
commonly purchased in milligram quantities prepared in organic solvent (ethanol is 
typical for such preparations). Given the number of preliminary experiments I wished 
to carry out and the expense associated with the purchase of 4-HNE, a decision was 
made to synthesise the material in-house. A method for the 3-step synthesis of 4-HNE 
was adapted from a paper by Gardner et al. (1992) with the expectation of yielding a 
large amount of the compound from relatively inexpensive materials.  
 
4.2.1.1  Chemicals and reagents 
Cis-3-Nonen-1-ol (97%) was purchased from Alfa Aesar (Lancashire, UK); 3-
chloroperoxybenzoic acid (77% and also known as MCPBA) and Dess-Martin 
periodinane (97%) were purchased from Sigma Aldrich (Dorset, UK). All other 
chemicals and solvents were either reagent or HPLC grade. All the chemicals were 
used as received unless otherwise stated. Chloroform was purified by adding 100 mL 
of purified H2O to 50 mL CHCl3 in a separating funnel. The mixture was vigorously 
shaken and the bottom organic layer was collected. This organic layer was washed 
with H2O a further 2 times after which excess di-potassium carbonate was added to 
the combined organic layers in order to remove any residual H2O. The solution was 
then filtered and placed into a clean flask. This treatment was performed in order to 
remove potential traces of ethanol, which would have competed with the cis-3-




4.2.1.2  Synthesis of 4-HNE 
20 mL of ethanol-free CHCl3 was placed into a round-bottom flask on ice and 
equilibrated for 5 mins with stirring. To this, 840 µL (5 mmol) of cis-3-nonenol was 
added and stirred for 5 mins. 1.5 g of MCPBA (8.7 mmol) was then added and the 
contents left to stir for 2 hrs. The solution was then removed from the ice bath, 20 mL 
of 10% NaHCO3 was added and left to stir for 45 mins. A separating funnel was then 
used to decant the lower CHCl3 layer into a clean flask. The organic layer was then 
washed a further 2 times with 20 mL of 10% NaHCO3 followed by a final wash of the 
combined CHCl3 layers with 20 mL of H2O. The CHCl3 layer was collected and placed 
into a beaker and excess anhydrous sodium sulphate was added to remove any 
residual H2O. This solution (containing the 3,4-epoxynonanol) was then filtered and 
placed into a clean round-bottom flask and the solvent was removed in vacuo using a 
rotary evaporator. 280 mg of epoxide (2 mmol) was evident from weighing the flask to 
which 10 mL of ethanol-free CHCl3 was added followed by the addition of a 2 molar 
excess of periodinane (2:1 periodinane : epoxide) which equated to 1.7 g of 
periodinane (4 mmol). This solution was left to stir at room temperature for 20 mins 
(forming the 3,4-epoxynonanal) and then 56 mL of diethylether and 16 mL of a 1.3 M 
NaOH solution were added and the mixture vigorously shaken for 30 seconds 
(breaking the oxygen bridge and subsequently forming the 4-hydroxy-2-nonenal). This 
solution was placed into a clean separating funnel and the aqueous NaOH (bottom 
layer) was removed. The organic diethylether layer was then washed a further 2 times 
with 20 mL of 1.3 M NaOH (each was left to stir vigorously for 10 mins before the 
aqueous layer was removed). The organic layer was then washed for a final time with 
20 mL of H2O after which, the diethylether layer was collected into a beaker and 
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excess anhydrous sodium sulphate was added. The organic layer was then filtered and 
placed into a clean round-bottom flask and the solvent removed in vacuo using a 




Figure 4.1: Reaction scheme of the synthesis of 4-HNE. The C3-C4 double bond of cis-
3—nonenol (1) is oxidised to an oxygen bridge (2) by MCPBA. The hydroxyl group is 
then oxidised to form the aldehydic functional group on C1 (3) through the addition of 
periodinane. Treatment with the base NaOH breaks the oxygen bridge to form a 
hydroxyl group on C4 and a double bond between C2-C3 thus forming the product 4-









The amount of product obtained was calculated by subtracting the weight of 
the empty flask from the weight of flask with product. A yield of 380 mg of 4-hydroxy-
2-nonenal was obtained. From this the % yield of 4-HNE was calculated:  
 
Theoretical yield = mmol x molecular weight 
= 5 mmol (3(z)nonenol) x 156.22 (molecular weight of 4-HNE) 
= 781.1 mg 
 
Therefore: 
Actual yield = (actual (mg) / expected (mg)) x 100 
= (380mg / 781.1 mg) x 100 
= 50% yield 
 
The sample was finally flushed with nitrogen to displace any oxygen present in the 
flask, sealed with paraffin wrap and stored at -80 ˚C to prevent oxidative degradation.  
 
4.2.1.3  Analysis by Nuclear Magnetic Resonance spectroscopy 
The synthesised 4-hydroxy-2-nonenal was assessed for authenticity and purity 
by Nuclear Magnetic Resonance spectroscopy (NMR) using a Bruker 400 MHz 
instrument. A purified 4-HNE sample was purchased from Cayman Chemicals and used 
as the reference material. The preparation solvent used was CDCl3 + 0.05% 
tetramethylsilane (TMS). The protons of the methyl groups of TMS are comparatively 
shielded compared with many other compounds and so serve as an internal standard 
(IS). TMS therefore marks one end of the range and the chemical shifts in ppm for 
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compounds are read in reference to how far downfield they have moved from zero 
ppm (TMS).  
 
4.2.1.4  Analysis by Mass Spectrometry 
Based upon the work published by Gioacchini et al. (1999) the synthesised 4-
HNE was analysed using mass spectrometry to provide additional structural 
confirmation against the reference sample. In this reference paper, it was noted that 
4-HNE can form a methyl-acetal structure when dissolved in methanol and so 
acetonitrile is recommended as the preferred solvent. All chemicals and solvents were 
either analytical or HPLC grade. All the chemicals were used as received unless 
otherwise stated.  
 
A 50 µg/mL sample of purchased standard 4-HNE was prepared in a solution of 
0.1 % formic acid in acetonitrile along with a 50 µg/mL sample of synthesised 4-HNE 
prepared in a solution of 0.1 % formic acid in acetonitrile. In addition, a 50 µg/mL 
sample of synthesised 4-HNE was prepared in a solution of 0.1 % formic acid in 
methanol. The instrument used was a Thermo-Fisher Accela UHPLC LTQ -MS linear 
ion-trap mass spectrometer system. A tune file was created for the purchased 
standard compound in which the electrospray voltage was set to 4 kV, the capillary 
temperature was set at 370˚C, capillary voltage at 15V and tube lens at 50V.  
 
4.2.1.5  Analysis by Liquid Chromatography coupled with Mass Spectrometry 
As a final step in confirming the authenticity of the synthesised 4-HNE 
compound against the reference material, chromatographic separations were carried 
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out using a Thermo-Fisher Accela UHPLC LTQ-MS system. A Waters XBridge BEH C18 
3.5 µm (2.1 x 150 mm) column was used with a solvent system containing 0.1 % formic 
acid in water (A) and 0.1 % formic acid in acetonitrile (B). The column temperature 
was set at 40˚C and the tray temperature at 4˚C. The following chromatographic 
gradient conditions were used: 




Parameters were also set to acquire two different scan events; full MS mode (m/z 50-
200) and MS/MS by CID at a normalised collision energy of 35% (m/z 50-200) with 
parent mass m/z 157. Multiple injections (>3) of both the reference material and the 
synthesised material were performed.  
 
4.2.2 Forming the peptide-4-HNE conjugate 
It is widely regarded in the literature that 4-hydroxy-2-nonenal preferentially 
forms Michael additions with three amino acid residues; lysine, histidine and cysteine. 
As a proof of concept to determine that such additions could be observed, it was 
necessary to form a peptide-4-HNE conjugate. Neurotensin, a 13-amino acid 
neuropeptide, was selected as it contains a single lysine residue and no histidine or 
cysteine residues. This afforded the opportunity to show the Michael addition 
between the 4-HNE and the lysine residue in a short-chain peptide. The sequence of 
Time (minutes) Solvent A (%) Solvent B (%) Flow (µL/min)
0 60 40 200
10 20 80 200
12 20 80 200
15 60 40 200
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neurotensin (NT) is as follows: pyroGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-
Leu-OH. In one letter notation the sequence is: pyro-QLYQNKPRRPYIL-OH with the K 
denoting the lysine residue.  
 
4.2.2.1  Chemicals and reagents 
Neurotensin (≥90%) was purchased from Sigma Aldrich (Dorset, UK). The 
synthesised 4-HNE was used to form the adduct. All other chemicals and solvents 
were either reagent or HPLC grade. All the chemicals were used as received unless 
otherwise stated. 
 
4.2.2.2  Formation of the neurotensin-4-HNE adduct 
A method was adapted from a paper by Rauniyar et al. (2009) and 4-HNE 
adducts of neurotensin were prepared by reaction of 1 mg/mL peptide with 2 mM 4-
HNE in 0.1 M phosphate buffer (pH 7.4) at 37˚C for 2 hours. Phosphate buffer was 
prepared by the addition of 2.83 g potassium hydrogen orthophosphate (KH2PO4) and 
0.6 g anhydrous disodium hydrogen orthophosphate (Na2HPO4) dissolved in 250 mL 
H2O. The solution was adjusted to pH 7.4 using 1M sodium hydroxide (NaOH). After 
the incubation, 1 mL of diethylether (DEE) was added to the sample, vortexed for 30 
seconds and spun for 1 minute in a centrifuge to extract the excess 4-HNE. The DEE 







4.2.2.3  Analysis of the neurotensin-4-HNE adduct by Mass Spectrometry 
A 1 µg/mL solution of neurotensin (NT) in 0.1 % formic acid with 50:50 
H2O:ACN was used to create a tune file for the NT by direct infusion at a flow of 10 
µL/min in full MS mode with a mass range of 50-2000 m/z. A 50 fold dilution (20 
µg/mL) was prepared of the 4-HNE-NT adduct sample in 0.1 % formic acid with 50:50 
H2O:ACN. This solution was used to create a tune file for the product ion m/z 610. 
 
4.2.2.4  Analysis of the neurotensin-4-HNE adduct by Liquid Chromatography 
coupled with Mass Spectrometry 
Chromatographic separations were carried out using a Thermo-Fisher Accela 
UHPLC LTQ-MS system to provide detailed analyses on the synthesised adduct. A 5-
fold dilution (4 µg/mL) of the original 50 fold dilution was prepared of the 4-HNE-NT 
adduct sample in 0.1 % formic acid with 50:50 H2O:ACN. A Waters XBridge BEH C18 
3.5 µm (2.1 x 150 mm) column was used with a solvent system containing 0.1 % formic 
acid in water (A) and 0.1 % formic acid in acetonitrile (B). The column temperature 
was set at 40˚C and the tray temperature at 4˚C. The chromatographic gradient 
conditions are illustrated in Table 4.2. Parameters were set to acquire three different 
scan events; MS1 CID 35% (m/z 50-200) with parent mass m/z 157, MS2 CID 35% (m/z 
150-600) with parent mass m/z 559 and MS3 CID 35% (m/z 165-2000) with parent 













4.2.2.5  Analysis of the neurotensin-4-HNE adduct by LC-MS/MS with Electron 
Transfer Dissociation 
Direct infusions using the 50 fold dilution (20 µg/mL) NT-4-HNE adduct sample 
were carried out at a flow of 10 µL/min. MS/MS ETD with an activation energy of 
500ms was used along with full MS scan of mass range 50-2000 m/z. The tune file 
from section 4.2.2.3 was used. Chromatographic separations were carried out using a 
Thermo-Fisher Accela UHPLC LTQ-MS system to provide detailed analyses on the 
synthesised adduct. A 5-fold dilution (4 µg/mL) of the original 50 fold dilution was 
prepared of the 4-HNE-NT adduct sample in 0.1 % formic acid with 50:50 H2O:ACN. 
Chromatographic conditions were as described in section 4.2.2.4 above. Parameters 
were set to acquire two different scan events; MS1 ETD 100ms (m/z 150-600) with 
parent mass m/z 559 and MS2 ETD 100ms (m/z 165-2000) with parent mass m/z 610. 
Multiple injections (>3) were performed. 
 
4.2.2.6  Assessment of the peptide-4-HNE adduct reaction completion time 
Although Rauniyar et al. (2009) gave an estimated reaction completion time of 
2 hours, I performed a series of adduct formations between neurotensin and 4-HNE 
Time (minutes) Solvent A (%) Solvent B (%) Flow (µL/min)
0 90 10 200
2 90 10 200
20 30 70 200
22 30 70 200
22.5 90 10 200
30 90 10 200
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with variable incubation times. The adducts were formed as previously described with 
the variable incubation times of 2, 4 and 6 hours respectively. Minor changes to the 
protocol were made. Purchased 4-HNE was used instead of the synthesised compound 
in these formations as the reactions were scaled down and any possible hindrance 
from impurities needed to be avoided. In addition, a second set of reactions were 
completed substituting the purchased standard 4-HNE material with a purchased 
standard tri-deuterated form of 4-HNE (D3-4-HNE). The tri-deuterated form was 
introduced as a means of creating an internal standard for later experiments, working 
towards the quantification of endogenous adducts in biological samples. 
 
Chemicals and reagents were as described previously in section 4.2.2.1. In 
addition, 4-HNE and tri-deuterated 4-HNE (D3-4-HNE) were purchased from Cayman 
Chemicals (Europe). As the reference materials, in particular the deuterated 4-HNE 
compound were expensive, micro reactions were carried out to form the deuterated 
and undeuterated 4-HNE-neurotensin adducts. The deuterated 4-HNE came prepared 
as 100 µg in 200 µL methyl acetate. As the compound was expensive, it was deemed 
necessary to use as little as possible without compromising the reaction. With the 
original reaction requiring 300 ng to 1 mg peptide (a 3.33 excess peptide to aldehyde) 
it was decided that a 2x excess of the aldehyde to peptide should be used, eliminating 
the risk of insufficient aldehyde to react with the peptide and also allow the 
determination of reaction completion.  
 
In order to satisfy equality between the D3-4-HNE and 4-HNE standard 
materials, an appropriate dilution (100 µg in 200 µL ethanol) of the 4-HNE stock (1 mg 
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in 100 µL ethanol) was prepared. An appropriate dilution (100 µg in 1 mL H2O) of the 
neurotensin stock solution (1 mg in 1 mL 0.1 M phosphate buffer) was also prepared. 
Phosphate buffer was prepared as described previously in section 4.2.2.2.  
 
Deuterated 4-HNE adducts of neurotensin were prepared by reaction of 250 ng 
peptide with 500 ng D3-4-HNE in 96.5 µL of 0.1 M phosphate buffer (pH 7.4) at 37˚C 
for 2, 4 and 6 hours respectively (total volume 100 µL). Undeuterated 4-HNE adducts 
of neurotensin were prepared in the same way. For the internal standard calibration 
analyses, appropriate aliquots of the neurotensin stocks were taken to give the 
following peptide concentrations: 250 ng, 500 ng, 750 ng, 1 µg, 2 µg, 4 µg, 6 µg and 8 
µg respectively. The concentration of the deuterated and undeuterated 4-HNE were 
further diluted to give 50 ng/µL. The adducts were formed as described above with 
the total volume remaining at 100 µL. Following incubation, 100 µL of diethylether 
(DEE) was added to each sample and gently vortexed for 30 seconds to extract the 
excess 4-HNE. The DEE layer was discarded and the extraction repeated once more. 
This method was adapted from a paper by Rauniyar et al. (2009). Chromatographic 
separations were carried out using a Thermo-Fisher Accela UHPLC LTQ-MS system to 
provide detailed analyses on the synthesised adducts. The chromatographic 
conditions used were as described in section 4.2.2.4 above. Parameters were also set 
to acquire two different scan events; MS1 CID 35% (m/z 150-600) with parent mass 
m/z 559 and MS2 CID 35% (m/z 165-2000) with parent mass m/z 611 (D3-4-HNE) and 





4.2.2.7  Formation of an alternative peptide-4-HNE conjugate 
As previously discussed, the literature states that 4-hydroxy-2-nonenal 
preferentially forms Michael additions with three amino acid residues; lysine, histidine 
and cysteine (Carini, 2004). Proof of concept in regards to the formation of a peptide-
4-HNE conjugate has already been demonstrated with neurotensin. As an additional 
evidentiary piece of experimental work, an alternative short-chain peptide-4-HNE 
conjugate was formed. Human angiotensin 1, a 10-amino acid neuropeptide, was 
selected as it contains two histidine residues and no lysine or cysteine residues. This 
allowed exploration of the Michael additions between the 4-HNE and the histidine 
residues in a short-chain peptide. The amino acid sequence of angiotensin (AT) is as 
follows: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu. In one letter notation the sequence 
is: DRVYIHPFHL with the H denoting the histidine residues. A mixture of both 
angiotensin and neurotensin was also incubated with 4-HNE to show the presence of 
both adducts in one solution. Chemicals and reagents were as described previously in 
section 4.2.2.1. In addition, Human angiotensin 1 (≥90%) was purchased from Sigma 
Aldrich (Dorset, UK). The synthesised 4-HNE was used to form the adducts. Phosphate 
buffer was prepared as described previously in section 4.2.2.2. 4-HNE adducts of 
angiotensin (AT) were prepared by reaction of 1 mg/mL peptide with 2 mM 4-HNE in 
0.1 M phosphate buffer (pH 7.4) at 37˚C for 2 hours. 4-HNE adducts of angiotensin and 
neurotensin were prepared by reaction of 1 mg/mL of each peptide with 4 mM 4-HNE 
in 0.1 M phosphate buffer (pH 7.4) at 37˚C for 2 hours. 
 
After the incubation, 1 mL (2mL for the AT/NT mixed solution) of diethylether 
(DEE) was added to each sample, vortexed for 30 seconds and spun for 1 minute in a 
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centrifuge to extract the excess 4-HNE. The DEE layer was discarded and the 
extraction repeated a further 2 times. This method was adapted from a paper by 
Rauniyar et al. (2009). A 50 fold dilution (20 µg/mL) was prepared from the original 
solution of AT-4-HNE in 0.1 % formic acid with 50:50 H2O:ACN. This was used to create 
a tune file for the AT by direct infusion at a flow of 10 µL/min followed by direct 
infusion analysis of the sample. Full MS mode, with a mass range of 50-2000 m/z was 
applied. 
 
To further characterise the AT-4-HNE conjugate in both its cleaved and 
preserved states, direct infusion analyses of the sample at a flow of 10 µL/min was 
carried out using the following scan events: MS/MS CID at a normalised collision 
energy of 35 (m/z 200-2000) with parent mass m/z 727 and MS/MS ETD 500ms (m/z 
200-2000) with parent mass m/z 727. 
 
4.2.3 Formation of protein-4-HNE adducts 
Following the formation of short-chain peptide-4-HNE adducts for angiotensin 
and neurotensin, the next stage was to look at adduct formation using an intact 
protein. Bovine Serum Albumin (BSA) was selected as a model protein and incubated 
with either deuterated or undeuterated 4-HNE (purchased materials) and then 
subjected to a tryptic digest. The incubation period prior to the digestion of the 
protein allows Michael adducts to form with lysine, histidine and cysteine residues 
near to the outer surface of the BSA. Once these adducts have been formed, the 
protein is digested using trypsin, cleaving the peptide chain into smaller fragments. 
Trypsin possesses a high cleavage specificity, preferentially cleaving at arginine and 
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lysine residues and exerts its protease activity whilst remaining suitably stable in an 
array of conditions. The resultant peptide ion fragments are then processed through 
SEQUEST and MASCOT software (amino acid sequence databases and search 
algorithms) to establish the fragments exhibiting a 4-HNE-modified site.  
 
4.2.3.1  Chemicals and reagents 
Bovine Serum Albumin (BSA) was purchased from Sigma Aldrich (Dorset, UK). 
Deuterated and undeuterated 4-HNE were purchased from Cayman Chemicals 
(Europe). All other chemicals and solvents were either reagent or HPLC grade. All the 
chemicals were used as received unless otherwise stated. 
 
4.2.3.2  Incubation and tryptic digestion protocol 
A 50 µl sample (2 mg/ml protein concentration prepared in H2O) was prepared 
and 1 uL of the relevant HNE stock (deuterated or undeuterated) was added. The 
solution was vortexed and incubated at 37˚C for 2 hours. Following incubation, 50 µl 
of trifluoroethanol (TFE) was added and the solution was vortexed again (protein 
concentrations may have varied as part of experiments, but the volume of 50 µl 
always remained the same). The addition of 11 µl of 150mM dithiothreitol (DTT) to 
give 15mM DTT was then carried out and the solution was heated to 55oC for 45 min. 
The samples were cooled to room temperature (~5min) and then 12 µl of 550mM 
iodoacetamide (IAM) was added to achieve a final concentration of 55mM IAM. The 
solution was then incubated in the dark at room temperature for 30 min.  The sample 
was diluted by adding 880 µl of 50mM Tris + 2mM CaCl2 pH 8.0 (to achieve 5% TFE 
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concentration). 20 µl of trypsin (Promega sequencing grade) was then added to give a 
final concentration of 1:25-1:50 enzyme:protein and the solution was incubated at 
37oC overnight. Following overnight incubation, 10 µl of formic acid (to get 1% v/v 
total) was added to stop the digestion. The sample was then cleaned up using solid 
phase extraction to remove the digest reagents. A C18 extraction cartridge (Varian 
bond elut) was placed in a vacuum box and primed first by the addition of 2 ml of 
methanol (add 2 x 1 ml) and then 2ml of H2O (add 2 x 1 ml). The sample was loaded 
using a glass pipette and allowed to pass through the column before adding 2 ml of 
water (2 x 1 ml) to wash through unwanted eluents. New tubes were then placed in 
the vacuum box and 2 ml of ACN (2 x 1ml) was added to elute the peptides. The 
samples were dried down in a water bath under nitrogen for approximately 20 min at 
65oC. The samples were then reconstituted into a solution of 200 µl of 90% H2O 10% 
ACN.  
 
Following the reduction step using DTT to reduce the disulphide bonds, the 
alkylation step (using IAM) adds an additional mass of 57 to cysteine residues prior to 
digestion. This carbamidomethyl modification prevents the cysteines from reforming 
disulphides and so modified peptide fragments will display an additional mass of 57 
for carbamidomethylation and an additional 157 for 4-HNE. The carbamidomethyl 
modification is illustrated as: 
-CH2-SH      +    I-CH2-CONH2                            -CH2-S-CH2-CONH2 




4.2.3.3  Data-dependent neutral-loss LC-MS/MS with ETD 
Both the deuterated and undeuterated 4-HNE-BSA digests were analysed using 
LC-MS/MS. A neutral-loss driven data dependent method was used to characterise the 
HNE-modified peptides. In this approach, when a neutral loss of 4-HNE is produced 
following MS/MS of 4-HNE-modified peptides, MS/MS by ETD is triggered on the 
product ion which produces the neutral-loss. This generates peptide ion fragments 
with the 4-HNE still bonded to the amino acid. Whilst neutral-loss indicates the 
presence of 4-HNE-modification, it does not allow the elucidation of the actual site of 
the post-translational modification, that is, specificity is lost with respect to the 
identity of the amino acid residue (due to fragmentation). When more than one site is 
present that is susceptible to modification by 4-HNE, ETD can be used as it provides an 
alternative fragmentation technique that allows the modified sites to remain intact, 
thus enabling specificity and unequivocal identification of adduct sites. The digested 
samples were chromatographically separated using a Thermo-Fisher Accela UHPLC 
LTQ/ETD-MS system to provide MS/MS analyses. Multiple injections (>3) were 
performed. A Waters XBridge BEH C18 3.5 µm (2.1 x 150 mm) column was used with a 
solvent system containing 0.1 % (v/v) formic acid in water (A) and 0.1 % (v/v) formic 
acid in acetonitrile (B). The column temperature was set at 40˚C and the tray 














All MS measurements were made using the following instrumental parameters 
to acquire the MS scans: MS1 full scan (m/z 350-1500) and MS2 data-dependent CID 
with normalised collision energy of 35% with fragmentation of ions within the set 
thresholds given below. From both the deuterated and undeuterated digests, the 
peptide sequences SHCIAEVEK (average mass 1015.16) and FKDLGEEHFK (average 
mass 1249.39) were chosen as model peptide sequences due to their consistent 
appearance and reasonable signal across a number of preliminary digests. For 
undeuterated 4-HNE, the precursor ion mass list consisted of ions 470 m/z for triply 
charged FKDLGEEHFK with a 4-HNE modified site and 615 m/z for a doubly charged 
SHCIAEVEK with a carbamidomethylated cysteine and a 4-HNE modified site. The 
neutral loss of 4-HNE from the triply or doubly charged peptide corresponds to mass 
losses of m/z 52 and m/z 78 in the spectra. For deuterated 4-HNE, the precursor ion 
mass list consisted of the same peptide sequences with ions 471 m/z and 617 m/z for 
triply and doubly charged peptides with d3-4-HNE, whilst the neutral loss list consisted 
of mass losses of m/z 53 and m/z 79 for the same respective charge states. The 
deuteration accounts for the m/z 1 difference between the values from the two 
digests. 
Time (minutes) Solvent A (%) Solvent B (%) Flow (µL/min)
0 90 10 200
2 90 10 200
40 10 90 200
47 10 90 200
47.5 90 10 200
60 90 10 200
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Operating the instrument in data-dependent mode (as illustrated in Figure 
4.2), the mass spectrometer performs a number of tandem MS scan events on ions 
that have been detected above a pre-set threshold (i.e. over a given intensity). The 
data-dependent analysis selects the most intense precursor ions from the MS scan 
with a minimum MS signal of 1000 counts. Scan event 1 is the MS full scan event over 
the range m/z 350-1500, which generates the precursor ions for scan event 2. Scan 
event 2 was an MS/MS product ion scan (CID) over the mass range m/z 200-2000 with 
a normalised collision energy of 35% and an activation time of 30 ms with an isolation 
width of 3.0 Da. Dynamic exclusion was applied with a repeat count of 3 and a repeat 
duration of 30 seconds in order to avoid oversampling the same ions. The peak 
exclusion list size was set at 100 with an exclusion duration of 2 minutes and a mass 
isolation width of 1.5 Da. Scan event 3 was triggered by scan event 2 following a 
neutral loss (pre-defined as described above) with spectra collected over the 200-2000 
m/z mass range (precursor ion window). This activates the ETD source with an 
isolation width of 2.0 Da and activation time of 500 ms. Once again, dynamic exclusion 














1 hour LC run
m/z = 52, 78
or






Figure 4.2: A flow diagram illustrating the various scan events and thresholds for data-
dependent analysis using MS/MS CID and MS/MS ETD.  
 
Peptide sequencing and protein precursor identification were carried out on 
the CID MS2 data obtained from the chromatographic separation of the digests (both 
deuterated and undeuterated). The data was analysed using the SEQUEST Browser 
(v.3.0, ThermoFisher) to create DTA files of all of the MS2 spectra obtained. This is a 
conversion from the Xcalibur software format to a generic ASCII file that can then be 
used across platforms. The following settings were used to generate the DTA files: 
bottom MW 500, top MW 2000, grouped scans 1, minimum number of ions 15 and 
minimum TIC 1000. The DTA files were merged using Mascot Daemon (Matrix Science, 
http://www.matrixscience.com) in order to upload a single file to the Mascot server. 
Correlations were then performed using the theoretical spectra from the Swiss Prot 
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protein database (accessed June 2010) against the bovine serum albumin digest and 
any mass spectra that exhibited an exact-match to a peptide sequence using the 
online available version of Mascot (Matrix Science, http://www.matrixscience.com) 
with the following algorithm parameters of; peptide tolerance ± 2.5 Da and MS/MS 
tolerance ± 1.0 Da. Mascot was also set to search for the variable modifications in 
peptide mass due to carbamidomethylation and the addition of 4-HNE. Sequences 
exhibiting a score that indicated homologies with greater than 95% probability were 
considered as confirmed by Mascot.  
 
4.2.4 Formation of protein-4-HNE adducts in bronchoalveolar lavage 
Following the tryptic digestion and neutral-loss LC-MS/MS (with CID and ETD) 
analysis of BSA-4-HNE adducts, the protocol was repeated using four BAL samples 
from selected COPD patients (as employed in Chapters 2 and 3), details outlined 
below: 
1.  Sample ID 33: Female COPD current smoker, age 60 years, 14 pack years. 
Lavage recovery 39%, total protein concentration 0.02 mg/mL. 
2.  Sample ID 38: Female ‘healthy’ smoker, age 71 years, 30 pack years. Lavage 
recovery 9.4%, total protein concentration 0.06 mg/mL. 
3.  Sample ID 39: Male never-smoker, age 68 years. Lavage recovery 50%, total 
protein concentration 0.08 mg/mL. 
4.  Sample ID 40: Male COPD ex-smoker, age 70 years, 50 pack years. Lavage 




The four BAL samples were individually split into equal volumes between 2 
vials, resulting in 8 sample vials. Of these newly-divided sets, half underwent protein 
precipitation, as described in section 4.2.4.2 whilst the other half remained untreated 
(Figure 4.3). The samples were then dried under nitrogen in vacuo and then 







Figure 4.3: BAL fluid sample pre-treatment for 4-HNE adduction experiments. 
 
4.2.4.1  Chemicals and reagents 
Details of the clinical bronchoalveolar lavage are found in Chapter 2. All other 
chemicals and solvents were either reagent or HPLC grade. All the chemicals were 
used as received unless otherwise stated.  
 
4.2.4.2  Precipitation of protein from the lavage samples 
The protein precipitation protocol for the BAL samples was adapted from the 
method described by Kay et al. (2008); 180 µL of acetonitrile was added to an 80 µL 
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sample of BAL (containing 80 µg of protein), gently vortexed for 30 seconds and then 
sonicated for 10 minutes. The sample was then vortexed gently for another 30 
seconds and sonicated for a further 10 minutes. Following this, the sample was 
centrifuged at 12,000 g at room temperature for 10 minutes. The supernatant (~250 
µL) was transferred to a clean vial and dried with nitrogen at room temperature in 
vacuo for 30 minutes. The sample was then reconstituted in 50 µL of water. 
 
4.2.4.3  Incubation and tryptic digestion protocol 
The tryptic digestion of the lavage was carried out as described in section 
4.2.3.2 with the following modifications: the starting concentration of protein in the 
lavage was 50 µg (estimated to be slightly lower in the precipitated samples) as 
opposed to 100 µg; no incubation with 4-HNE or d3-4-HNE was performed. The 
digestion was performed on both the precipitated and unprecipitated BAL samples. 
 
4.2.4.4  Data-dependent neutral-loss LC-MS/MS with ETD of the digested BAL 
Data-dependent analyses was performed as described in section 4.2.3.3 with 
the exemption of neutral-loss scan events for deuterated 4-HNE. Only one injection 





4.3 Results & Discussion 
4.3.1 Assessing the purity of the 4-hydroxy-2-nonenal synthesis  
 Authenticity and purity of the synthesised 4-HNE were confirmed by Nuclear 
Magnetic Resonance (NMR) and mass spectrometry. 
 
4.3.1.1  Assessing the synthesis using Nuclear Magnetic Resonance 
spectroscopy 
 
Below is an estimation of the expected 1H NMR values obtained by using 
ChemDraw software ver. 11.0 (Cambridgesoft) based upon the chemical structure of 
4-HNE (Figure 4.4). 
 
 
Figure 4.4: ChemDraw single proton NMR prediction of 4-hydroxy-2-nonenal based 
upon the structure. 
 
The values in blue represent the predicted chemical shifts (ppm) downfield 
from TMS (internal standard, set at 0 ppm) that are expected for this compound. 




Figure 4.5: ChemDraw single proton NMR estimation for 4-hydroxy-2-nonenal. 
 
 
 Approximately 2 mg of reagent grade 4-HNE (purchased from Cayman 
Chemicals) was placed into solution with 700 µL of CDCl3 (deuterated chloroform) + 
0.05 % TMS.  The sample was analysed via NMR and the spectrum obtained is 
illustrated in Figure 4.6. A scraping of the synthesised 4-HNE compound 
(approximately 25 mg) was placed into solution with 700 µL of CDCl3 + 0.05 % TMS.  







Figure 4.6: Single proton NMR spectrum of the reagent grade 4-HNE. 
 
The original file for the reference HNE was unavailable and so a scanned 
version of the hard copy is shown. However, this spectrum was enhanced by the 
technician and so the range below 6.2 ppm is not presented. In addition, detailed 
information was not available to calculate the coupling constants for the enhanced 
areas although overlaying the two spectra (reference material and synthesised 
compound) showed that the values were identical. Therefore, for purposes of 
comparison this lower range for the synthesised compound will be assessed against 







Figure 4.7: Single proton NMR spectrum of the synthesised 4-HNE. 
 
 The data from the predicted spectrum, the synthesis reference paper 
(method adapted from Gardner et al. 1992) and the in-house synthesised compound 
can be found in Table 4.4 below. The coupling constant J, is calculated by the 
following formula: 
 
J Hz = δ ppm x MHz 
 
 The reference paper characterised only from C1 to C4. The coupling constants 
for the synthesised compound satisfy the values of the reference paper and also the 
ChemDraw prediction. Figures 4.8 to 4.11 are enhancements of the synthesised 
compound 1H spectrum. 
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Table 4.4: NMR spectra data – chemical shifts (ppm) registered downfield from 
tetramethylsilane. 1H = single proton, d = doublet, dd = double doublet, dddd = 
quartet of doublets, dtd = doublet triplet doublet, s = singlet, b = broad, m = multiplet, 




 Aldehyde groups typically exhibit a chemical shift of between 9.0-10.0 ppm. 
The hydrogen attached to the aldehyde is shifted further downfield based upon the 
anisotropy of the carbonyl group (C=O) in addition to the inductive effect of the 
oxygen which expresses electronegativity. Magnetic anisotropy can be explained as 
the effect of unsaturated π electrons upon protons within close proximity. In the case 
of aldehydes, the electronegativity of the oxygen in conjunction with the electron 
dense double bond cause significant deshielding and reduction of electron density of 
the attached hydrogen proton which results in a large downfield chemical shift. The 
doublet observed for the aldehyde is due to the weak coupling of the aldehydic 
hydrogen to the hydrogen present on the other side of the carbonyl group. Figure 4.8 
clarifies the presence of an aldehyde at 9.60 ppm with the characteristic doublet 
observed. 
ChemDraw 1H prediction Gardner et. al (1992) Lipids, 27, 9, 686-689 Synthesised 4-HNE
CHO = 9.68 (d ) 9.56 (1H, d, J = 7.9) 9.60 (1H, d, J = 7.8)
H on C-2 = 6.26 (dddd ) 6.29 (1H, dddd, J  = 15.7, 7.9, 1.6) 6.3 (1H, dddd, J  = 15.6, 8, 1.6)
H on C-3 = 6.84 (dd ) 6.81 (1H, dd, J = 15.7, 4.7) 6.8 (1H, dd, J = 15.6, 4.8)
H on C-4 = 3.9 (dtd ) 4.42 (1H, dtd,  J = 6.5, 4.7, 1.6) 4.44 (1H, m )
OH = 2.8 (d ) 1.85 (1H, d, J  = 4.4)
H on C-5 = 1.48 (m ) 1.63 (1H, m )
C-6 to C8 = 1.27 (m ) 1.33 (1H, m )




Figure 4.8: Enhancement of the aldehydic group (CHO) of the synthesised 4-HNE 
which exhibits a doublet formation. 
 
 Alkenes can exhibit two different types of absorptions; vinyl and allylic. Vinyl 
absorptions typically have a chemical shift of 4.5-6.5 ppm but the splitting patterns of 
vinyl protons are complicated as the protons on double bonds are rarely equivalent 
magnetically despite being located on the same carbon. Vinyl hydrogens become 
deshielded by the diamagnetic anisotropy caused by the π electrons in the double 
bond resulting in three distinct types of spin interactions in alkenes; cis, trans and 
geminal (terminal methylene). These splitting patterns cannot, therefore, be explained 
by the n + 1 rule (also known as spin-spin splitting). Cis coupling constants are typically 
between 6 – 15 Hz corresponding with the cis-formation of C2 and C3 of the 
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synthesised compound. C2 and C3 display unique splitting behaviour and chemical 
shifts in accordance with that of cis-alkenes (Figure 4.9).  
 
 
Figure 4.9: Enhancement of the cis-alkenes (vinyl hydrogens = hydrogens attached to a 
double bond) of C2 and C3 of the synthesised 4-HNE. C3 exhibits a double doublet and 





Figure 4.10: Enhancement of the C4 multiplet of the synthesised 4-HNE. 
 
 
 The C4 of the synthesised compound exhibited a multiplet at 4.44 ppm 
(Figure 4.10). The chemical shift δ value is identical to the value from the reference 
paper of 4.42 ppm. It is worth noting that as no chromatographic purification was 
carried out, this may have affected the resolution of the C4 multiplet which should 
have exhibited a doublet-triplet-doublet (dtd). However, no significant impurities were 
apparent following analyses and so it was decided that the compound was of a 





Figure 4.11: Enhancement of the aliphatic region of the synthesised 4-HNE. This 
encompasses the hydroxyl group on C4, followed by C5, C6-C8 and the methyl CH3 
group.  
 
 Hydroxyl protons demonstrate variable absorption positions with chemical 
shifts anywhere from 0.5–5.0 ppm. Concentrated solutions possess increased 
hydrogen bonding between molecules resulting in the increased deshielding of 
protons. Such deshielding will show absorption at the higher end of the range (4-5 
ppm) whilst mildly concentrated solutions (with less hydrogen bonding) typically 
absorb at the lower end of the range (0.5-1.0 ppm). The reference paper did not give a 
value for the hydroxyl group and the predicted value fell at 2.80 ppm. However, as the 
hydroxyl group of the synthesised compound fell at 1.85 ppm and within the 
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described range, it was deemed an acceptable confirmation of its presence (Figure 
4.11).  
 
 The C5 and C6-C8 regions exhibited multiplicity and low resolution rendering 
it difficult to calculate the coupling constants (J). However, the chemical shift values 
were similar to the predicted values; the C5 and C6-C8 predicted values were 1.48 and 
1.27 ppm respectively and the synthesised compound values were 1.63 ppm for C5 
and 1.33 ppm for C6-C8. Both sets of values displayed multiplet peaks (Figure 4.11).   
 
 The methyl group was characterised by a triplet conforming to the n + 1 rule 
of multiplicity as the resonance peak of the methyl protons is split by two equivalent 
protons on the adjacent carbon atom (n = 2 therefore n + 1 = 3). The synthesised 
compounds δ value for the methyl group (0.90 ppm) corresponds with the predicted 
value of 0.88 ppm in addition to the predicted triplet peaks (Figure 4.11). 
 
4.3.1.2  Assessing the synthesis using Mass Spectrometry 
The purchased standard 4-HNE was directly infused into the ESI source using a 
syringe pump at a rate of 10 µL/min. The instrument was set to acquire full scan 







Figure 4.12: Direct infusion of purchased standard 4-HNE prepared in a solution of 0.1 
% formic acid in acetonitrile (>3 injections). Parent ion of m/z 157.2 can be seen as 
well as m/z 139.1 which constitutes the common loss of water. 
 
4-HNE has an average mass of 156.22 with the protonated molecule having a 
m/z 157.22 (i.e. [M + H]+ =  157.22). An abundant ion at m/z 157.2 was seen in Figure 
4.12 which represents the 4-HNE protonated molecule. An ion at m/z 139.2 is also 
observed which is characteristic of the 4-HNE undergoing a loss of water (157.2 – 18) 
in the mass spectrometer due to the presence of the hydroxyl group on carbon-4. The 
direct infusion was repeated for this sample using tandem mass spectrometry 
(MS/MS). Tandem mass spectrometry by collision induced dissociation (CID) with 
helium as the collision gas at an energy of an arbitrary value of 35% was utilised over a 






Figure 4.13: Direct infusion of purchased standard 4-HNE prepared in a solution of 0.1 
% formic acid in acetonitrile with MS/MS collision induced dissociation of 35%, parent 
ion m/z 157 (>3 injections). Product ions of m/z 139.1, 121.1, 97.1, 81.1, 69.1 and 57.1 
are observed. 
 
The fragmentation pattern for the MS/MS by CID of the standard 4-HNE is 
shown in Figure 4.13. In addition to the water loss from m/z 157.2 resulting in m/z 
139.1, further water loss is observed from this species forming m/z 121.1. The 
obtained spectra will serve as a reference against the spectra of the synthesised 4-
HNE. The synthesised 4-HNE was directly infused into the ESI source using a syringe 
pump at a rate of 10 µL/min. The instrument was set to acquire full scan spectra over 





Figure 4.14: Direct infusion of synthesised 4-HNE prepared in a solution of 0.1 % 
formic acid in acetonitrile (>3 injections). Parent ion of m/z 157 can be seen as well as 
m/z 139.1 which constitutes the common loss of water.  
 
The full MS spectrum for the synthesised 4-HNE shares great similarities with 
the full MS spectrum of the reference 4-HNE material. Both show the parent ion m/z 
157 and the water loss resulting in m/z 139. Additional ions at 159.2 and 141.2 are 
also seen. The direct infusion was repeated for this sample with MS/MS performed 
using CID with a normalised collision energy of 35% over a mass range of m/z 50-200. 
Again, the spectrum for the MS/MS by CID of the reference material is identical to the 
spectrum obtained for the MS/MS by CID of the synthesised material, producing the 





Figure 4.15: Direct infusion of synthesised 4-HNE prepared in a solution of 0.1 % 
formic acid in acetonitrile with MS/MS collision induced dissociation of 35%, parent 
ion m/z 157 (>3 injections). Product ions of m/z 139.1, 121.1, 97.1, 81.1, 69.1 and 57.1 
are observed. 
 
Following the direct infusion (MS full scan 100-200 m/z) of the synthesised 
sample prepared in methanol, as indicated by the reference paper (Gioacchini et al. 
1999) an ion at m/z 171 was observed which corresponds to the addition of a methyl 
(CH3 +) group as an adduct to the neutral 4-HNE molecule; specifically, the addition of 
a protonated methanol molecule to a neutral 4-HNE molecule followed by the loss of 
water (Figure 4.16). Methanol readily undergoes electrochemical oxidisation and is 
affected by the occurrence of electrochemical reactions taking place at the 
electrospray needle (Van Berkel et al. 1991). This is in contrast to the sample prepared 
in acetonitrile with an abundant ion at m/z 157 which corresponds to the 4-HNE 
molecule (Figure 4.14). This unfavourable adduct formation of the molecule in 
methanol confirms the preferred use of acetonitrile as the sample solvent for MS 
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analysis. This is of particular importance if quantitative analysis is to be performed as 
the degree of adduct formation is unknown.  
 
Figure 4.16: Direct infusion of synthesised 4-HNE prepared in a solution of 0.1 % 
formic acid in methanol (>3 injections). A dominant ion of m/z 171.2 due to 




4.3.1.3  Assessing the synthesis using Liquid Chromatography coupled with 
Mass Spectrometry 
The previous spectra clearly demonstrate the similarities between the 
purchased standard 4-HNE and the synthesised 4-HNE. The introduction of the liquid 
chromatography sought to further characterise the compound to indicate the level of 
purity. Figures 4.17 and 4.18 do not highlight any differences between the purchased 
and synthesised 4-HNE samples; the retention times are 4.26 and 4.29 minutes 
respectively with no other peaks present. Similarly, the MS and MS/MS CID spectra do 
not highlight any significant differences in the ions or fragmentation between the 





Figure 4.17: LC-MS separation of purchased standard 4-HNE prepared in a solution of 






Figure 4.18: LC-MS separation of synthesised 4-HNE prepared in a solution of 0.1 % 






Figure 4.19: LC-MS separation of purchased standard 4-HNE prepared in a solution of 
0.1 % formic acid in acetonitrile (>3 injections). Parent ion of m/z 157.1 can be seen as 





Figure 4.20: LC-MS separation of synthesised 4-HNE prepared in a solution of 0.1 % 
formic acid in acetonitrile (>3 injections). Parent ion of m/z 157.1 can be seen as well 






Figure 4.21: LC-MS separation of purchased standard 4-HNE prepared in a solution of 
0.1 % formic acid in acetonitrile with MS/MS collision induced dissociation of 35%, 
parent ion m/z 157 (>3 injections). Product ions of m/z 139.1, 121.1, 97.1, 81.0, 69.1 




Figure 4.22: LC-MS separation of synthesised 4-HNE prepared in a solution of 0.1 % 
formic acid in acetonitrile with MS/MS collision induced dissociation of 35%, parent 
ion m/z 157 (>3 injections). Product ions of m/z 139.2, 121.1, 97.1, 81.1, 69.1 and 57.1 




In conclusion, the NMR, direct infusion MS and LC-MS/MS data of both the 
reference material 4-HNE and the synthesised material 4-HNE confirm the authenticity 
and therefore the successful synthesis of 4-hydroxy-2-nonenal. No significant 
impurities were noted and thus it can be concluded that a relatively pure compound 
was synthesised without the need to perform further fractional chromatographic 
purification.  
 
4.3.2 Analysis of the 4-HNE-modified neurotensin  
 Preliminary experiments investigating the identification and 
quantification of 4-HNE adducts were performed with neurotensin as a simple model 
peptide. The average mass of neurotensin = 1672.92 and the average mass of 4-HNE = 
156.22. 
 
4.3.2.1  Analysis of the 4-HNE-modified neurotensin using mass spectrometry 
 The spectrum exhibited the dominant charge state of NT; a 3+ charge state of 
m/z 558.8 and a 2+ charge state of m/z 837.2. Given the increased intensity of the 
558.8 ion, it was noted that this was the preferred charge state for the NT molecule 
(Figure 4.23). Using this value, the expected product ion (NT + 4-HNE) was calculated 





Figure 4.23: Direct infusion of neurotensin in a solution of 0.1 % formic acid in 50:50 
H2O:ACN (>3 injections). The dominant 3+ charge state of m/z 558.8 can be seen as 




The product ion for the 4-HNE-modified peptide was calculated as follows: 
NT = 1672.92 
+ 
4-HNE = 156.22 
 
= 1829.14 combined 
-1 (hydrogen) = 1828.14 
+3 (3 protons)   1831.14 




Following incubation of 4-HNE with neurotensin a 50-fold diluted sample was directly 
infused into the ESI source using a syringe pump at a rate of 10 µL/min. The 
instrument was set to acquire full scan spectra over the range m/z 50-2000 and the 
following spectrum was obtained (Figure 4.24). 
 
 
Figure 4.24: Direct infusion of 4-HNE-modified neurotensin prepared in a solution of 
0.1 % formic acid in 50:50 H2O:ACN (50x dilution, >3 injections). A strong ion of m/z 
558.7 which reflects the 3+ charge state of NT is observed along with m/z 837.1 
reflecting the 2+ charge state of NT. The product ion m/z 610.6 is also identified.  
 
The product ion m/z 610.6 was observed in the sample. This product ion was 
further characterised by applying collision induced dissociation at a normalised 
collision energy of 35% to the direct infusion of the sample (MS/MS range of m/z 165-
2000, parent ion m/z 610) which yielded a dominant ion of m/z 837. The m/z 837 ion 
is identified as the neurotensin-4-HNE adduct (NT 2+ charge state) with the 4-HNE 





Figure 4.25: Direct infusion of 4-HNE-modified neurotensin prepared in a solution of 
0.1 % formic acid in 50:50 H2O:ACN (50x dilution) with MS/MS collision induced 
dissociation of 35%, parent ion m/z 610 (>3 injections). Product ions of m/z 837.0, 
720.4, 655.9, 558.3 and 534.9 are observed.  
 
 
4.3.2.2  Analysis of the 4-HNE-modified neurotensin by LC-MS/MS 
The 5-fold dilution (4 µg/mL) of the 4-HNE-NT adduct sample (in 0.1 % formic 
acid with 50:50 H2O:ACN) was analysed using LC-MS/MS. The 4-HNE M+H ion of m/z 
157 was analysed utilising LC-MS/MS with collision induced dissociation at a 
normalised collision energy of 35% (Figure 4.26). The same was applied to the analysis 
of the NT 3+ charge state of m/z 559 (Figure 4.27) and the NT-4-HNE+ product ion m/z 




Figure 4.26: LC-MS separation of 4-HNE-modified neurotensin prepared in a solution 
of 0.1 % formic acid in 50:50 H2O:ACN (5x dilution of original 50x dilution) with MS/MS 
collision induced dissociation of 35%, parent ion m/z 157 (>3 injections). Product ions 
of m/z 117.2, 107.2 and 158.2 are observed with a retention time of 1.40 mins.  
 
Figure 4.27: LC-MS separation of 4-HNE-modified neurotensin prepared in a solution 
of 0.1 % formic acid in 50:50 H2O:ACN (5x dilution of original 50x dilution) with MS/MS 
collision induced dissociation of 35%, parent ion m/z 559 (>3 injections). Product ions 





Figure 4.28: LC-MS separation of 4-HNE-modified neurotensin prepared in a solution 
of 0.1 % formic acid in 50:50 H2O:ACN (5x dilution of original 50x dilution) with MS/MS 
collision induced dissociation of 35%, parent ion m/z 610 (>3 injections). Product ions 
of m/z 837.0, 558.3 and 355.0 are observed with a retention time of 10.56 mins.  
 
A table was constructed (Table 4.5) containing the calculated y-ions for 
neurotensin which enabled the identification of the ions observed in Figure 4.27. The 
possible b-ions were also calculated, but the spectra did not exhibit any of these which 
indicate that the charge has been retained on the C-terminus of the peptide. The 
fragmentation process is influenced by the presence and position of basic amino acids 
within a peptide chain. Basic amino acids such as arginine, lysine, histidine and proline 
mainly induce the formation of y-ions when present and positioned near to the C-
terminal side of the peptide (a fuller description of b- and y-ions is presented in 










The abundant ion m/z 837.0 was identified as the neurotensin-4-HNE adduct 
(NT 2+ charge state) with the 4-HNE bond cleaved from the peptide. The second most 
abundant ion m/z 558.3 was also identified as the neurotensin-4-HNE adduct (NT 3+ 
charge state), again with the 4-HNE bond cleaved. Collision induced dissociation 
induces ergodic processes where the commonly observed cleavages are of the 
weakest bonds of the precursor ions. For peptides, the lowest energy barrier to 
fragment is found in the backbone amide bond and so b- and y-ions are formed. In 
addition, post-translational modifications typically possess even lower energy barriers 
than those of backbone cleavages and as a result, they are also cleaved (see Appendix 
A1.2). This results in a loss of information with regard to the site of post-translational 
modification. For unequivocal identification of the adduct, it is necessary to preserve 
the labile 4-HNE bond and maintain its integrity with the peptide backbone. 
 
y1 L-OH 130.2 131.2 66.6 44.7
y2 IL-OH 243.3 244.3 123.2 82.4
y3 YIL-OH 406.5 407.5 204.8 136.8
y4 PYIL-OH 503.6 504.6 253.3 169.2
y5 RPYIL-OH 659.8 660.8 331.4 221.3
y6 RRPYIL-OH 816.0 817.0 409.5 273.3
y7 PRRPYIL-OH 913.1 914.1 458.1 305.7
y8 KPRRPYIL-OH 1041.3 1042.3 522.2 348.4
y9 NKPRRPYIL-OH 1155.4 1156.4 579.2 386.5
y10 QNKPRRPYIL-OH 1283.5 1284.5 643.3 429.2
y11 YQNKPRRPYIL-OH 1446.7 1447.7 724.9 483.6
y12 LYQNKPRRPYIL-OH 1559.8 1560.8 781.4 521.3
y13 QLYQNKPRRPYIL-OH 1688.0 1689.0 845.5 564.0
y ion Peptide sequence Mass 2+ 3+1+
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4.3.2.3  Preservation of the adducted site utilising Electron Transfer 
Dissociation 
4-HNE forms a labile bond with the lysine residue of the neurotensin and as 
such, the bond is easily broken upon the use of collision induced dissociation (CID). 
Although CID-generated spectra offer sufficient data for the determination of peptide 
sequences (forming b- and y- fragment ions), for proteins that have undergone a post 
translational modification, the weakly bound modification is preferentially cleaved 
from the peptide backbone during the high-energy collision event. This cleavage limits 
the structural identification of the peptide and the site of modification.  
 
In order to effectively preserve the site of post translational modification of 
the peptide by 4-HNE, an alternative form of ion activation can be used called electron 
transfer dissociation (ETD). The Thermo LTQ-MS system used in this chapter has an 
ETD module attached that can ensure such preservation of the labile bond. In 
principle, the ions entering the ETD become subject to the transfer of an electron to 
the peptide ion via an ion-ion reaction (by reagent gas anions and gas phase ion/ion 
chemistry). This reaction results in the formation of singly charged radical anions 
which transfer a single electron to peptides that are multiply protonated. The peptide 
backbone is then fragmented in a sequence-independent manner; the fragmentation 
is independent of the bond-dissociation energy, forming c- and z- fragment ions with 
modifications remaining intact with the peptide chain. Direct infusions of the 50 fold 
dilution (20 µg/mL) of NT-4-HNE adduct sample were carried out with MS/MS ETD 
with an activation energy of 500ms. MS/MS ETD of the precursor ions m/z 559 and 




Figure 4.29: Direct infusion of 4-HNE-modified neurotensin prepared in a solution of 
0.1 % formic acid in 50:50 H2O:ACN (50x dilution) with MS/MS electron transfer 
dissociation of 500ms, parent ion m/z 559 (>3 injections). A product ion of  m/z  558.7 





Figure 4.30: Direct infusion of 4-HNE-modified neurotensin prepared in a solution of 
0.1 % formic acid in 50:50 H2O:ACN (50x dilution) with MS/MS electron transfer 
dissociation of 500ms, parent ion m/z 610 (>3 injections). Product ions of m/z 1829.1, 





Three abundant ions of m/z 1829.1, 914.4 and 609.3 are of particular interest. 
Calculations were performed to identify these ions; m/z 1829.1 was identified as the 
m + H ion of the NT-4-HNE adduct, m/z 914.4 was identified as the adduct 2+ charge 
state and m/z 609.3 was identified as the adduct 3+ charge state. The 4-HNE bond 
remains intact for each of these ions therefore confirming the preservation of the 
adducted site. 
 
The 5-fold dilution (4 µg/mL) of the 4-HNE-NT adduct sample (in 0.1 % formic 
acid with 50:50 H2O:ACN) was further analysed using LC-MS/MS ETD. These 
chromatographic separations were exposed to a lower ETD activation energy of 
100ms as an experimental measure to observe any differences in the fragmentation 
patterns. It was determined that an activation energy of 100ms was too low to induce 
appropriate fragmentation of the m/z 610 ion (Figure 4.32) and that 500ms (Figure 
4.30) resulted in a more informative, conclusive fragmentation. However, for complex 






Figure 4.31: LC-MS separation of 4-HNE-modified neurotensin prepared in a solution 
of 0.1 % formic acid in 50:50 H2O:ACN (5x dilution of original 50x dilution) with MS/MS 
electron transfer dissociation of 100ms, parent ion m/z 559 (>3 injections). Product 





Figure 4.32: LC-MS separation of 4-HNE-modified neurotensin prepared in a solution 
of 0.1 % formic acid in 50:50 H2O:ACN (5x dilution of original 50x dilution) with MS/MS 
electron transfer dissociation of 100ms, parent ion m/z 610 (>3 injections). Product 




4.3.2.4  Determining the peptide-4-HNE adduct reaction completion time 
Figure 4.33: LC-MS separation of D3-4-HNE-modified neurotensin with MS/MS 
collision induced dissociation of 35%, parent ion m/z 559 (>3 injections). Product ions 




Figure 4.34: LC-MS separation of D3-4-HNE-modified neurotensin with MS/MS 
collision induced dissociation of 35%, parent ion m/z 611 (>3 injections). Product ions 




Figure 4.35: LC-MS separation of 4-HNE-modified neurotensin with MS/MS collision 
induced dissociation of 35%, parent ion m/z 559 (>3 injections). Product ions of m/z 





Figure 4.36: LC-MS separation of 4-HNE-modified neurotensin with MS/MS collision 
induced dissociation of 35%, parent ion m/z 610 (>3 injections). Product ions of m/z 




There were no significant differences between the spectra for the variable 
timed incubation reactions of 2, 4 and 6 hours respectively. A general decrease in peak 
intensity was observed for the deuterated adducts when compared to the 
undeuterated adducts which may be due in part to ion suppression (Figures 4.33-
4.36). However, as peak intensities did not increase for ions of interest in direct 
correlation with an increase in incubation time, it was concluded that the reaction had 
reached completion within 2 hours.  
 
Analyses of varying peptide concentrations to a constant concentration of 
deuterated or undeuterated 4-HNE were conducted to explore the differences, if any, 
between the intensities of the peaks. Given the conclusive results that the incubation 
reaches completion at 2 hours, this incubation time was used to form the adducts. The 
calibration curves were calculated using the median values of the peak areas and 
heights of the relevant ion (m/z 610 or 611) taken from multiple injections (>3) and 






Figure 4.37: Calibration curve of the 4-HNE-NT adduct m/z 610 ion (peak area vs. 








Figure 4.38: Calibration curve of the deuterated-4-HNE-NT adduct m/z 611 ion (peak 









Figure 4.39: Calibration curve of the 4-HNE-NT adduct m/z 610 ion (peak height vs. 







Figure 4.40: Calibration curve of the deuterated-4-HNE-NT adduct m/z 611 ion (peak 







The calibration curves for the 4-HNE-NT show a plateau effect at 6-8 µg of 
peptide (to a constant of 50 ng 4-HNE). This may indicate that there is no longer any 
residual 4-HNE available to form a conjugate with the peptide.  If 8 µg is taken as the 
maximum amount of peptide needed to conjugate with the 4-HNE in its entirety 
leaving no residual 4-HNE, this equates to 5 nM of peptide to 0.03 nM of 4-HNE; 16.6 
times the concentration of peptide to 4-HNE. 
 
A great variability was observed in the calibration curves for the deuterated 4-
HNE-NT; whilst the general curve is similar to that of the 4-HNE, the data lack 
consistency in both the peak areas and heights. In some instances, a 2-fold decrease is 
seen for the deuterated 4-HNE to the undeuterated 4-HNE but this was not 
demonstrated consistently across the concentration range. The median values taken 
from multiple injections (>3) of the standards for both the peak area and height are 
presented in Tables 4.6 and 4.7. The peak heights were measured as the intensity of 
signal from the detector (in this case a dynode) and as such, are taken as “counts”. 
The peak area does not have a defined unit. 
 




Neurotensin (ug) HNE (ng) Peak area Peak height Ion intensity
0.25 50 3638 312 3.18 E2
0.5 50 7639 555 5.55 E2
0.75 50 5180 410 4.13 E2
1 50 8987 761 7.62 E2
2 50 11908 1298 1.30 E3
4 50 17474 1668 1.67 E3
6 50 25939 2389 2.39 E3
8 50 26827 2313 2.31 E3
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A possible explanation for this variability is that a limiting effect is observed on 
the dynamic range of ion traps. When there are too many ions present in the trap, 
space-charge effects result in the diminished performance of the ion-trap analyzer. As 
a workaround solution, the use of automated scans allows the rapid counting of ions 
before they enter the trap, therefore limiting the number of ions gaining entry. 
Automatic gain control (AGC) allows the use of applied voltage amplitude to control 
the transmission of ions. However, given that the analysis is dynamic and the window 
of ions at a given time becomes a moving target, this limitation of ion entry results in 
an inconsistent number of ions entering the ion-trap consequently resulting in variable 
data. To overcome the variability observed in the analysis of the internal standards, it 
would be beneficial to analyse them using a triple quadrupole instrument. The 
fragmentation process of quadrupole instruments differs from that of linear ion-traps.  
The absence of any consistent measurable ratios between the deuterated and 
undeuterated 4-HNE may be explained further by the differences in electronegativity 
between the two compounds. Whilst CID at a normalised energy of 35% was sufficient 
to fragment the undeuterated 4-HNE adducts, the stronger covalent bonds of the 
deuterated 4-HNE adducts may require a higher CID energy to obtain reproducible 
Neurotensin (ug) d3-HNE (ng) Peak area Peak height Ion intensity
0.25 50 6359 662 6.34 E2
0.5 50 11957 1051 1.06 E3
0.75 50 5932 628 6.40 E2
1 50 4752 360 3.60 E2
2 50 5348 651 6.51 E2
4 50 11273 1128 1.13 E3
6 50 8231 740 7.44 E2
8 50 14236 1197 1.20 E3
218 
 
fragmentation. However, the deuterated compound was to be used as an internal 
standard against which endogenous 4-HNE adducts could be measured; hence if the 
CID energy is increased in order to reproducibly fragment the internal standard, this 
would lead to the sub-optimal fragmentation of the endogenous markers. The use of a 
triple quadrupole instrument would allow the circumvention of this inherent issue and 
facilitate the quantification of the endogenous modifications without compromising 
their fragmentation. 
 
4.3.2.5  Analysis of the 4-HNE-modified peptides using mass spectrometry 
 As modification by 4-HNE of the lysine residue had been demonstrated in the 
short-chain peptide neurotensin, it was necessary to demonstrate this could also 
occur in an alternative short-chain peptide with more than one binding site and so 
angiotensin was used due to the two histidine residues within its sequence. Histidine 
is another of the targeted amino acid residues as described previously in section 
4.2.2.7. The average mass of angiotensin = 1296.48, neurotensin = 1672.92 and the 
average mass of 4-HNE = 156.22. 
 
A 50 fold dilution (20 µg/mL) was prepared from the original solution of AT-4-
HNE (in 0.1 % formic acid with 50:50 H2O:ACN). Direct infusions of this sample 
produced the following representative spectra (Figure 4.41). In addition, a mixture of 
both angiotensin and neurotensin was also incubated with 4-HNE to show the 





Figure 4.41: Direct infusion of 4-HNE-modified angiotensin prepared in a solution of 
0.1 % formic acid in 50:50 H2O:ACN (50x dilution) with full MS 50-2000 (>3 injections). 






Figure 4.42: Direct infusion of 4-HNE-modified angiotensin and neurotensin prepared 
in a solution of 0.1 % formic acid in 50:50 H2O:ACN (50x dilution) with full MS 50-2000 
(>3 injections). Additional ions of m/z 558.7, 837.1 and 610.6 are observed.  
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These spectra exhibit the dominant charge states of AT; a 3+ charge state of 
m/z 433.0, a 4+ charge state of m/z 325.0 and a 2+ charge state of m/z 648.9. Given the 
increased intensity of the m/z 433.0 ion, it was noted that this was the dominant 
charge state for the AT molecule. From these values, the expected product ions were 
calculated as; (AT-4-HNE)2+ =727, (AT-4-HNE)3+ = 485 and (AT-4-HNE)4+ = 363. The AT-
NT-4-HNE mixed solution gave an additional three ions of m/z 558.7 and m/z 837.1 
(which are characteristic of the NT 3+ and 2+ charge states respectively) and an m/z 
610.6 ion which has been identified as the NT-4-HNE 3+ product ion (figure 4.41). One 
can assume that the labile bond has been cleaved in the case of NT (a neutral loss of 
156). The AT-4-HNE conjugate was further characterised in both its cleaved and 
preserved states through direct infusion analyses of the sample carrying out both 
MS/MS CID at a normalised collision energy of 35 and MS/MS ETD 500ms on the AT-4-







Figure 4.43: Direct infusion of 4-HNE-modified angiotensin prepared in a solution of 
0.1 % formic acid in 50:50 H2O:ACN (50x dilution) with MS/MS collision induced 
dissociation of 35%, parent ion m/z 727 (>3 injections). Product ions of m/z 648.9 and 
1296.6 are observed. 
 
 
Figure 4.43 shows the neutral loss ion m/z 648.9 (identified as the AT-HNE 2+ 
ion) which has undergone a neutral loss of m/z 78, equivalent to a doubly-charged 4-
HNE molecule. In addition, the angiotensin singly-protonated molecule ion was seen 
at m/z 1296.6. Upon the activation of ETD, the neutral loss no longer occurs and the 
labile 4-HNE bond remains intact as demonstrated in Figure 4.44 by ions m/z 726.7 





Figure 4.44: Direct infusion of 4-HNE-modified angiotensin prepared in a solution of 
0.1 % formic acid in 50:50 H2O:ACN (50x dilution) with MS/MS electron transfer 
dissociation of 500ms, parent ion m/z 727 (>3 injections). Product ions of m/z 726.7 
and 1453.5 are observed. 
 
 
4.3.3 Analysis of the protein-4-HNE conjugates 
Data-dependent analyses were conducted as outlined in the methods section 
4.2.3.3. Incubation and digestion of the model protein BSA was carried out in order to 
assess the degree of post-translational modification by 4-HNE and to identify the 
modified fragments against those held on the Mascot database.  The spectra obtained 
from the LC-MS/MS CID at a normalised collision energy of 35% for both m/z 469.8 
and 615.1 are presented in Figures 4.45 and 4.46. The deuterated 4-HNE digest only 




Figure 4.45: LC-MS separation of 4-HNE-BSA digest (full ms m/z 350-1500) with data-
dependent collision induced dissociation of 35% for ion m/z 469.8 (>3 injections). 







Figure 4.46: LC-MS separation of 4-HNE-BSA digest (full ms m/z 350-1500) with data-
dependent collision induced dissociation of 35% for ion m/z 615.1 (>3 injections). 
Dominant product ions of m/z 1082.6, 953.5, 854.4, 848.5, 688.4, 606.0, 597.6, 537.0 






Figure 4.47: LC-MS separation of deuterated 4-HNE-BSA digest (full ms m/z 350-1500) 
with data-dependent collision induced dissociation of 35% for ion m/z 616.7 (>3 
injections). Dominant product ions of m/z 1085.7, 956.6, 857.5, 848.5, 688.4, 607.3, 
598.9, 537.1 and 384.3 are observed.  
 
 
The digested samples were then analysed using the data-dependent neutral-
loss parameters in which the additional ETD scan event was activated if a neutral loss 
of either m/z 52 or 78 was detected (m/z 53 or 79 for deuterated digests). Figures 
4.48 and 4.49 show the spectra for the peptide fragment precursor ion m/z 469 arising 
from the 4-HNE BSA digests. Under CID conditions, the neutral-loss ion is shown as 
m/z 417.5, resulting from a neutral-loss of m/z 52; this ion is shown intact as m/z 







Figure 4.48: LC-MS separation of 4-HNE-BSA digest (full ms m/z 350-1500) with data-
dependent collision induced dissociation of 35% for ion m/z 469.7 (>3 injections). 







Figure 4.49: LC-MS separation of 4-HNE-BSA digest (full ms m/z 350-1500) with data-
dependent electron transfer dissociation of 100ms for ion m/z 469.9 (>3 injections). 






Figures 4.50 and 4.51 show the spectra for the peptide fragment precursor ion m/z 
615 arising from the 4-HNE BSA digests. Under CID conditions, the neutral-loss ion is 
shown as m/z 536.9, resulting from a neutral-loss of m/z 78; this ion is shown intact as 
m/z 615.0 under ETD conditions therefore demonstrating the intact post-translational 
modification. 
 
Figure 4.50: LC-MS separation of 4-HNE-BSA digest (full ms m/z 350-1500) with data-
dependent collision induced dissociation of 35% for ion m/z 615.2 (>3 injections). 
Dominant product ions of m/z 1082.6, 953.5, 854.4, 848.4, 688.4, 606.0, 597.3, 536.9 




Figure 4.51: LC-MS separation of 4-HNE-BSA digest (full ms m/z 350-1500) with data-
dependent electron transfer dissociation of 100ms for ion m/z 615.2 (>3 injections). 
Dominant product ions of m/z 1229.6, 1171.6, 1099.5, 970.7, 742.4 and 615.0 are 
observed.  
 
Figures 4.52 and 4.53 show the spectra for the peptide fragment precursor ion 
m/z 470 arising from the deuterated 4-HNE BSA digests. Under CID conditions, the 
neutral-loss ion is shown as m/z 417.5, resulting from a neutral-loss of m/z 53; this ion 








Figure 4.52: LC-MS separation of deuterated 4-HNE-BSA digest (full ms m/z 350-1500) 
with data-dependent collision induced dissociation of 35% for ion m/z 470.7 (>3 
injections). Dominant product ions of m/z 625.6, 567.4, 558.6, 509.7, 458.6 and 417.5 






Figure 4.53: LC-MS separation of deuterated 4-HNE-BSA digest (full ms m/z 350-1500) 
with data-dependent electron transfer dissociation of 100ms for ion m/z 470.7 (>3 
injections). Dominant product ions of m/z 836.5, 705.3, 640.4, 578.3, 574.2, 470.6 and 




Figure 4.54: LC-MS separation of deuterated 4-HNE-BSA digest (full ms m/z 350-1500) 
with data-dependent collision induced dissociation of 35% for ion m/z 616.6 (>3 
injections). Dominant product ions of m/z 1085.5, 956.4, 857.4, 848.4, 688.4, 607.5, 
598.7, 536.8 and 384.3 are observed.  
 
 
Figure 4.54 shows the spectra for the peptide fragment precursor ion m/z 616 
arising from the deuterated 4-HNE BSA digests. Under CID conditions, the neutral-loss 
ion is shown as m/z 536.8, resulting from a neutral-loss of m/z 79. A data-dependent 
electron transfer dissociation at 100ms for m/z 616.6 was not observed in the 
deuterated 4-HNE-BSA digest. However, based upon the neutral-loss data the intact 
ion would have been shown by m/z 616 demonstrating the intact post-translational 
modification. 
 
These data-dependent neutral-loss experiments demonstrated the ability to 
locate sites of post-translational modification in simple protein digests, following 
incubation with 4-HNE (either deuterated or undeuterated). To investigate whether 
this could be applied to a more complex and heterogeneous biological matrix, the 
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experiment was repeated using selected human bronchoalveolar lavage samples 
obtained from patients with COPD and aged matched controls; both current and ex-
smokers. 
 
4.3.4 Analysis of the lavage-4-HNE conjugates 
The analysis of the data generated from the 4 BAL digests revealed that those 
that had undergone protein precipitation yielded some identifiable fragments. No 
peptide matches were obtained from the ‘native’ unprecipitated samples. Peptide 
modifications that were identified are shown in Table 4.8, and reflect a panel of 
proteins one would not expect in this extracellular compartment. Individual samples 
were only injected once due to the limited sample volume, so these data should be 
viewed as purely illustrative and not as a definitive assessment of the methodology. 
The dynamic range of protein concentrations within bronchoalveolar lavage is 
extensive with albumin being the dominant protein content followed by 
Immunoglobulin (Ig) G, IgA and transferrin (Hatch, 1993). These species account for in 
excess of 80% of lavage total protein. Although the unprecipitated samples did not 
yield any identifiable data, modified fragments were identified in the precipitated 
samples. It should be noted that the precipitation protocol was relatively ‘soft’ and 
that it should be viewed as reducing the concentration of the dominant protein 
species within the RTLF, rather than eliminating them. Thus one would have expected 
to have obtained peptide fragments following the tryptic digest corresponding to 
these dominant protein species, particularly albumin, in both the native and protein 
precipitated samples. This was not the case suggesting that the digest conditions were 
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not optimal and further work would be required to optimise the methodology for 
more complex biological matrices.  
 
Table 4.8: Protein identification of BAL samples from a panel of COPD patients 
following protein precipitation. The “protein hit” refers to the accession entry from 
Mascot and the underlined residues within a given sequence indicate that the residue 





Proteins that were identified from the lavage samples were unique to each of 
the four distinct sample groups. Sample ID 33 (female COPD current smoker) did not 
yield any identifiable protein fragments. However, this sample contained the lowest 
total protein concentration of the four samples (0.02 mg/mL) and so endogenous 
protease activity may have contributed towards degradation of the sample, therefore 
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affecting the identification of peptide sequences. Sample ID 38 (female healthy 
smoker) yielded seven protein hits from Mascot with three of the fifteen resulting 
peptide sequences exhibiting modification by 4-HNE and one sequence with a 
carbamidomethyl modification. Sample ID 39 (male never-smoker) yielded three 
protein hits from Mascot. Of the six resulting peptide sequences, only one exhibited 
modification by 4-HNE. Sample ID 40 (male COPD ex-smoker) yielded five protein hits 
from Mascot. Of the thirteen resulting peptide sequences, two exhibited modification 
by 4-HNE only, one displayed carbamidomethylation and one possessed three 
carbamidomethylations in addition to a single modification by 4-HNE. The identified 
proteins from the samples (fifteen proteins in total) were not representative of 
expected proteins associated with the respiratory tract lining fluid from individuals 
with COPD. Sample ID 39 (male non-smoker) was identified as containing ubiquitin-
protein ligase which can both alter cellular function and target proteins for 
degradation by the proteosome. Sample ID 40 (male COPD ex-smoker) was identified 
as containing metallothionein, an important intracellular endogenous cysteine-rich 
antioxidant protein with metal-chelating properties. An increased presence of such a 
protein may be induced by oxidative stress. The only identifiable trend across the 
sample groups (excluding sample ID 33) was the apparent increase of protein hits for 
the healthy current and COPD ex-smoker compared to the healthy non-smoker (7, 5 








The aim of this chapter was to develop a method that would permit the 
identification and quantification of proteins that had undergone oxidative post-
translational modification via 4-HNE adduction in bronchoalveolar lavage samples (or 
other complex biological matrices). The rationale for focusing specifically on oxidative 
post-translation protein modifications was based on the absence of global indicators 
of the presence of oxidative stress in the airway lining fluids of COPD patients 
(Chapters 2 and 3). I therefore hypothesised that more subtle changes might be 
occurring within this compartment leading to functional changes in proteins relevant 
to disease pathology, either reflecting increased oxidative damage to specific proteins 
or a reduced capacity to eliminate modified proteins.  
 
Whilst in Chapter 2 I saw no change in 4-HNE measured by immunoassay in 
lavage fluids, total or per unit protein, there is an existing literature in COPD 
demonstrating increased 4-HNE adduct formation in biopsies from COPD patients by 
immunohistochemistry (Rahman, 2002), with evidence that this is associated with the 
degree of airway obstruction. The stable lipid peroxidation product 4-HNE is a potent 
alkylating agent that has been shown to react with DNA and proteins, generating 
adducts with cysteine, lysine, and histidine residues (Esterbauer, 1991) that are 
capable of inducing specific cellular stress responses such as cell signalling and 
apoptosis (Uchida, 1993; Uchida, 1999). It was therefore an appealing marker to 
pursue, allied to a technology with the potential to identify modified proteins, as well 




In order to accomplish this significant task, a series of pilot experiments were 
performed with the aim of developing a suitable validated analytical method based 
upon mass spectrometry. A typical approach for quantitative analysis involves the use 
of reliable and stable internal standards. In mass spectrometry, deuterated 
compounds are typically employed as internal standards as they are equivalent in 
every way to their analogue, with the exception that a sufficient number of hydrogen 
(or carbon) atoms are deuterated to give a measurable mass shift. In the first part of 
this chapter I looked at whether there was any difference in signal intensity for a 
short-chain peptide (neurotensin) modified by deuterated and undeuterated 4-HNE 
(0.25-8 µg peptide incubated with 50 ng of relevant 4-HNE). The undeuterated 
adducts demonstrated a linear response, effectively forming a plateau between 6-8 
µg. However, variability was noted for the deuterated adducts and the linear response 
that was observed for the undeuterated 4-HNE adducts was not reproducible to the 
same extent over a series of injections carried out on different days. In order that the 
deuterated adduct can be employed as an internal standard for quantification, this 
variability must be eliminated. Therefore, analysis using a quadrupole MS instrument 
would have been desirable to overcome the limitations of ion-trap instruments 
(further explained in Chapter 5).  
 
Having demonstrated the formation of 4-HNE adducts with simple peptides the 
next logical step was to attempt modifying and then digesting a typical representative 
protein. BSA was used as the model protein and was subsequently incubated with 
deuterated and undeuterated 4-HNE. The protein was then digested with trypsin and 
an attempt was made to locate peptides from the protein which were modified by 4-
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HNE and a comparison of the two sample types was made. Quantitative protein mass 
spectrometry typically involves two types of approach known as “bottom up” and “top 
down”. With the top down approach, the proteins are left intact and the intact protein 
intensity is measured for a given concentration. This is often a difficult approach due 
to the very large masses involved and the difficulty in chromatographically separating 
out the intact proteins. The bottom up approach circumvents these difficulties by 
digesting the protein into smaller peptides and separating and measuring these 
peptide fragments instead. However, this introduces the significant problem of 
understanding which peptides can be treated as being representative of the intact 
protein in terms of their signal intensity. In order to get around this issue, a number of 
peptides from the digested protein are typically used as the quantitative markers.  The 
peptide sequences SHCIAEVEK (average mass 1015.16) and FKDLGEEHFK (average 
mass 1249.39) were chosen as model peptide sequences for both the deuterated and 
undeuterated digests due to their consistent appearance and reasonable signal across 
a number of preliminary digests.   
 
The work was successful in locating the post translational modifications for 
both the deuterated and undeuterated 4-HNE peptides (from the model protein) but 
failed to find consistency in signal intensities across the two digest types. This meant 
that tackling the biological sample was feasible but not quantifiable at this stage. 
Human bronchoalveolar lavage samples from 4 subjects were either subjected to 
precipitation methods or left untreated and digested prior to quantification of 4-HNE 
adducts. Several modifications were identified for the precipitated samples however, 
no identifiable data was found for the untreated samples. Whilst identification of 
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some modifications were made, their origins cannot be assured at the present time 
and so further work will be required to confirm their authenticity before progressing 
onto their quantification. As the digests produce a very large number of peptides in a 
complex matrix there is always the problem of peptide identification by random 
chance and therefore a more significant finding might be deemed to be the absence of 
modified peptides from the most abundant proteins in airway lining fluids namely: 
albumin, immunoglobulin (A and G) heavy and light chains and transferrin (Hatch, 
1993), especially within the ‘native’ unprecipitated samples. At this time and given the 
preliminary nature of these pilot studies it is safer to conclude that the method has 
not worked in the lavage samples. A diagrammatic illustration of the experiments 
conducted along with the experiments that are further required can be found in 
Figure 4.55 below. 
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Rationale: Proof of concept that a 
4-HNE adduct could be formed with 
a short-chain peptide containing a 
single target amino acid residue
Rationale: Proof of concept that a 
4-HNE adduct could be formed with 
a short-chain peptide containing 
two target amino acid residues
Rationale: Development of concept 
to confirm and characterise the 
formation of  4-HNE adducts in a 
model protein
Rationale: Development of concept 
to confirm and characterise the 
endogenous formation of 4-HNE 
adducts in a complex biological 
matrix
Rationale: Development of concept 
to confirm, characterise and 
quantify the endogenous formation 
of 4-HNE adducts in a complex 
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Figure 4.55: A flow diagram of the mass spectrometry experiments conducted in 
Chapter 4. Proof of concept was required for the formation and characterisation of 4-
HNE adducts in a short-chain peptide (neurotensin) with a single binding site followed 
by an alternative short-chain peptide (angiotensin) with two binding sites. This was 
then applied to a model protein (BSA) followed by tryptic digestion and data-
dependent analysis. The analysis of BAL samples was premature and did not yield any 
significant results. This diagram illustrates the experiments that are further required 
for progression towards the identification and quantification of endogenous 4-HNE 
adducts in lavage samples.  
238 
 
Due to time constraints, the decision to examine adduct formation in lavage 
samples was probably premature and there would have been considerable merit in 
working through a variety of major airway lining fluid proteins, singularly and in 
combination, before progressing to human lavage samples. In addition, in these 
preliminary studies no account was made of the potential formation of peptides 
through the action of endogenous proteases within the lavage samples, which would 
have the potential to significantly affect the ultimate peptide population within the 
digest. Therefore, pre-treatment of the lavage samples with a commercially available 
protease inhibitor cocktail may have been appropriate to prevent proteolytic 
degradation by endogenous proteases and to inhibit the protease activity from lysates 
through repetitive freeze-thaw cycles prior to analysis. Nevertheless, there is a 
sufficient body of preliminary data to suggest there is merit in pursuing this method 
further. Whilst absolute quantification of protein bound 4-HNE remains an extremely 
challenging objective by MS techniques, the semi-quantitative identification of 
adduction sites within protein remains a feasible target and one with the potential to 










PhD synopsis, critique and suggestions for future work 
 
It has been argued that oxidative stress plays a significant role in the aetiology 
and progression of COPD; however the published data demonstrating this are scant 
and largely based on indirect measurements of antioxidants and oxidative damage 
markers in plasma, exhaled breath condensate and induced sputum (as reviewed in 
chapter 1). There is a paucity of data actually addressing oxidative stress in the regions 
of the lung directly affected by this disorder, particularly the distal airways and alveoli 
which undergo significant destruction and remodelling in emphysema. In the study 
described in chapter 2 we attempted to address this gap in the published literature by 
examining the concentrations of antioxidant and oxidative damage markers in alveolar 
lavage samples obtained from COPD patients, both ex- and current smokers.  
 
5.1 Oxidative stress and inflammation in COPD – Chapter 2 
I hypothesised that COPD would be associated with increased oxidative stress 
in the airway lumen, specifically, within the respiratory tract lining fluids sampled by 
bronchoalveolar lavage. Further, we anticipated that any oxidative signals observed in 
the COPD ex-smokers would be magnified in those patients who had continued to 
smoke post-diagnosis. In contrast to this view I observed an absence of clear signals of 
oxidative stress; either in terms of decreased antioxidant concentrations, or increased 
levels of protein and lipid oxidation products in COPD patients, relative to their aged 
matched controls. Increased concentrations of GSH and decreased concentrations of 
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vitamin C were observed in smokers, either ‘healthy’ subjects or COPD patients, 
relative to their age and smoking status matched controls. In addition, the 
endogenous metal chelators transferrin, lactoferrin and ferritin were measured in the 
lavage samples with only the latter being significantly increased in current smokers. 
These data do not therefore support the contention that oxidative stress is elevated in 
the distal airways of stable COPD patients. They do however, support the previously 
published evidence for increased airway GSH in current smokers (Rahman, 1996). The 
association with increased ferritin concentrations however, would tend to suggest 
that this reflects leakage from injured cells rather than a regulated adaptation to the 
cigarette smoke insult. 
 
One potential explanation for the lack of contrast between the aged controls 
and the COPD patients is that age-related declines in antioxidant status have occurred 
that limited the capacity to discriminate clear disease-related signals. The 
concentration of low molecular weight antioxidants and enzymatic antioxidant 
activities has been shown to decrease with age in human populations, though many of 
these measurements have been restricted to plasma and circulating blood 
lymphocytes (Rizvi, 2007). An additional group of young healthy adults were therefore 
recruited to permit me to examine potential age-related declines in respiratory tract 
lining fluid antioxidant concentrations. I found evidence of increased vitamin C 
oxidation with age, in the absence of an equivalent increase in the concentration of 





In addition, the pattern of inflammation we observed in the COPD patients was 
characterised by an increase in the numbers of macrophages and lymphocytes, 
consistent with a chronic inflammatory profile. In pulmonary conditions with 
established evidence of oxidative stress, such as asthma, adult respiratory distress 
syndrome and cystic fibrosis there is often a more neutrophilic/eosinophilic 
inflammatory profile. We therefore investigated an additional group of young mild 
asthmatics to examine whether the lack of oxidative stress in COPD reflected the 
absence of a disease related increase in PMNs. Contrary to the published literature 
(Kelly, 1999), I found no evidence of increased oxidative stress in this group who were 
largely indistinguishable from the young healthy controls in terms of their antioxidant 
levels. This may have reflected their mild clinical status and underlying absence of 
neutrophilia in comparison with previous studies (as discussed in detail in chapter 2). 
Nevertheless, neither the examination of ageing or alternative inflammatory profiles 
fully explained the absence of oxidative stress in the COPD patient groups.  
 
These data therefore failed to confirm the original hypothesis and appeared to 
suggest that there is not a significant oxidative burden in the lungs of stable COPD 
patients in the absence of concurrent smoking. It should be acknowledged that this 
does not preclude the possibility that oxidative stress is restricted in this population to 
periods of exacerbation, or that this group may have a restricted capacity to mount 
protective adaptations to acute oxidative insults, as has been suggested by other 
authors (Goven, 2008). A recent paper by Behndig (2009), has shown that cellular 
enzymatic antioxidants in asthmatics (Cu, Zn, superoxide dismutase, glutathione 
peroxidase, glutathione disulphide reductase and catalase) are up-regulated, relative 
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to aged matched young adults. These same antioxidant enzymes are significantly 
decreased with age, but not further impaired in COPD patients, consistent with the 
data in the current study. This study did not however, include a group of young 
healthy smokers so it was not possible to evaluate whether a protective adaptive 
response would occur in these subjects relative to aged COPD current smokers.  
 
5.2 Metal homeostasis in COPD – Chapter 3 
 Having failed to demonstrate the presence of oxidative stress in COPD, I 
decided to examine whether the age-related increase in oxidation markers could be 
attributed to increased concentrations of catalytic metals at the air-lung interface, 
specifically Cu and Fe. Under normal conditions these metals are rapidly and 
efficiently sequestered into cells in ferritin (Fe) or metallothionein (Cu, Zn, Cd) to 
prevent them promoting damaging oxidation reactions. Failure of these mechanisms 
can result in the presence of unchelated pools of Fe and Cu, referred to as the non-
transferrin and non-caeruloplasmin bound pools respectively, which would promote 
oxidative stress.  Increases in these metals in the RTLFs could reflect either increased 
necrotic cell death, or the inhalation of exogenous sources such as cigarette smoke, 
particularly of relevance to COPD. 
  
 To address this question I adopted two approaches. The first involved the 
determination of metal concentrations within BAL fluid digests following a relatively 
mild nitric acid digest. For these analyses I focused on Fe and Cu, for the reasons 
outlined above, but also As and Cd, as markers of cigarette smoke inhalation and Zn, 
as a major non-catalytic metal. Zn was studied due to its presence with Cu at a 1:1 
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stoichiometry in extracellular superoxide dismutase. It was assumed that a 
proportionate increase in Cu and Zn would likely reflect an increased expression of 
this critical antioxidant enzyme, whilst deviations from this relationship would be 
reflective of alternative sources. The second approach was based on an indirect 
assessment of ‘free’ Fe and Cu within the lavage fluids, i.e. that unbound by 
transferrin, lactoferrin or caeruloplasmin. The assay examined the catalytic oxidation 
of ascorbate added to the lavage fluids with time, in the presence or absence of the 
exogenous chelators DTPA and NTA, to either inhibit or promote metal dependent 
oxidations. In this assay, the role of NTA further allowed the potential contribution of 
Fe and Cu to ascorbate oxidation to be discriminated, as Fe-NTA sponsors increased 
oxidation whilst Cu-NTA is inhibitory.  
 
 Due to the reasons discussed at length in chapter 3, I was unable to obtain a 
robust measurement of Fe. Nevertheless, I did observe increased concentrations of 
both Cu and Zn with age. No differences were apparent in any of the measured metals 
between the COPD patient groups, with their respective age and smoking matched 
controls. The age-related increase in Cu was associated with an increased rate of 
ascorbate oxidation, which was inhibited by DTPA and augmented by NTA in the aged 
population. This latter observation provided some, albeit indirect, evidence for a non-
transferrin Fe pool in the RTLFs of aged subjects. Further, the presence of increased 
Cu and Zn, or enhanced rates of ascorbate oxidation appeared correlated with the 
markers of oxidation reported in chapter 2. These data therefore represent the first 
reported evidence of an increase in catalytic metal activities in the aged population, 
specifically within the lung. There was however, consistent with the results from 
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chapter 2, no evidence of increased oxidative stress or altered metal handling related 
to disease status.  
 
5.3 Discussion of mass spectrometry analysis – Chapter 4 
The previous two experimental chapters failed to demonstrate any substantive 
evidence of oxidative stress in the airways of stable COPD patients. As argued above, 
this picture may be somewhat altered during periods of disease exacerbation, when 
the age-related degradation of cellular antioxidant defences might result in transient 
increases in oxidative damage and tissue injury. This however, remains to be 
determined. One might argue that whilst the data in chapters 2 and 3 examined gross 
indicators of oxidative stress, or altered metal handling, the role of biological 
oxidation/reduction reactions in COPD pathogenesis may be rather more subtle, 
acting through functional oxidative post translational modifications of enzymes and 
cell signalling molecules. A classic example being the oxidative inactivation of alpha-1-
antitrypsin in lavage fluids recovered from smokers (Carp, 1980), reflecting the 
oxidation of critical methionine residues at the active site of the enzyme (Taggart, 
2000). Over recent years the methods for examining ‘functional’ oxidations or 
reductions in proteins have advanced considerably (Burgoyne, 2011), with the role of 
thiolation (Antelmann, 2011), nitration (Monteiro, 2008) and protein adduction 
reviewed extensively (Ferrington, 2004). 
 
The aim of this chapter was to develop a method to permit the identification of 
proteins that had undergone post translational modification via 4-HNE adduction in 
bronchoalveolar lavage samples. Such an approach, targeted at identifying specific 
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proteins and protein regions adducted by 4-HNE rather than the overall level of 
oxidation within the RTLF, was thought to be valuable in examining the pathogenesis 
of COPD rather than simply the presence of oxidative stress.  In order to accomplish 
this significant task, a suitable semi-validated analytical method based upon mass 
spectrometry had to be established and well characterised.  
 
A typical approach for such a quantitative analysis involves the use of reliable 
and stable internal standards. In mass spectrometry deuterated compounds are used 
as internal standards, which are equivalent in every way to their analogue, with the 
exception that a sufficient number of hydrogen (or carbon) atoms are deuterated to 
give a measurable mass shift. In order to quantify proteins in complex biological 
samples, a suitable internal standard had to be employed. Quantitative protein mass 
spectrometry typically involves two types of approach known as bottom up and top 
down. With the top down approach, the proteins are left intact and the intact protein 
intensity is measured for a given concentration. This is often a difficult approach due 
to the very large masses involved and the difficulty in chromatographically separating 
out the intact proteins. The bottom up approach circumvents these difficulties by 
digesting the protein into smaller peptides and separating and measuring these 
peptide fragments instead. However, this introduces the significant problem of 
understanding which peptides can be treated as being representative of the intact 
protein in terms of their signal intensity. In order to get around this issue, a number of 




The first part of this chapter looked at whether there was any difference in 
signal intensity for a short chain peptide (angiotensin and neurotensin) modified by 
deuterated and undeuterated 4-HNE. Having determined that there is no difference in 
signal for deuterated versus undeuterated 4-HNE modified peptides, the next logical 
step was to attempt modifying and then digesting a typical representative protein. 
BSA was used as the model protein and was subsequently incubated with deuterated 
and undeuterated 4-HNE in parallel. The protein was then digested with trypsin and 
an attempt was made to locate peptides from the protein which were modified by 4-
HNE and a comparison of the two sample types was made. The work was successful in 
locating the post-translational modifications (PTMs) for both the deuterated and 
undeuterated 4-HNE peptides (from the protein) but failed to find consistency in 
signal intensities across the two digest types. This meant that tackling the biological 
sample was not feasible at this stage. 
 
 To take this work forward, which was not possible in this project, the 
variability between the deuterated and undeuterated 4-HNE modified digests would 
need to be eliminated. To do this, I would first look to identify suitable peptide 
sequences that are consistently observed in the undeuterated digests and then go on 
to confirm whether these are also observed in the deuterated digests. If the variability 
was not eliminated, I would then look to the original digest protocol to see whether 
sample losses are occurring during the different stages of the protocol (denaturing, 
reducing, alkylating and drying down steps), which could be indicative of signal 
variability. If this was the case, then various aspects of the digestion protocol would 
have to be investigated. If reproducible results could then be obtained, the next stage 
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would be to use the human lavage as the biological matrix/proteins to undergo 
digestion and apply the same approach to quantify the PTMs. Prior to injection onto 
the LC-MS system, a set of varying concentrations of deuterated digest would be 
mixed with a set of lavage digest samples and following MS analysis, a comparison of 
the signal intensities of the deuterated 4-HNE peptides could be compared to the 
lavage peptide signals to relatively quantify the amount of protein that has undergone 
post-translational modification by 4-HNE in varying disease severity. This would serve 
as a molecular measure of the extent of oxidative stress observed in varying COPD and 
control samples and could be a more selective and sensitive approach in comparison 
to current immunological-based methods. 
 
There are other factors which should also be considered in order to mitigate 
the limitations of the current work undertaken. It is possible that the protein 
precipitation method utilised may have affected the recovery of BAL proteins and 
negatively affected the proteomic analysis. In attempting to reduce/remove albumin 
as the large dominating protein in the BAL samples, it is possible that other smaller 
proteins were also removed in the process. The addition of organic solvents, in this 
case acetonitrile, precipitates high molecular weight proteins and leaves behind low 
molecular weight proteins (<30 kDa) in the solution; immuno-depletion methods were 
avoided due to disadvantages such as low sample throughput, specificity issues and 
the potential for non-specific albumin-bound protein loss. However, whilst acetonitrile 
may have allowed the dissociation of albumin-bound molecules, these lower 
molecular weight proteins may have been inadvertently removed from the sample 
through ‘trapping’ in the web-like structure created by the denatured larger proteins 
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(Merrell et al. 2004). These acknowledged difficulties led to the development of an in-
tube chromatographic absorbent method to enrich low molecular weight proteins by 
the group of Wu et al. (2010) which has sought to eliminate such losses. Alternatively, 
precipitation plates can be used. The volume of acetonitrile and the centrifugal force 
applied during the precipitation method in the experimental work may have been too 
aggressive for the low volume BAL samples used and so this should be considered in 
future work where an in-tube absorbent method or precipitation plates could instead 
be employed.  
 
In addition to possible precipitation issues, false discovery rates in database 
searches may have been apparent, affecting the specificity of protein identification. 
Computational analysis is performed by correlating the acquired MS/MS spectra with 
predicted theoretical fragmentation spectra contained within a protein sequence 
database such as Mascot. Due to the potential of false-positives, decoy databases 
should be used for large scale experiments. Such decoy searches consist of repeating 
the search using identical parameters against a database with reversed or randomised 
sequences; thus the number of positive matches found is an efficient way of 
estimating the validity of the matches found from the target database. It has also been 
suggested in the literature that multiple search tools and multi-stage strategies 
(iterative analysis) should be used to increase the overall rate of peptide identification 
(Bern et al. (2011); Ma, (2010); Larsen et al. (2006)).   
 
The mass accuracy and resolution capabilities of the mass spectrometry 
equipment used in proteomic research can have a significant effect on the resultant 
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spectral data which in turn impacts subsequent peptide identification. In terms of 
analytical sensitivity, the merits of utilising a triple quadrupole instrument instead of a 
linear ion trap have already been acknowledged. Sensitivity can be further increased 
by using nanoelectrospray ionisation LC/MS which, when coupled with a quadrupole, 
results in increased sample concentrations (on column), lower flow rates (limiting 
dilution by the mobile phase) and increased ionisation efficiency (Cutillas, 2005). 
There are other mass analysers available which afford higher mass accuracy and 
resolution such as the Orbitrap which traps ions in an electrostatic field and causes 
them to oscillate in complex spiral patterns (much like a satellite in orbit) followed by 
Fourier transformation to generate accurate mass spectra. The ability to resolve and 
measure m/z values with greater accuracy can reduce the number of false positives 
from database searching algorithms and provide greater confidence in determining 
the amino acid sequence of peptide/proteins together with any ligands that may be 
present.  
 
5.4 Final conclusion and suggestions for future work 
I found no simplistic relationship between COPD and the presence of oxidative 
stress. Rather, I uncovered evidence of age-related changes at the air-lung interface 
suggestive of the presence of a non-transferrin bound Fe pool. These data are the first 
evidence of disturbances in the antioxidant network and metal handling capacity in 
the aged healthy lung. Whilst these changes could not be related to disease state they 
may imply that the aged airway is more susceptible to injury during periods of 
inflammation, i.e. as would be observed during airway infections and COPD 
exacerbations. As mentioned previously, the results presented within this thesis build 
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upon earlier observations in this group of patients demonstrating age-related 
decreases in cellular enzymatic antioxidants. Further, there is an emerging literature 
suggesting that adaptive stress pathways in COPD are impaired. These observations 
further support the view that the aged airway would be more sensitive to oxidative 
stress arising from airway inflammation. The presence of an unchelated pool of Fe at 
the lung surface also raises the possibility that the aged air-lung interface would be a 
more hospitable environment for bacterial infection, which would further augment 
airway injury.  
 
Taken as a whole, the literature on oxidative stress in COPD is unconvincing 
and insufficiently robust. By focusing on airway responses in this study with 
appropriate age and smoking matched controls, I had hoped to have overcome many 
of the more obvious limitations of the published literature. Despite this, the role of 
oxidative stress in the pathogenesis and progression of COPD remains oblique. As 
discussed above, there would be merit in extending these analyses into patients with 
more advanced COPD or those undergoing acute exacerbations; however such studies 
raise significant ethical concerns. There is also the question as to whether the 
approach of looking at global markers of oxidation, in one-off samples, is somewhat 
naïve and whether a more targeted approach is required, for example, focusing on 
oxidative post-translational modifications to proteases and antiproteases. In the final 
chapter of this thesis, I attempted to develop a methodology that would permit the 
identification of such adducts within the RTLF. I was only able to progress this 
methodology to establish proof of principle and clearly this method still requires 
further development. However, the requirement for robust adductomic approaches is 
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now widely acknowledged and the preliminary work presented within this thesis 
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A1.1 Peptide ion fragmentation 
Identification of peptide sequences by mass spectrometry involves the 
fragmentation of a peptide into smaller m/z fragments. The cleavage of a peptide 
occurs primarily through charge-directed pathways with the cleavage being initiated 
by a charge that is transferred to the locality of the cleavage site (Wysocki, 2005). Such 
transfers are facilitated by heteroatomic proton affinity, for example carbonyl oxygen 
situated along the backbone of a peptide. Traditional methods of activation result in 
differing cleavages; CID produces b- and y-ion pairs following cleavage across amide 
bonds whilst ECD and ETD activation produce c- and z-ion pairs following extensive 
cleavage along the backbone of the peptide for precursor ions with multiple charges. 




























Figure A1.1: Fragmentation of the peptide main chain giving rise to the nomenclature 
of b/y and c/z ion types. 
 
Cleavages of the backbone that occur at the amide bond result in b- and y-ions; 
retention of the charge at the N-terminus produces b-ions whilst retention of the 
charge at the C-terminus produces y-ions. When homolytic cleavage occurs at the N-
Cα bond, c- and z-ions result; retention of the charge at the N-terminus produces c-
ions whilst retention of the charge at the C-terminus produces z-ions.   
 
A1.2 Ergodic and non-ergodic processes 
Depending upon the activation method used, fragmentation will occur either 
in a sequence-dependent or sequence-independent manner. CID is described as an 
“ergodic” ion activation method in which fragmentation is sequence-dependent. As 
the rate of dissociation is slower than the rate of energy randomisation, the energy is 
redistributed in the vibrational modes of the ion. The energy is distributed among the 
internal modes of the ion in equal probability, leading to preferential cleavage of the 
weakest bonds. Under these conditions, the fragmentation is dependent upon the 
energy that is deposited and so for higher molecular-weight compounds an increased 
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energy transfer is desirable. ECD and ETD are described as “non-ergodic” ion 
activation methods in which fragmentation is sequence-independent. As the rate of 
dissociation is faster than the rate of energy randomisation, bond cleavage can be 
induced with minimal energy as the rapid dissociation occurs before the energy is 
randomised over the vibrational modes of the ion – a highly desirable feature for the 
fragmentation of high molecular-weight compounds. As a consequence the weakest 
bonds, such as post-translational modifications, remain intact and the sequence-
independent fragmentation allows for greater characterisation of the peptide.  
 
